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Abstract 
Influenza A viruses are major human and avian pathogens. Despite a species barrier, 
subtypes of influenza A can transmit from the avian reservoir to humans and widely 
spread in the population. Since H5N1 viruses circulate in the avian reservoir and cause 
high lethality rates when transmitted to humans, infections with the H5N1 subtype pose 
an ongoing threat. Although human-to-human transmission is a rare event, rapid 
evolution of the virus might result in a strain, which gains the ability to spread in the 
human population, leading to high morbidity and mortality. Advanced surveillance by 
understanding the mechanisms by which influenza viruses acquire the ability to cross 
the species barrier from birds to humans and new strategies to improve current 
vaccines are needed to control future pandemics. In this study, the fatal human case 
isolate A/Thailand/1(KAN-1)/2004 (H5N1) (KAN-1) was analyzed to examine 
mechanisms of H5N1 viruses to overcome host range restriction. 
! We were able to identify an adaptive mutation in KAN-1 hemagglutinin (HA). A 
polymorphism leading to an amino acid change in the HA that was previously reported 
to be positively selected during replication in humans altered the organ tropism of KAN-
1 in mice and ferrets. In the mouse model we found an increased replication of the 
selected variant in the lung. 
• In a genetic analysis of the KAN-1 virus, we identified further mutations crucial for 
adaptation to the mammalian host. Interestingly, the KAN-1 polymerase was poorly 
adapted to human cells, in contrast to other H5N1 viruses isolated from humans. We 
identified the NEP protein as a new pathogenicity factor of H5N1 viruses in humans, 
which is able to overcome this incomplete adaptation of the KAN-1 and avian H5N1 
polymerases in human cells. Furthermore, functional studies revealed that the 
restriction of avian influenza polymerases in mammals is due to a general defect in 
RNA-replication and not transcription. 
• Since the human MxA GTPase is an important factor in the immune response against 
influenza viruses, we analyzed its antiviral activity against KAN-1. KAN-1 proved to be 
sensitive, while an isolate of the 2009 pandemic was relatively resistant to MxA. We 
were able to determine the viral nucleoprotein (NP) as the determinant for MxA 
sensitivity in vitro and in vivo. In addition, we identified mutations in NP responsible for 
resistance against MxA and could draw conclusions about the evolution of NP.  
• Based on our knowledge about protein-protein interactions in the polymerase 
complex, we developed a new strategy to create polymerase assembly mutants as a 
basis for live attenuated vaccines against H5N1. Vaccination of mice with these 
mutants showed protection against homologous and heterologous challenge with lethal 
doses of H5N1 viruses including KAN-1, therefore providing new options for live 
attenuated vaccine design. 
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Zusammenfassung 
Influenza-A-Viren sind wichtige humane und aviäre Krankheitserreger. Trotz einer 
Speziesbarriere können aviäre Influenza-A-Viren von Wasservögeln auf Menschen 
übertragen werden. Sporadisch kann es dabei zu einer Etablierung des Virus in der 
menschlichen Bevölkerung kommen, woraus eine Pandemie resultieren kann. Humane 
Infektionen mit aviären Influenza-A-Viren des Subtyps H5N1 stellen dabei eine stete 
Bedrohung dar. Das Verständnis der Mechanismen, durch die Influenza-A-Viren die 
Spezies-Barriere zwischen Vögeln und Menschen überwinden und Verbesserungen 
der derzeitigen Impfstrategien sind essentiell für die Kontrolle von zukünftigen 
Pandemien. Das in dieser Arbeit verwendete H5N1 Virus A/Thailand/1(KAN-1)/2004 
(H5N1) (KAN-1) wurde aus einem Menschen isoliert, der an dieser Infektion starb. Es 
lässt sich an diesem Beispiel detailliert untersuchen, welche Veränderungen ein H5N1 
Virus benötigt, um die Speziesbarriere vom Vogel zum Menschen zu überschreiten. 
• Wir konnten eine Adaption im KAN-1 Hämagglutinin (HA) nachweisen, indem wir für 
eine im Menschen positiv selektionierte Mutation im HA-Protein einen veränderten 
Gewebetropismus in der Maus und im Frettchen beobachten konnten. Im Mausmodel 
konnten wir eine erhöhte Replikation dieser Virusvariante in der Lunge feststellen. 
• Durch eine genetische Analyse des KAN-1 Virus konnten wir entscheidende 
Mutationen für die Adaption an den Säuger identifizieren. Interessanterweise zeigte 
sich, dass im Gegensatz zu anderen humanen H5N1-Viren die KAN-1-Polymerase nur 
schwach an den Menschen angepasst ist. Mit dem Nachweis, dass eine Mutation im 
NEP Protein von KAN-1 die nicht genügend angepasste Polymerase kompensiert 
identifizierten wir NEP als neue Pathogenitätsdeterminante der H5N1-Viren im 
Menschen. Zudem zeigten mechanistische Studien einen Replikationsdefekt der 
aviären Influenza-Polymerasen im Menschen. 
• Da die menschliche GTPase MxA ein wichtiger Faktor der Immunantwort gegen 
Influenza-Viren ist, analysierten wir ihre antivirale Aktivität gegen KAN-1. KAN-1 erwies 
sich als sensitiv, während ein Isolat der Pandemie von 2009 relativ resistent gegenüber 
MxA war. Wir konnten das virale Nukleoprotein (NP) als die Determinante für MxA-
Sensitivität in vitro und in vivo bestimmen. Zudem identifizierten wir Mutationen in NEP, 
die verantwortlich für die Resistenz gegenüber MxA sind und konnten Rückschlüsse 
auf die Evolution von NP ziehen. 
• Basierend auf unserem Wissen über Protein-Protein-Wechselwirkungen innerhalb 
des Polymerase Komplexes entwickelten wir eine neue Strategie zur Entwicklung von 
Polymerase-Assembly-Mutanten als Basis einer Lebendvaccine gegen H5N1. Die 
Impfung von Mäusen mit diesen Mutanten vermittelte einen Schutz vor homologer und 
heterologer Infektion mit tödlichen Dosen von H5N1 Viren inklusive KAN-1. Diese neue 
Strategie bietet daher eine Ergänzung zu bereits verfügbaren Lebend-Impfstoffen.  
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1 Introduction 
 
1.1 Relevance of influenza research 
 
Influenza A viruses are major human and avian pathogens, infecting the respiratory 
system or the gastrointestinal tract of the host. In humans, influenza virus infection 
leads to febrile respiratory illness. The disease is characterized by a sudden onset of 
high fever, cough, headache, sore threat and muscle pain from which most patients 
recover after several days up to two weeks. However, influenza may produce life-
threatening complications, such as pneumonia or acute lung failure especially in 
children, elderly or immuno-compromised persons. Damage to the respiratory mucosa 
even allows the entry of other pathogens, which can result in secondary bacterial 
infections. Incomplete protection by vaccines and the emergence of resistant viruses to 
currently used antiviral drugs pose a challenge in the fight against influenza infections.  
Recurring epidemics and sporadic pandemics account for significant morbidity and 
mortality among humans as exemplified by the 1918 pandemic with up to 50 million 
deaths worldwide (156). Influenza outbreaks have been recorded since the middle 
ages (99) and the 2009 pandemic once more demonstrates the topicality. The 
pandemic threat is caused by zoonotic infections of immunologically naïve humans 
with avian or swine derived influenza viruses. The mechanisms by which influenza 
viruses stably adapt to humans are still largely not elucidated. Research in this field 
and the development of improved vaccines are needed to prepare for future 
pandemics.  
 
1.2 The influenza A virus 
 
1.2.1 Taxonomy 
 
Influenza viruses, with the genera A, B, C, the Thogoto- and the Isavirus form the 
family orthomyxoviridae. This family is characterized by a single-stranded, segmented 
RNA genome with negative orientation. While influenza C viruses circulate in humans 
and pigs, influenza B viruses have been isolated only from humans and rarely from 
seals (8). Influenza A viruses show the greatest host range and infect humans as well 
as many other mammals, e.g. pigs, horses and whales and many species of birds. Wild 
waterfowl is the primary host reservoir of the influenza A viruses (61). 
Influenza viruses differ by the number of genome segments (eight for influenza virus A 
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and B, seven for influenza virus C). Influenza A viruses can also be distinguished by 
the variability of the surface antigen proteins. 16 HA subtypes and 9 NA subtypes are 
known (2, 35). The World Health Organization standardized the nomenclature for 
influenza viruses in 1980. The isolate is designated in the order genus, host species 
(not required for human influenza A viruses), place of isolation, isolate number and 
year of isolation. In the case of influenza A viruses, the subtype is also added in 
parentheses, for example: A/Thailand/1(KAN-1)/2004 (H5N1).  
 
1.2.2 Morphology and encoded proteins 
 
Influenza viruses are spherical or filamentous structures, with a diameter of about 100 
nm (15). The segmented RNA genome, encapsidated by many molecules of the 
nucleoprotein, forms a helical capsid (6). At its ends, the trimeric RNA dependent RNA 
polymerase (RdRP) is bound. The complex, consisting of RdRP, RNA and NP is known 
as ribonucleoprotein (RNP) 
(Fig. 1). Another protein 
found in virus particles in low 
copy number is the nuclear 
export protein NEP (NS2) 
(127, 177). The 
nucleoproteins of the RNP 
interact with the matrix 
protein (M1), which forms a 
layer inside of the plasma 
membrane of the host cell 
derived lipid envelope (139). 
The M2 protein, which forms 
a homotetramer and 
functions as a proton channel, is embedded as a transmembrane protein in the 
envelope membrane in small quantities (77). As virus-encoded glycosylated surface 
proteins (spikes) the hemagglutinin (HA) and neuraminidase (NA) are incorporated into 
the lipid envelope and protrude about 10 nm with a diameter of about 3 nm (136). The 
HA exists as a homotrimer and mediates receptor binding and membrane fusion. The 
NA exists as a homotetramer and mediates cleavage of the receptor (162). 
 
 
Fig. 1: Schematic drawing of an influenza virion 
(from (154)) The viral RNPs are enclosed by the M1 
protein layer inside of the cell derived lipid bilayer. The HA, 
NA and M2 proteins are integral membrane proteins. 
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1.2.3 Replication cycle 
 
Adsorption, penetration, uncoating 
The replication cycle of the influenza virus begins with the adsorption of infectious 
virions on permissive host cells, initiated by binding of the hemaglutinin to the cellular 
receptor sialic acid. For successful virus infection a cleavage of the hemagglutinin 
precursor HA0 into the subunits HA1 and HA2 that stay connected via a disulfide bridge 
is essential (73). The adsorption of the virus particle to the cell is mediated by binding 
of the receptor-binding site of 
the hemagglutinin to sialic 
acid (140). Sialic acids are 
sugars that occur as 
modifications of membrane 
proteins and glycolipids on 
cell surfaces of most animal 
tissues, explaining the wide 
host range of influenza 
viruses. The hemagglutinin of 
avian influenza viruses binds 
preferentially to α2,3-linked sialic acids, whereas human influenza isolates recognize 
α2,6-linked sialic acids (91, 129). Receptor-mediated endocytosis leads to penetration 
of the cell membrane (Fig. 2). A subsequent acidification of the endosomal vesicles by 
cellular H+-ATPases causes an irreversible conformational change in the hemagglutinin 
(138, 170). The hydrophobic fusion peptide at the amino terminus of HA2 is stretched 
and integrated into the endosomal membrane, which causes the membrane fusion by 
further conformational changes (169). The viral proton channel M2 transfers the 
acidification of the endosome to the interior of the virion (120), which dissolves the 
RNP complexes from the M1 matrix protein (58). Ensuing membrane fusion, the RNP 
complexes reach the cytoplasm and are actively transported through the nuclear pore 
complex into the nucleus of the host cell, utilizing nuclear localization signals (NLS) of 
the proteins PB1, PB2, PA and NP (171, 172). 
 
Transcription, translation and protein modification 
Since influenza viruses possess an RNA genome of negative polarity, which cannot be 
translated from the cellular ribosomes, the viral RNA dependent RNA polymerase 
(RdRP) starts by transcribing mRNA from the viral RNA (vRNA) template of the RNP. 
To initiate trancription, the RdRP needs 5'-cap structures that serve as a primer for the 
Fig. 2: The influenza virus life cycle (from (142)) 
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viral polymerase. For this purpose, influenza viruses make use of the so-called cap-
snatching. In this process, the PB2 protein binds cap structures of cellular mRNAs (50, 
159) and thereby enables the endonuclease within PA to cleave the mRNA 9-17 
nucleotides behind the 5'-end (29, 178). By adding a guanine complementary to the 
vRNA, PB1 initiates transcription. The elongation proceeds up to the uridine-rich region 
approximately 15-22 nucleotides in front of the 5'-end of the vRNA (78), where the 
RdRP reiterate the incorporation of A residues thereby synthesizing the 3’-polyA tail. 
The mRNAs derived from the gene segments 7 and 8 are processed post-
transcriptionally by the cellular spliceosome. For the following translation, all viral 
mRNAs are exported to the cytoplasm (172), where the virus exploits the cellular 
translation machinery. At the beginning of the infection, the proteins of the polymerase 
(PB2, PB1, PA), NP, NS1, NS2, and M1 are synthesized as early proteins on free 
ribosomes and transported by means of their nuclear localization signal, or their small 
size into the nucleus (96, 103, 107, 172). The integral membrane proteins (HA, NA, 
M2) are synthesized in the later stages of infection and in contrast to the other viral 
proteins at ribosomes of the rough endoplasmic reticulum (rER). These proteins 
undergo post-translational modifications on their way from the rER via the cis-and 
trans-Golgi network to the plasma membrane of the cell. HA and NA are glycosylated in 
the ER and Golgi apparatus and further processed. The N-terminal signal sequence of 
the HA is cleaved in the ER lumen by a signal peptidase. The terminal sialic acids of 
the attached oligosaccharides are removed by neuraminidases to prevent cross-linking 
of the HAs with the carbohydrate side chains (11). In the case of a multibasic cleavage 
site in the amino acid sequence of the HA0 precursor protein, HA can already be 
activated in the Trans-Golgi network by the ubiquitous protease furin (149). Multibasic 
cleavage sites are a characteristic of highly pathogenic avian influenza viruses of 
subtypes H5 and H7. Further post-translational modifications for example are 
palmitoylation (152) and phosphorylation of M2 (59), sumoylation of NS1 and NEP 
(111, 176) and NEP phosphorylation (127). 
 
Genome replication 
In contrast to mRNA-transcription, the replication of the viral genome is primer 
independent. First, a full length copy RNA (cRNA) of the vRNA is synthesized and 
serves as a template for new viral genomes (vRNAs) (76). Early in the infection only 
mRNA synthesis is observed, whereas increasing amounts of cRNA are found later in 
infection. It is still controversially discussed, whether there is a switch from transcription 
to replication. A first hypothesis says that the polymerase performs full-length cRNA 
synthesis from the beginning of the infection. However, the cRNA transcripts are 
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shorter due to impaired elongation in the absence of newly synthesized NP (60, 135). 
Additionally the cRNA needs to be stabilized by NP and the viral polymerase, in order 
not to be degraded (163). The second hypothesis favors the model of a switch from 
transcription to replication mediated by binding of free NP molecules to the polymerase 
(105). Furthermore, the NEP (NS2) protein was shown to alter the relative efficiency of 
transcription and replication (128) possibly via the generation of small viral RNAs which 
correspond to the first 22-27 nt of each vRNA 5’end and which accumulate to high 
numbers during viral infection (118, 160). 
The increased accumulation of vRNA to cRNA points towards differences in generation 
of these two full-length RNA species. For vRNA synthesis, one current model describes 
that the reaction is carried out by a non-resident polymerase in trans. This might result 
in initiation of several polymerases during one polymerization cycle and explain the 
higher abundance of vRNA above cRNA during the infection. 
The structures of vRNA and cRNA promoter regions determined by NMR demonstrated 
some remarkable differences that might indicate two distinct RNP conformations (115). 
In fact, there is evidence that different regions in the polymerase recognize the vRNA 
or cRNA promoter. In the current model, cRNA sythesis is believed to initiate at 
nucleotide position 2 on the vRNA, while the first nucleotide is subsequently added. 
The underlying mechanism for vRNA sythesis is suggested to be a prime and re-align 
mechanism, in which the first two bases are transcribed at the internal positions 4 and 
5 of the cRNA and then shifted to the 3’ end of the template terminus to allow 
generation of a full length vRNA. 
 
Morphogenesis and release of virus particles 
Since the replication of influenza viruses, in contrast to most RNA viruses, takes place 
in the nucleus, the newly synthesized vRNPs must be transported from the nucleus to 
the cell membrane. For export, a nuclear accumulation of the M1 protein is necessary 
(87). Nuclear export is mediated by the NEP protein, which has a nuclear export signal 
(NES) and interacts with cellular CRM1 and nucleoporin (109). The interaction between 
NEP and the vRNPs is mediated by M1 (165, 177). The assembly of the virions takes 
place at the plasma membrane of infected cells in specific plasma membrane domains, 
the so-called lipid rafts, where the surface proteins HA, NA and M2 are accumulated 
(133, 180). HA and M2 are present as tetramers to form complexes, NA is arranged as 
a trimer. Despite a strong intracellular expression, M2 is of low abundance in both the 
cell membrane, as well as in virions (179). A crucial role in the morphogenesis plays 
the M1 protein, since it interacts with the vRNPs, as well as the cell membrane. It is 
believed that the process of release is initiated by a direct interaction of M1 with the 
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cytoplasmic domains of HA and NA (10, 43, 44). To ensure production of infectious 
virus particles, packaging of each of the eight genome segments is required. Although 
the mechanism for efficient genome packaging is not clearly understood, it was shown 
that it doesn’t take place randomly, but rather by selective incorporation via packaging 
sequences in the vRNAs (37). During the budding process, the viral neuraminidase 
cleaves off terminal sialic acids from the viral surface as well as from the host cell and 
thus prevents agglutination of virions with the host cell and each other (112). Moreover, 
uncleaved HA0 is cleaved by extracellular proteases in HA1 and HA2. 
 
1.3 Human Influenza 
 
Influenza A viruses that have efficiently adapted to humans can be transferred easily 
through airborne transmission and spread quickly. In the upper respiratory tract, 
epithelial cells are infected first (92, 93) and newly formed viruses are released at the 
apical side of the plasma membrane into the airway. The virus can spread to the lower 
respiratory tract, where the ciliated cells and mucus-producing layers of skin are 
destroyed. Macrophages, neutrophils and T-cells migrate into the infected areas to 
eliminate the virus, where especially macrophages secrete pro-inflammatory cytokines, 
which are responsible for the systemic symptoms of influenza. In exceptional cases 
this might result in a cytokine storm that leads to death (117).  
Every 1-2 years new epidemic influenza A strains appear under the pressure of the 
adapted immune system. The strains differ mainly by positively selected mutations in 
the surface proteins HA and NA. This process is called antigenic drift, which is 
generated by the large error rate and the lack of a proofreading function of the viral 
polymerase (167, 173). Another way to evade the immune response is the exchange of 
entire gene segments (reassortment) between different Influenza A subtypes. Such 
reassortant viruses may arise, when two different influenza viruses infect a single cell. 
When the exchange of gene segments involves surface proteins, this reassortment is 
called antigenic shift. The coexistence of humans, pigs and poultry under poor hygienic 
conditions favors such processes, because pigs are highly susceptible for human and 
avian influenza viruses. Due to the processes of antigenic drift and antigenic shift, 
there is no lasting immunity against influenza viruses, neither after natural infection or 
vaccination against a former strain. 
In contrast to mild to moderate epidemics occurring almost every winter season, 
pandemics are rare events, taking place every 10 to 50 years for at least 500 or more 
years back in the past (99). Typically for influenza pandemics is the shift in mortality 
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from the elderly to younger age groups. In the last hundred years, four pandemics with 
different severity were recorded. Remarkably, all human influenza pandemics 
originated from avian influenza. The 1918 pandemic has been the most devastating 
pandemic in human history, claiming up to 50 million lives (66). From archived 
formalin-fixed lung autopsy materials and from frozen unfixed lung tissue of a flu victim, 
who was buried in November 1918 in the permafrost, the entire genome of the 
pandemic strain has been reconstructed (155) and the virus was identified as an H1N1 
virus, which appeared to be a descendant of a bird virus (125). The two following 
pandemics were caused by reassortant viruses containing three (H2N2 1957) or two 
(H3N2 1968) genes of avian origin (69). The most recent pandemic was the H1N1 
pandemic in 2009. The virus was identified to be a triple reassortant with genes of 
swine, human and avian origin (104, 141). It contains none of the hallmarks of highly 
pathogenic avian influenza viruses and only some human aa signatures that were 
already present in the swine viruses (22). Noteworthy, pandemic influenza seem to 
have a strong dependence on viruses of avian origin. Thus, in the recent past, serious 
illness monitored in people infected with viruses of avian origin raised public health 
interest and concern for a future pandemic. 
 
1.4 Avian Influenza 
 
The entire range of influenza A virus subtypes is found in wild aquatic birds (166), 
which therefore form the natural 
reservoir of all influenza A viruses (Fig. 
3). The most abundant low pathogenic 
avian influenza viruses (LPAIV) 
generally do not cause disease in their 
natural hosts. Viral replication takes 
place in the epithelia of the 
gastrointestinal tract and virus particles 
are excreted in high titers (168). 
However, domesticated poultry is 
considered particularly vulnerable to 
influenza, as LPAIV infection can already reduce growth rates in broiler poultry (20). 
When adapting to poultry, LPAIV of subtypes H5 and H7 also possess the potential to 
mutate into a highly pathogenic avian influenza virus (HPAIV) form (20, 90). These 
highly pathogenic variants are distinguished mainly by a multibasic cleavage site in the 
Fig. 3: Host spectrum of influenza A viruses 
(from (61)) Influenza A viruses have a broad 
host spectrum with wild waterfowl as their 
natural reservoir. 
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HA precursor protein, which may be cleaved by ubiquitous proteases such as Furin, 
enabling the systemic spread of the virus (62, 63, 73). In contrast, the monobasic 
cleavage site of most LPAIV is cleaved by trypsin-like proteases, which leads to 
restricted organ tropism. 
HPAIV infections are not only devastating for poultry farms, but also possess a threat 
on public health, as documented transmission of avian influenza to humans 
predominantly occurred in association with HPAI epizootics (154). 
 
1.4.1 The H5N1 epizootic 
 
In 1997 the first disease in humans caused by an H5N1 strain was documented (1). 
Within a year, this epizootic caused 18 human cases and six deaths in Hong Kong 
(101). H5N1 continued to circulate in birds in China and reappeared in epizootic form in 
2003. Rapid evolution of viruses in birds, acquisition of mutations that were also found 
in the genome sequence of the 1918 isolate and growing numbers of human zoonotic 
infections suggest H5N1 as a possible base for another pandemic (148). Although the 
H5N1 influenza remains largely a disease in birds, infection of humans still occurs 
frequently through direct contact with diseased poultry. To date (2011-12-06) the WHO 
confirmed 571 human H5N1 cases resulting in 335 deaths (59%). The virus analyzed 
in this study, A/Thailand/1(KAN-1)/2004 (KAN-1), was isolated from a fatal case in 
Thailand in the beginning of 2004, when widespread H5N1 infections were recognized 
in Thailand and Viet Nam (123). The patient was a 6 year old before healthy boy, who 
suffered approximately 4-5 weeks from the H5N1 infection (25). Subsequently, the 
KAN-1 virus was shown to be highly pathogenic for mice and ferrets (47, 86). 
Although H5N1 is the most devastating influenza zoonosis in humans, other avian 
influenza A viruses were also able to infect humans and cause disease, such as H7N7 
and H9N2 (36, 80). 
 
1.4.2 Host specificity factors 
 
Many biological properties affect the host specificity of influenza viruses. The 
combination of host and viral factors determines the virulence of a virus isolate in a 
particular host.  
Few mutations in an apathogenic LPAIV H7N1 virus in Italy resulted in 1999 in a HPAIV 
version that reached mortality rates up to 100% in domestified poultry, while humans 
beeing in close contact, did only rarely show seroconversion and never got diseased 
(9, 70, 124). On the other hand, infections with HPAIV influenza viruses of the H5N1 
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subtype lead to high mortality rates in humans (151), while the virus often causes mild 
disease in wild waterfowl (119). Despite significant research, the molecular mechanism 
of how influenza viruses switch hosts remains poorly understood.  
Every single viral protein fulfills a variety of functions for effective propagation of the 
viral infection. The question of which factors determine the viral pathogenicity, virulence 
and host range of influenza A viruses is not yet fully understood. However, 
comprehension of the function of individual proteins is steadily increasing. The 
hemagglutinin plays a central role in tissue tropism and systemic spread of the virus. It 
is responsible for receptor binding and membrane fusion, two essential functions for 
successful infection of a cell. For the membrane fusion, the proteolytic cleavage of HA0 
into HA1 and HA2 is essential and the expression of proteases mediating this cleavage 
is important for organ tropism of the virus, exemplified by the efficient activation of 
HPAIV hemagglutinin by ubiquitous furin-like proteases (72). Furthermore, the tissue 
tropism and host specificity are significantly influenced by the receptor specificity of the 
hemagglutinin. The different distribution of α2,3- and α2,6-linked sialic acids in a 
particular host and between different species is an important factor that determines the 
spread of a virus isolate (12, 64).  
The neuraminidase is another important virulence factor. The transfer of an avian 
influenza A virus from wild birds to domestified poultry results in most cases in a 
deletion in the NA stalk region, which decreases the enzyme activity. For H5N1 isolates 
from chickens it has been shown that this stalk deletion restores a balance between 
haemagglutinin and neuraminidase-binding activity that was disturbed by the reduced 
receptor-binding ability of the HA in the new host (90, 164). It was also shown that the 
mouse-adapted A/WSN/33 neuraminidase specifically contributes to activation of the 
hemagglutinin by recruitment of the protease plasminogen (45, 46).  
Besides the glyocproteins, especially the polymerase genes have been shown to 
contribute to pathogenicity and host range (3). A replacement of the PB1 gene of a 
human isolate with the one of an avian virus (as occurred in the 1957 pandemic) 
increases pathogenicity in mice (23). Furthermore, single amino acid changes, which 
will be described in the following, have been shown to affect pathogenicity and host 
range. While avian influenza A virus isolates almost exclusively contain a glutamic acid 
at position 627 of the polymerase PB2 protein (PB2-E627), this position is frequently 
mutated to a lysine in human-derived isolates, including H5N1 isolates that cause a 
high morbidity in humans (56, 150). Mutation to PB2-E627K is accompanied by 
improved viral replication at low temperatures (57) and enhanced binding of the viral 
polymerase to the nucleoprotein in human cells (75). However, fatal infections of 
humans with avian viruses of the H5N1 subtype that retained the avian like glutamic 
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acid at position 627 of PB2 are frequent. Interestingly, the 2009 H1N1 pandemic virus 
also harbors 627E, but additionally possesses a lysine at position 591 (PB2-K591), 
which is able to partially, but not completely, compensate for the lack of the PB2-
E627K mutation (94). Other mutations known to play a role in host adaptation 
processes are the exchange of aspartic acid with asparagine at position 701 in PB2 
(PB2-D701N) (38, 79), which can confer high pathogenicity to avian H5N1 and H7N7 
viruses in mice and the substitution of a threonine to an alanine residue at position 271 
(PB2-T271A) which has been suggested to enhance polymerase activity in mammalian 
cells (18). The PA protein of the 2009 pandemic H1N1 was shown to carry three 
mutations, conferring high activity to the polymerase in human cells (19). Furthermore, 
adaptation to human importin α by the influenza polymerase proteins, but also the 
nucleoprotein was suggested to play a crucial role in interspecies transmission and 
pathogenicity (39, 40). 
During an infection, the host innate immune system has to be countered by influenza A 
viruses. The influenza nucleoprotein was shown to determine the level of sensitivity to 
the mammalian antiviral protein Mx (30). The small viral protein PB1-F2 induces cell-
specific apoptosis, thereby eliminating cells of the innate immune system (24). In 
addition to the clear role of the NS1 protein in interferon antagonism, PB1-F2 and PB2 
contribute to the inhibition of innate immunity pathways (34, 48, 161).  
Furthermore, a C-terminal PDZ-binding-motif, elevating pathogenicity was proposed for 
avian influenza NS1. Also the NS1 localization seems to play a major role in the 
infection cycle (70, 110). However, only little experimental work has been performed to 
evaluate the potential as a pathogenicity determinant for the viral proteins M1, M2 and 
NEP. However, a mutation in NEP was suggested to be positively selected in a mouse-
adapted virus, but experimental data are lacking (17). 
 
1.5 Influenza vaccines 
 
Influenza vaccination protects from infection and disease, although the frequent 
immune escape of influenza viruses requires annual updating of the vaccine strains to 
adapt to changes in the HA and NA genes. Emerging viruses like H5N1 pose a serious 
threat to the human population, as it is immunologically naïve to these viruses. The 
annual vaccine consists of two different FluA and one FluB strain. Strains are chosen, 
which are thought to most likely represent the majority of circulating strains in the 
following season. Two types of vaccines are currently used: a chemically inactivated 
virus delivered by injection, and a live-attenuated influenza virus vaccine based on a 
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cold-adapted master strain, delivered as a nasal-spray (4, 83). The inactivated vaccine 
elicits an antibody response recognizing the respective HA and NA subtypes. It has 
proven to be of suboptimal efficacy in the elderly population, the same population that 
is most endangered by seasonal influenza (137). In contrast, it is believed that the live 
vaccine not only induces humoral, but also a cellular immune response that confers 
long-lived and heterosubtypic immunity (13, 33, 88, 145). However, for safety reasons, 
administration is restricted to healthy persons between 2 and 49 years of age (4). The 
degree of attenuation is crucial for the efficacy of the live-attenuated vaccine. A strong 
attenuation reduces risk at administration, but this is accompanied with decreased 
protection. In the currently used live vaccine, the attenuation is fixed due to the use of a 
specific master strain. Identification of new viral target sites to vary the degree of 
attenuation would contribute to safety and efficacy of live attenuated viruses. 
 
1.6 The interferon system and the antiviral protein Mx  
 
 As a component of the innate immune response, the interferon (IFN) system can react 
rapidly against an infection by inducing mechanisms to counteract spread of the 
infection, thereby offering the adaptive immune system enough time to develop a 
highly specific response (102). Type I Interferons whose main representatives are IFN-
α and IFN-β and the recently discovered type III interferons including IFN-λ1, -λ2 and -
λ3 are important factors interfering with viral replication (5, 98, 147). They are induced 
upon recognition of pathogen associated molecular patterns (PAMPs) by pattern 
recognition receptors 
(PRRs) (153) such as RIG-
I, MDA-5 and toll-like 
receptors (TLRs) that 
activate the transcription 
factor IRF-3 and lead to 
elevated expression of IFN 
by different mechanisms. 
Alternatively the 
transcription factor NF-κB 
induces the synthesis of 
IFN. The secreted 
interferons bind their 
respective membrane-
Fig. 4: The Interferon-system (adapted from (52)) 
Viral target structures are recognized by the cellular 
receptors MDA5, RIG-I and PKR, which results in the 
synthesis and secretion of type I and III interferon (IFN). The 
binding of IFN-β and IFN-λ to their respective receptor 
activates the JAK / STAT signaling cascade, thereby inducing 
the expression of interferon-stimulated genes (ISGs).  
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bound receptor and induce the expression of various IFN-stimulated genes (ISG) (146) 
via the JAK-STAT signaling pathway, such as RIG-I, MDA5, the 2'-5'-oligoadenylate 
synthetase (OAS), PKR and Mx proteins (132). While many ISGs interact with other 
cellular factors and exert relatively non-specific effects (26, 55, 68), Mx proteins have 
an intrinsic antiviral activity and act autonomously without the need for additional IFN-
induced factors (7, 53, 144) (Fig. 4). The resistance to influenza A viruses observed in 
specific inbred mice carrying the Mx gene coined the nomenclature Mx (myxovirus 
resistance) (81, 82). Mx proteins belong to the family of large dynamin-like GTPases 
and have been identified in many vertebrates, including fish, birds, pigs, rodents and 
humans (54). Mx proteins contain three domains, the N-terminal GTPase domain, 
which binds and hydrolyzes GTP, a middle domain, which is involved in homo-
oligomerization and a C-terminal GTPase effector domain, which serves primarily to 
detect viral target structures (65, 183). The murine Mx1 has a nuclear localization 
signal and therefore localizes in the nucleus, in contrast to the cytoplasmic human MxA 
(183). The antiviral mechanism of Mx has been extensively investigated by using 
primarily murine Mx1, as Mx1-positive mice have proven to be a suitable model 
organism for in vivo studies with influenza (49, 51, 182) and since Mx1-expressing 
swiss 3T3 cells efficiently interfere with primary transcription of influenza A viruses 
(143). However, despite its different localization, human MxA is able to inhibit early 
steps of influenza A virus replication, but primary transcription seems not to be affected 
(116). Despite these differences, Mx1 and MxA seem to recognize the same viral 
target structures. By insertion of a nuclear localization signal, MxA localizes into the 
nucleus and is able to interfere with the primary transcription, as Mx1 (183). The 
general mechanism of action thus seems to be indistinguishable between Mx1 and 
MxA. The N-terminal GTPase domain is crucial, as point mutations in Mx1 (K49A) and 
MxA (T103A) that prevent GTP hydrolysis, diminish the antiviral activity (121, 122). 
Mx1 and MxA interfere with the replication of all influenza A viruses. Nevertheless the 
degree of antiviral effect differs strongly between different strains. Influenza A viruses 
of avian origin show a Mx-sensitive phenotype, whereas human influenza A viruses 
show a relatively resistant phenotype (30). The artificial exchange of gene segments in 
a polymerase reconstitution system co-transfected with Mx expression plasmid 
revealed that NP is the determinant of Mx-sensitivity, which is further underscored by a 
physical interaction of MxA with the influenza NP (158). The strong sensitivity 
conferred by avian influenza NP might be explained by the observation that avian Mx 
appears to possess no protective function against influenza A viruses (134). Porcine 
Mx on the other hand is highly polymorphic, but so far tested porcine Mx only shows 
intermediate antiviral activity against infuenza A viruses (100, 113, 114). 
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1.7 Objectives of the underlying thesis 
 
Zoonotic transmission poses a constant risk for the introduction of novel avian 
influenza viruses into the human population. Therefore, to identify and characterize 
host specificity determinants that drive the emergence of new pandemic influenza 
strains and to develop strategies to fight newly emerging influenza A viruses is of 
upmost importance. In this study we were analyzing the human H5N1 isolate 
A/Thailand/1(KAN-1)/2004 (KAN-1) of a fatal case to identify adaptive mechanisms and 
the potential of KAN-1 to serve as a basis for a live attenuated vaccine. 
 
• In a first approach, we wanted to investigate and characterize adaptive 
mutations in KAN-1 enabling efficient infection and replication in human cells. We 
especially focused on a polymorphism in the hemagglutinin of this human H5N1 isolate 
and wanted to determine viral growth and organ tropism in mice. Based on a predicted 
avian precursor virus of KAN-1, we intended to identify adaptive mutations in the 
polymerase and NEP and analyze the principle defect of avian influenza polymerases 
restricting virus replication in human cells. 
 
• As H5N1 viruses are to date unable to efficiently transmit in the human 
population, we hypothesized that KAN-1 might be insufficiently adapted to the innate 
immune system of humans, particularly to the human antiviral protein MxA. We 
therefore compared the sensitivity of the KAN-1 polymerase towards Mx proteins in cell 
culture and suitable mouse models to the pandemic strain from 2009. 
 
• The pandemic potential of H5N1 viruses requires a fast and flexible vaccine 
development. By targeting the highly conserved PB1-PA binding domain in the 
influenza A polymerase, we wanted to provide proof of principle for a new strategy to 
attenuate influenza viruses for the optimization of live attenuated influenza vaccines. 
This strategy might be attributable for seasonal as well as H5N1 and other influenza A 
viruses with pandemic potential. 
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2 Results and discussion 
 
2.1 Identification and characterization of a polymorphism in 
the HA 
 
The objective of this thesis was, to characterize the human H5N1 isolate 
A/Thailand/1(KAN-1)/2004 (KAN-1) to gain increased understanding of adaptive 
mechanisms that enable avian influenza viruses to cross the species barrier to 
humans. In a first step, we started sequencing the open reading frames of the 
complete viral genome of the KAN-1 virus stock passaged three times in MDCKII cells. 
As the hemagglutinin is a fundamental factor for adaptation of avian viruses to 
mammals, we analyzed the sequence of the hemagglutinin gene of the KAN-1 virus 
stock first. Interestingly, we identified a non-synonymous adenine / guanine 
polymorphism with 
similar nucleotide ratios 
present in the HA 
segment (Figure 5A). 
This nucleotide 
heterogeneity either 
encodes a lysine or a 
glutamate at amino acid 
position 222 (H3 
nomenclature) of the HA 
protein. The H5N1 consensus sequence has a lysine at this position. The 
polymorphism at position 222 of the HA was also identified in a report, where the 
authors analyzed viral quasispecies in tissues of H5N1 infected persons (74), including 
the patient infected with KAN-1. Since the published crystal structure of the HA 
revealed that position 222 is located in the receptor binding domain (148) and the 
hemagglutinin protein has been previously described to be crucial for host switch (42), 
we addressed the potential biological function of the identified heterogeneity and 
infected BALB/c mice with the KAN-1 virus stock. The polymorphism was retained in 
the extracted lung RNA, while only the lysine variant of KAN-1 was found in the brain 
(Figure 5B), suggesting a different organ tropism of the two virus variants. To further 
investigate this point, we generated recombinant viruses and tested these for 
pathogenicity and organ tropism in BALB/c mice. rKAN-1 HA222K revealed a higher 
pathogenicity with a LD50 of 3 PFU compared to rKAN-1 HA222E with a LD50 of 200 PFU. 
Fig. 5: Sequence analysis of the KAN-1 hemagglutinin. 
Nucleotide position 725-733 of the hemagglutinin gene 
sequence obtained from RT-PCR products are shown of (A) 
the KAN-1 isolate virus stock and (B) viral RNA isolated from 
indicated mouse organs 6 days post infection with an 
infectious dose of 1000 PFU of the KAN-1 isolate.  
A   B 
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Thus, HA222E, which was positively selected in the human lung, showed to be less 
virulent in the mouse model, whereas HA222K showed to be more virulent. This is in line 
with the strong brain tropism and high viral titers in the brain of rKAN-1 HA222K infected 
animals (86, manuscript 3.1). Human H5N1 infections are also associated with viral 
dissemination to the brain (41), which is unusual for influenza infections in general. 
Mimicking these infections in humans, H5N1 viruses were also reported to have a 
strong brain tropism in mice (84). 
Surprisingly, lung titers of mice infected with rKAN-1 HA222E were higher at all 
investigated time points (86, manuscript 3.1). Viruses isolated from mouse brain 
tissue infected with this virus showed a HAE222K reversion, indicating that the HAK222E 
mutation indeed increases replication efficiency in the lung, while lowering replication 
efficiency in the brain. Thus, we could show a positive effect of the HAK222E mutation on 
replication kinetics in the lung of mice, while the mutation resulted in a disadvantage in 
replication in the brain. Concluding, the heterogeneity in HA222 was likely retained by 
KAN-1 to maintain tissue tropism for efficient replication in both the lung and the brain.  
Although the mouse model is discussed controversially for influenza research because 
mice are not a natural influenza virus host and several parameters are different to 
humans, e.g. receptor distribution and immune system (108), we could demonstrate 
that the positive effect of the mutation selected in the human lung can be also shown in 
the mouse lung. However, the finding that increased replication efficiency in the lung 
does not correlate with higher virulence is rarely observed. Possibly, it reflects the 
limitations of the mouse model, since heavy brain infections as seen in the mouse, 
were only rarely found in humans (41). To address this, we tested the KAN-1 virus in 
the ferret model, which is considerd a more suitable animal model to mimic influenza 
disease than the mouse model (108). In the ferret model, KAN-1 replicated to high 
titers in the brain and sequencing of viral RNA in the brain again only revealed the 
HA222K variant of KAN-1 (Holznagel et al., submitted, data not shown). Sequence 
analysis of the lung showed to be heterogeneous for aa position 222, as seen in the 
mouse lung. Thus, the ferret model confirmed our mouse data, suggesting that aa 
position 222 in the hemagglutinin indeed is responsible for an altered organ tropism. 
Remarkably, seasonal human strains exhibit high replication efficiency in humans, 
while not causing strong tissue damage like observed with H5N1 infections. An 
adaptation to a new host that is accompanied with lower pathogenicity is a widespread 
phenomenon and seems to be important for co-evolution (14). Adaptational mutations 
in the HA are frequently associated with a switch in receptor binding preference. 
Whereas avian influenza viruses bind preferentially to α-2,3 linked sialic acids, 
seasonal human isolates bind α-2,6 linked sialic acids (12, 64). Receptor-binding 
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studies revealed that, as expected, the common avian HA222K variant bound efficiently 
to α-2,3 whereas there was no binding detected to α-2,6 linked sialic acids. The HA222E 
variant did not increase α-2,6 binding, but even reduced binding to α-2,3 linked sialic 
acids, except for the Su-SLex analogue (86, manuscript 3.1). Reduced binding to α-
2,3 linked sialic acids is an advantage in the human lung, as these receptors are often 
found on airway mucus (27) and binding of the virus to mucins would impair viral 
spread. Although the increased binding property to the analogue Su-SLex might have 
just happened by coincidence, a positive effect for the virus can’t be excluded. For 
instance, cells from the immune system could be targeted and neutralized by this 
altered receptor preference, resulting in lower virus clearance. 
Concluding from this part of the data, we studied the mutation HAK222E that was 
positively selected in the human lung and could show increased replication in the 
mouse lung and human airway cells. The data of Konchanagul et al. show additional 
positive selected mutations in the HA segment isolated from the KAN-1 infected patient 
(74). However, none of these mutations show a frequency high enough to be present in 
the consensus sequence of KAN-1. These quasispecies were most likely 
counterselected, as the virus stock we were analyzing was passaged multiple times in 
MDCK cells. The viral quasispecies are important for propagation of mutant viruses 
and often do not show up in sequence databases. As human infections with H5N1 are 
mostly infections where the virus doesn´t transmit to other humans (dead end), these 
mutant viruses are lost before they can further adapt and propagate in the human 
population. Nevertheless it is important to study these early stages of adaptation to 
humans, to predict emerging viruses with the potential to spread from human to 
human.  
 
2.2 Adaptation of an avian precursor of KAN-1 to humans 
 
The mutation HAK222E in the HA protein increased replication of the KAN-1 virus in the 
lung, but did not account for the high pathogenicity of the virus in mice. Therefore, we 
wanted to investigate the adaptation process that conferred the high virulence of rKAN-
1 HA222K (as follows named KAN-1) in mammals. Analysis of the complete KAN-1 
genome revealed no further heterogeneities, but a comparison to avian H5N1 strains 
revealed possible adaptive mutations. To identify pathogenicity determinants usually 
an isolate being highly pathogenic in a certain animal model is compared to a virus 
comprising low pathogenicity in this system. In recent studies, these viruses differed 
often by 32-50 mutations (79, 130), mostly due to divergent evolution in avian hosts. In 
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the case of KAN-1, we wanted to investigate the mutations that were acquired by the 
virus to gain the ability to replicate efficiently in mammals. To understand the evolution 
of this virus isolate a direct avian precursor virus of KAN-1 needed to be identified. 
However, due to the rapid evolution of avian viruses in birds (181), it is difficult to 
isolate a direct precursor of a human isolate and in the case of KAN-1 no direct 
precursor is available. Therefore we used the influenza sequence database to model a 
potential avian precursor virus. By analyzing the available genome sequences, we 
could show that KAN-1 differs from the consensus sequence of avian H5N1 isolates in 
Thailand in 2003-2004 by only 9 amino acids. Seven of these amino acids were unique 
for KAN-1 and not common for avian isolates and therefore mutating these to avian-like 
aa most likely represents the avian precursor virus of KAN-1 (AvianPr). However, we 
were not able to identify an avian isolate with exactly the same sequence, most likely 
due to the high mutation rate of influenza viruses, but several isolates share a very 
similar sequence pattern e.g. VSMU (A/open-bill stork/Thailand/VSMU-20-AYA/2004 
(H5N1)) with only three different amino acids, one in HA, M1 and M2, respectively 
(Mänz et al., submitted, manuscript 3.2). 
 
2.2.1 Identification of adaptive mutations in the polymerase 
 
We hypothesized that AvianPr would be attenuated in mammals. Indeed, infection of 
BALB/c mice revealed that AvianPr is attenuated by about 3 log10 compared to KAN-1 
(Mänz et al., submitted, manuscript 3.2). The possible mutations responsible for this 
difference in pathogenicity are spread over the five genes PB2, PB1, PA, NA and NS. 
To find out which genes contribute to the high pathogenicity of KAN-1, we created 
reassortant viruses between KAN-1 and AvianPr. Besides the hemagglutinin, the 
polymerase was shown to play a crucial role in adapting avian influenza viruses to 
mammals (3, 56, 130). As the three polymerase proteins PB2, PB1 and PA build a 
functional complex, we examined the four amino acid differences in the polymerase in 
Fig. 6: The KAN-1 virus carries multiple adaptive mutations beside the hemagglutinin  
(A) Characterization of reassortant viruses of KAN-1 and AvianPr in BALB/c mice.  
(B) Reporter activity of indicated polymerases in the polymerase reconstitution assay. 
See also Manuscript 3.2. Fig. 1b and 2a 
A            B 
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conjunction. Additionally, we substituted amino acids of the NA- and NS-segment. 
Determination of the LD50 of the reassortant viruses revealed as expected a strong 
contribution of the four mutations found in the KAN-1 polymerase, as AvianPr-3P-KAN-
1 showed a reduction of LD50 by 1.9 log10 (Figure 6A). Interestingly, also the single 
mutations in NS and NA reduced the LD50 by 0.7 and 0.4 log10 respectively. To dissect 
the role of the single mutations in the polymerase, we were taking advantage of the 
polymerase reconstitution assay (minireplicon). Avian polymerases were demonstrated 
to comprise only low activity, while human isolates as shown for the isolate A/Viet 
Nam/1203/2004 (H5N1) (Vn-1203) show high polymerase activity in human cells (130). 
The mutation E627K in PB2 was shown to restore efficient replication in humans. 
Interestingly, KAN-1 is lacking the adaptive mutation E627K, which suggests the 
presence of other compensatory mutations in the polymerase. Thus we compared the 
AvianPr, AvianPr-PB2-E627K, KAN-1 and Vn-1203 polymerases in the minireplicon 
system to estimate their activity level (Figure 6B). Although an increase in activity of 
the KAN-1 polymerase compared to AvianPr polymerase could be observed, the 
activity stayed one to two log10 below the activity of the Vn-1203 or AvianPr-PB2-
E627K polymerases at 6, 9 and 12 hours post transfection. This suggested that the 
adaptive mutations in the KAN-1 polymerase are far less efficient in increasing the 
polymerase activity in human cells than for the Vn-1203 polymerase. In the avian cell-
line LMH, all polymerases exhibited high polymerase activity in the polymerase 
reconstitution assay, proving that the AvianPr polymerase is active in avian cells (Mänz 
et al., submitted, manuscript 3.2). The lack of enhanced activity of the KAN-1 and 
Vn-1203 polymerases in avian cells might be attributed to mutations that increase or 
decrease interaction with cellular factors that differ between human and avian cells, as 
suggested by others (95, 97), or that the experimental system does not allow for 
discrimination, as the AvianPr polymerase already exhibits high activity in avian cells. 
Interestingly, when examining the single mutations that were responsible for increased 
activity in mammalian cells, we identified PB2-E627K and PA-K142E for Vn-1203 and 
PB2-D701N and PA-K142R for KAN-1 (Mänz et al., submitted, manuscript 3.2). Both 
viruses acquired an adaptive mutation in the C-terminus of the PB2 Protein and 
additionally a mutation at the same aa position (K142) of the PA Protein. PA-K142E 
was reported before to increase virulence of an H5N1 virus in mice (71), hence here 
we show that the increased virulence might result from the higher polymerase activity 
in mammals. Surprisingly KAN-1 carries a mutation at exactly the same position as Vn-
1203, but this position is changed to a completely different amino acid. As the N-
terminus of PA influences promoter binding (67), the position 142 might be involved in 
the regulation of the synthesis of the three different RNA species. 
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2.2.2 Avian influenza polymerases compensate a replication defect to 
facilitate efficient replication in mammals 
 
As previously described, avian influenza polymerases comprise high activity in avian 
cells, while in mammalian cells the activity is strongly reduced. We wanted to know, if 
the synthesis of all three viral RNA species is inhibited in mammalian cells, or if only a 
sub-step is affected. Others examined before the levels of the three viral RNA species 
and observed a strong reduction of all RNA species in human cells with an avian 
influenza polymerase compared to a human influenza polymerase (94). Because of the 
strong interdependency of the viral RNAs (cRNA and mRNA levels are dependent on 
the vRNA template, vRNA levels are dependent on cRNA levels), no conclusion could 
be drawn weather the defect of the avian influenza polymerase is a general defect in all 
three steps of viral RNA synthesis, or just an intermediate step in RNA replication. 
There were several hints towards a defect being restricted to RNA replication. 
Mutations at positions 3, 5, 8 in the vRNA (up-promoter) resulted in almost 100% 
activity of an avian polymerase in a polymerase reconstitution system (28). 
Furthermore in vitro experiments mimicking primed transcription did not show 
significant difference between a polymerase containing PB2-627E or PB2-627K 
(unpublished data).  Therefore, we speculated that the low level of mRNA transcripts in 
human cells produced by avian polymerases is due to low availability of vRNA 
template. To prove this hypothesis, we used a polymerase complementation assay. 
The replication competent polymerase AvianPr-PB2-E627K was mutated in the cap-
binding domain (PB2-361A, PB2-404A) to abrogate cap-binding and therefore lacks 
mRNA synthesis (Figure 7A,B, panel 3). The AvianPr polymerase that only shows very 
poor activity (Figure 7A,B, panel 2) was able to complement the transcription deficient 
polymerase and lead to full activity (Figure 7A,B, panel 4). Thus an avian polymerase 
Fig. 7: Complementation assay. (A) Schematic overview of the assay. The transcription inactive 
polymerase containing PB2-E627K-Tr-def was complemented with the AvianPr polymerase in the 
polymerase reconstitution assay. (B) Primer extension assay was performed to analyse the three 
viral RNA species.  
See also Manuscript 3.2 Fig. 3a,b 
A                          B 1        2       3       4           1    2    3    4 
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is able to transcribe a provided encapsidated vRNA template to mRNA. If the avian 
polymerase can also utilize cRNA provided by the transcription deficient polymerase 
has to be further analyzed. To prove this observation in a setting of a viral infection, we 
infected cycloheximide treated HEK-293T cells with the recombinant viruses AvianPr, 
or AvianPr-PB2-E627K, respectively. As both polymerases showed the same mRNA 
transcription level (Mänz et al., submitted, manuscript 3.2), we conclude that PB2-
E627K does not increase the transcription rate, but very efficiently boosts the 
replication rate of the polymerase. Additionally, substantial amounts of cRNAs are 
generated by the AvianPr polymerase. However, these transcripts are not bona fide 
templates for generating vRNA copies. Most strikingly, the avian and even the AvianPr-
PB2-E627K polymerase are unable to use these cRNAs, highlighting the intrinsic 
defect of these transcripts. Interestingly, the AvianPr polymerase is able to synthesize 
vRNA from cRNA transcripts provided by infection with the AvianPr-PB2-E627K virus, 
indicating that the AvianPr polymerase is able to synthesize all three viral RNA 
species, when an adequate template is provided (Mänz et al., submitted, manuscript 
3.2). Adaptive mutations in the KAN-1 polymerase also increase RNA replication 
(Mänz et al., submitted, manuscript 3.2). Thus, after crossing the species barrier to 
humans, the defect in replication has to be compensated by adaptive mutations in the 
polymerase or other proteins as discussed below. 
 
2.3 Identification of NEP as a new pathogenicity factor 
 
Although we previously showed that the mutations in the KAN-1 polymerase 
compensate partially for the lack of PB2-E627K (Figure 6B), we observed a strong 
delay of the KAN-1 polymerase in reporter activity compared to AvianPr-PB2-E627K or 
Vn-1203 polymerases (Figure 6B). As KAN-1 is an extremely virulent virus, 
comparable to Vn-1203 (47), it was unlikely that its polymerase activity in the 
reconstituted polymerase system is sufficient to confer this high pathogenicity in a viral 
infection. The observation that the KAN-1 NS segment was needed to prevent adaptive 
mutations in infected mice makes the possibility likely that NS1 or NEP is a cofactor for 
efficient KAN-1 polymerase activity (Mänz et al., submitted, manuscript 3.2). Due to 
the data presented in 2.2.2 that avian polymerases are forced to compensate a 
replication defect in human cells, we considered the NEP protein as an interesting 
target, as it was shown by others to increase the replication capability of influenza 
polymerases (128). Coexpression of KAN-1 NEP in the minireplicon assay indeed 
increased the reporter activity (Figure 8B). AvianPr NEP reduced the reporter activity 
  Results and discussion 
 21 
slightly at 25ng coexpressed NEP expression plasmid. To investigate if there is a  
replication enhancing effect of NEP on the AvianPr polymerase, we performed a primer 
extension assay to 
measure mRNA, cRNA 
and vRNA levels (Figure 
8A). Coexpression of 
AvianPr NEP showed an 
increase in cRNA level, 
but no change in mRNA 
and vRNA level, 
indicating that AvianPr 
NEP is active, but lacks 
the ability to efficiently 
boost AvianPr 
polymerase activity. 
Astonishingly, KAN-1 
NEP strongly increased all three RNA species, but most prominently cRNA and vRNA 
levels. Although we cannot exclude a direct effect of KAN-1 NEP on mRNA levels, we 
favor the hypothesis that the increase in mRNA level is due to an increase in vRNA 
template. Thus, KAN-1 NEP can efficiently compensate the replication defect of avian 
polymerases in mammals. To investigate if the positive effect of KAN-1 NEP can also 
be seen in a viral infection, we infected human cells with the recombinant viruses 
AvianPr and AvianPr-NS-KAN-1. Primer extension analysis revealed a strong increase 
in all three RNA species of AvianPr-NS-KAN-1 infected cells, compared to AvianPr 
infected cells (Mänz et al., submitted, manuscript 3.2). To investigate, if adaptive 
mutations in NEP are a general mechanism for H5N1 viruses to adapt to humans, we 
used the sequence database and screened for mutations that were present in human 
H5N1 isolates, but absent in avian isolates. We were able to identify several amino 
acids with adaptive potential. AvianPr NEP with the potential adaptive mutations 41C 
and 75G was tested in the minireplicon system. Additionally we included the mutation 
NEP-7L that is common in the Indonesian H5N1 lineage that caused most of the 
human H5N1 infections while retaining PB2-627E to 89%. We were also interested in 
the NEP of the 2009 pandemic H1N1 (NEP-CA/04), as these viruses comprise PB2-
627E. Interestingly all human isolates possessing PB2-627E were shown to code for 
an NEP with reporter activity enhancing function, indicating a common adaptive 
mechanism (Figure 8B). In contrast, avian isolates and the human isolate Vn-1203 
possessing PB2-627K did not show an enhancing activity compared to KAN-1 NEP. 
 
Fig. 8: Adaptive mutations in NEP increase polymerase 
activity. Polymerase reconstitution assay performed using 
AvianPr polymerase and co-expression of 25 ng empty vector or 
the indicated NEP expression plasmid. (A) mRNA, cRNA and 
vRNA levels were measured by primer extension assay. Co-
expression of KAN-1 NEP leads to enhanced levels of all three 
viral RNAs. (B) Adaptive mutations in NEP of human PB2-627E 
viruses increase reporter activity. * NEP-Vn-1203, ** NEP-KAN-1 
 
A    B 
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Interestingly, the NEP-7L mutation that is found in all avian and human isolates of the 
Indonesian H5N1 lineage increased AvianPr polymerase activity to intermediate levels. 
As infections of humans in Indonesia occurred relatively often, the NEP-7L mutation 
might contribute to the infectivity of these virus strains, by enabling the virus a basal 
replication in humans. This enhanced replication would raise the probability of the 
H5N1 virus to acquire adaptive mutations and therefore increase the chance of a 
productive infection and disease in the human host.  
Our data indicate for the first time that the NEP protein of influenza can act as a 
pathogenicity factor. Although we can only speculate about the mechanism by which 
NEP increases the replication activity of influenza polymerases, we could demonstrate 
that NEP specifically associates with the PB1 and PB2 subunits (Mänz et al., 
submitted, manuscript 3.2). In our model, this interaction might also help to stabilize 
cRNPs by direct contact with the polymerase. Furthermore, we provide a link between 
the adaptive mutation E627K in PB2 and adaptive mutations in NEP, since both 
increase the replication capability of avian influenza polymerases in human cells to 
overcome the restriction in the new host.  
The restriction phenotype has been studied in detail, however many aspects remain 
elusive. As influenza viruses replicate in the intestine of the avian host at 42°C and in 
the human upper respiratory tract at 33°C, there might be a great discrepancy in 
optimal temperature of avian and human influenza polymerases (57). Indeed, shifting 
the temperature in human cells changes the relative polymerase activities of human 
and avian polymerases, but the general defect of avian polymerases in human cells 
remains (89). Inefficient binding of the polymerase to NP was suggested to hamper 
avian polymerases in mammalian cells (75), but the inefficient NP-polymerase 
interaction might be just the result of a low polymerase activity, as described by Resa-
Infante et al. (126). Additionally, insufficient adaptation to human importin α was found 
to be a reason for the restriction of avian influenza polymerases in humans (39, 40). 
Importin α might be required for the formation of an active polymerase complex (16). 
Interestingly, the mechanistical function of the first and still most frequent occurring 
mutation discovered to overcome the restriction of avian influenza polymerases in 
human cells (PB2-E627K) is not known. Polymerases change their conformation 
substantially during their phases of transcription as exemplified by the T7 polymerase 
(32). It is therefore likely that the influenza polymerase exists in different conformations 
for mRNA, cRNA and vRNA synthesis. One of these conformational changes that are 
needed to fulfill all functions necessary for a complete replication cycle might be 
restricted in human cells. This would explain, why avian polymerases are still able to 
perform primed transcription, but are unable to synthesize bona fide cRNA templates. 
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The NEP protein might be a cofactor enabling the influenza polymerase to change its 
conformation suitable for replication. The interaction of NEP with RNPs (21) together 
with the finding that NEP binds to PB1 and PB2 (Mänz et al., submitted, manuscript 
3.2) strongly supports this hypothesis. If the interaction is direct or indirect and whether 
binding to PB1 or PB2 is important for the replication enhancing function still has to be 
proven. However, we favor the model of a direct interaction of NEP with PB2 that 
influences the conformation of the RNP and subsequently stabilizes the viral RNA. 
Adaptive mutations in the polymerase like PB2-E627K might also change the 
preference of the influenza polymerase to change its conformation. This would suggest 
a more intrinsic effect of the adaptive mutations on the viral polymerase in avian as 
well as human cells. Another possibility as the defect of avian polymerases in humans 
might be a lack of efficient encapsidation of the newly synthesized cRNA. This would 
render the resulting cRNPs unsuitable targets for further replication and even would 
make the cRNA prone for rapid degradation. 
 
2.4 Role of the antiviral protein Mx in influenza evolution 
 
Although the KAN-1 virus like other human H5N1 isolates is highly virulent in 
mammalian animal models and a boy succumbed to the KAN-1 infection, H5N1 viruses 
are to date very inefficient in spreading in the human population. We showed that the 
adaptive mutations in the KAN-1 genome mainly influence polymerase activity (PB2, 
PA and NEP) or are found in the glycoproteins (HA, NA). These mutations are 
sufficient for replication, but seem to be insufficient for transmission. Thus, the 
adaptation process of human H5N1 viruses is not completed. It is of importance to 
identify the missing link to a completely human adapted virus. 
One of these missing factors might be adaptation to the antiviral protein Mx, which 
counteracts influenza virus replication efficiently. This antiviral effect was shown to be 
most prominent against avian influenza viruses, while seasonal human isolates and the 
pandemic virus A/Brevig Mission/1/1918 (H1N1) (1918) showed to be relatively 
resistant (30). The viral factor that is decisive for resistance or sensitivity to Mx in the 
minireplicon system has been identified to be the nucleoprotein NP (30). 
Although the human H5N1 isolate Vn-1203 harbors several adaptive mutations, this 
virus was shown to be highly sensitive to the antiviral activity of Mx (131, 157). As Vn-
1203 and KAN-1 share the same amino acid sequence in the NP, KAN-1 was expected 
to be sensitive to Mx as well. We therefore used KAN-1 as a tool to identify the 
determinants of Mx resistance in vitro and in vivo.  
  Results and discussion 
 24 
2.4.1 The viral NP determines Mx sensitivity in vivo 
 
We hypothesized that viruses that spread efficiently in the human population would 
prove Mx resistant in vivo, in contrast to avian viruses, which should be sensitive. 
Therefore, to analyze whether the viral NP is the determinant of Mx sensitivity in vivo, 
we first compared KAN-1 (H5N1) and the pandemic H1N1 virus from 2009 (pH1N1) in 
the minireplicon. We chose pH1N1 since its NP gene originated from classical swine 
flu viruses and we speculated that it should have acquired mutations that would confer 
Mx resistance. Furthermore, since the pH1N1 has only circulated in humans for a 
restricted timeframe, additional mutations acquired during this short time might have 
increased its Mx resistance. This would put us in a position to not only confirm NP as a 
determinant for Mx sensitivity in vivo but to additionally identify the specific amino acid 
residues that confer resistance or sensitivity. 
Indeed, the H5N1 polymerase and NP showed to be sensitive, while the pH1N1 
polymerase and NP were relatively resistant towards the antiviral activity of Mx (Figure 
9A). Exchange of polymerase subunits and the NP confirmed that the NP is the 
determinant of Mx sensitivity in vitro for this virus pair (Figure 9B).  
To test if this is also the case in a viral infection, we created the recombinant viruses 
H5N1 and H5N1 coding for the NP of pH1N1 (H5N1-NP(pH1N1)) and infected cells 
stably expressing the antiviral protein Mx1, MxA or an empty vector (NEO). Western 
blot analysis revealed efficient expression of viral proteins of both viruses in Neo cells. 
PA levels were strongly reduced in Mx1 and MxA expressing cells infected with H5N1, 
while PA levels were only slightly reduced in H5N1-NP(pH1N1) infected cells (182, 
manuscript 3.3). We next infected MDCKII cells lacking an antiviral active Mx-protein 
with H5N1 or H5N1-NP(pH1N1), respectively. H5N1-NP(pH1N1) showed a delayed 
growth rate, indicating that the NP of pH1N1 might attenuate the H5N1 virus. 
Astonishing, despite the attenuated phenotype of H5N1-NP(pH1N1) in cells lacking the 
Fig. 9: The viral nucleoprotein is the determinant of Mx-sensitivity in vitro and in vivo. (A) 
Reporter activity of H5N1 is strongly restricted by Mx1 in the minireplicon system, while reporter 
activity of pH1N1 is only slightly reduced by the antiviral activity of Mx1. (B) The nucleoprotein of 
pH1N1 renders H5N1 relatively resistant to Mx1 in vitro. (C) BALB/A2G/-Mx1 mice were infected 
with 2*106 PFU of H5N1 or H5N1-NP(pH1N1). While all mice infected with KAN-1 survived the 
infection, 88% of mice infected with H5N1-NP(pH1N1) succumbed the infection. 
See also Manuscript 3.3 Fig. 1A,D and Fig. 4G.  
A     B       C 
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antiviral protein Mx and reduced titers in Mx negative mice, this virus showed 
increased pathogenicity in the Mx positive mouse strain BALB/A2G/-Mx1 (Figure 9C). 
This confirmed that the viral NP is the determinant of Mx sensitivity not only in vitro, but 
also in vivo and that in contrast to pH1N1, H5N1 viruses such as KAN-1 did not acquire 
Mx-resistance enhancing mutations. Interestingly the reassortant KAN-1 virus carrying 
the NP of pH1N1 was attenuated (182, manuscript 3.3) making it unlikely that this 
reassortant virus will evolve in nature. 
 
2.4.2 Identification of mutations in NP conferring Mx-resistance 
 
Our data in 2.4.1 together with the work of others (30) indicate that adaptation to the 
human antiviral protein MxA is very important for the propagation of a virus in the 
human population. We also wanted to know whether the attenuation of KAN-1 carrying 
the pH1N1 NP is due to the Mx-resistance enhancing mutations. This might explain, 
why H5N1 viruses did not efficiently acquire Mx-resistance enhancing mutations and 
did not yet spread efficiently in the human population. Obtaining knowledge about 
these mutations would improve our understanding of the adaptation process of avian 
influenza viruses that cross the species barrier to humans and potential dangerous 
viruses could be identified at an early stage of adaptation. Additionally, these mutations 
might provide a powerful tool to investigate the molecular mechanism of Mx. We 
showed before that the KAN-1 virus is sensitive to the antiviral effect of Mx and 
therefore might be a good tool to study these mutations. The pH1N1 NP is able to 
render KAN-1 Mx resistant. Thus, some of the amino acid differences between KAN-1 
and pH1N1 NP should be responsible for the difference in Mx sensitivity. Unfortunately 
these two viruses differ in 32 amino acids. As it is unlikely that the resistance conferred 
by pH1N1 NP is caused by only one amino acid, we were looking for a more suitable 
virus possessing an NP that confers high resistance to Mx and displays less amino 
acids differences. We identified the NP of the 1918 pandemic virus as a suitable target, 
as its amino acid sequence is still very avian like (155), but can confer high Mx 
resistance in the minireplicon system (30). The 14 amino acid differences between 
KAN-1 and 1918 NP are spread over the whole protein. Exchanging amino acids in the 
KAN-1 background towards 1918 NP, we identified the mutations R100I/V, L283P and 
F313Y to be crucial in mediating resistance to Mx1 in the minireplicon system (31). To 
investigate the importance of these mutations in a viral infection, we first created 
recombinant A/Puerto Rico/8/1934 (H1N1) (PR8) virus that is highly virulent for Mx 
positive mice (49), and the two mutant viruses PR8-NP-V100R, P283L and PR8-NP-
P283L, Y313F that each lack two Mx-resistance conferring mutations. Infection of Mx-
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negative B6 mice revealed no change in virulence of the mutant viruses. Astonishingly, 
infection of Mx-positive mice revealed an increased LD50 value of 2,5 and 3,8 log10 of 
the mutant viruses compared to PR8 WT (Figure 10A). This further highlights these 
mutations as essential for Mx-resistance of PR8. To investigate, if these mutations can 
also confer Mx-resistance to the sensitive KAN-1 virus, we created recombinant KAN-1 
viruses harboring the 100V, 283P, 313Y triple mutations, the 100V, 313Y mutations, or 
only the 283P mutation. A growth curve performed in MDCKII cells revealed a one to 
two log10 attenuation due to the introduced mutations for KAN-1-NP-283P and KAN-1-
NP-100V,283P,313Y (Figure 10B), as examined before with the H5N1-NP(pH1N1) 
virus. KAN-1-NP-100V,313Y showed a delayed growth phenotype, but catches up with 
wt 24 hours post infection (Figure 10B). As KAN-1-NP-100V-313Y showed only slight 
attenuation, we infected 
BALB/A2G/-Mx1 mice with 106 
PFU and analyzed weight 
changes for 12 days. The KAN-1-
NP-100V-313Y virus containing 
two amino acids that confer 
partial resistance to Mx1 exhibited 
higher pathogenicity than the wild 
type KAN-1 virus (Figure 10C). 
These data confirm the 
importance of Mx-resistance 
enhancing mutations in the case 
of an infection under Mx pressure.  
Sequence analysis in the 
influenza database revealed that 
mutations E53D, F313V and 
I316M are unique for NP of 
pH1N1 viruses. We created recombinant viruses with these three positions mutated to 
the consensus in the classical swine influenza viruses pH1N1-NP-53E,313F,316I and 
the single mutant pH1N1-NP-53E, to see if the NP mutations in pH1N1 also attenuate 
the virus as observed for KAN-1. Indeed, growth curves in MDCKII cells revealed 
enhanced growth rate with both mutant viruses compared to pH1N1 (Figure 10D). 
Unlike the mutations observed in the polymerase, NEP and glycoproteins of KAN-1 
that are often found in human isolates, the mutations conferring Mx-resistance are only 
rarely found in human H5N1 isolates. As KAN-1 carrying one or several of these 
mutations showed to be attenuated in the absence of antiviral active Mx, we speculate 
Fig. 10: Identification of Mx-resistance conferring 
amino acids. (A) A/Puerto Rico/8/1934 (H1N1) WT 
virus (PR8) and the two mutants PR8-NP-V100R, 
P283L and PR8-NP-P283L, Y313F were tested for 
pathogenicity in Mx1 negative (B6-Mx-/-) and Mx1 
positive mice (B6-Mx+/+). (B) Growth kinetics of KAN-1 
mutant viruses in MDCKII cells. Cells were infected with 
an MOI of 0.001. (C) Mx1 positive mice (BALB/A2G/-
Mx1) were infected with 106 PFU oft he two indicated 
viruses. Weight was analysed for 12 days p.i. (D) 
Growth kinetics of pH1N1 mutant viruses in MDCKII 
cells. Cells were infected with an MOI of 0.001. 
A            B 
C            D 
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that it is far more difficult for an avian influenza virus to adapt to Mx than to have 
adaptive mutations in the polymerase. Mutations in the polymerase immediately 
improve viral growth, in contrast to mutations in NP that confer resistance to Mx. These 
mutations have an intrinsic negative effect on viral growth and only a positive effect in 
the presence of Mx. Thus it needs a fine balancing to acquire suitable mutations in NP 
that do not attenuate the virus too much, but are able to confer high Mx-resistance. 
Fortunately to date, H5N1 viruses were not able to mutate efficiently in this direction.  
 
2.5 Attenuation of influenza A viruses by targeting 
polymerase assembly 
 
The rapid evolution of influenza viruses poses a constant threat to human health. It 
remains difficult to predict a new pandemic with the emergence of dangerous viruses 
all of a sudden. Thus, it is of great concern to improve the primary defense against 
influenza viruses, the vaccines. Live attenuated viruses were shown to often produce a 
better and longer lasting immunity than inactivated vaccines. However, live attenuated 
viruses have to deal with serious safety issues, as the virus still has to replicate in the 
vaccinated person. It is difficult to generate a virus that is adequately attenuated for 
save administration, but still replicates sufficiently to be immunogenic. We wanted to 
use our findings about the polymerase complex to contribute to safety and efficiency of 
live attenuated viruses. Thereby, the creation of a live vaccine with desirable 
attenuation would be ideal. Additionally the introduced mutations should remain stable 
in the viral genome. We decided to follow up our detailed analysis of the highly 
conserved PB1-PA binding domain (174, 175). Weakening the binding between PB1 
and PA resulted in less efficient polymerase complex formation and reduced 
polymerase activity in vitro of the model virus SC35M (85, manuscript 3.4). While we 
identified several mutations with the potential to create a stable attenuated virus, we 
concentrated on the mutation PA-W706E to test its feasibility in a life attenuated KAN-1 
vaccine. As expected, introduction of the mutation PA-W706E into the genome of KAN-
1 resulted in low level of polymerase activity in the minireplicon system (data not 
shown). Recombinant viruses were strongly attenuated in cell culture and also in 
animal experiments ((85, manuscript 3.4), Figure 11A and 11B). Notably, vaccinated 
BALB/c mice with the attenuated virus KAN-1 PA706E survived an otherwise lethal 
challenge with 100 LD50 of wildtype KAN-1 virus (Figure 11C).  
These data indicate that our approach for generation of attenuated viruses can be used 
to improve available live attenuated vaccines or to generate a new live attenuated  
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vaccine by combining available strategies with our new approach. As the emergence of 
new pandemic strains is still difficult to predict, a rapid strategy to create influenza 
vaccines with high potential against all kind of influenza strains is needed. Targeting a 
highly conserved region like the PB1-PA binding domain would provide such a rapid 
strategy feasible for all known influenza A strains. 
 
2.6 Conclusions 
 
In summary, we have shown that adaptation of avian influenza viruses to humans is a 
multigenic process that we are just starting to understand. The human H5N1 isolate 
KAN-1 proved to be a powerful tool to investigate adaptive mechanisms. In this study 
we could show that an avian virus gained adaptive mutations to increase fitness in 
distinct parts of the viral life cycle. The positive selected mutation K222E in the 
hemagglutinin changes its receptor binding properties, thereby increasing replication of 
the KAN-1 virus in the lung. Adaptive mutations in the NEP protein or the polymerase 
increase genome replication and subsequently also genome expression. The 
observation that a virus can mutate either position 627 in the PB2 protein or the NEP 
protein demonstrates the flexibility of influenza viruses. However, even after enabling a 
fully competent replication cycle, influenza viruses are restricted by the human innate 
immune system. Mx resistance enhancing mutations, which seem to be a prerequisite 
of pandemic and seasonal influenza viruses, are difficult to acquire by H5N1 viruses, 
most likely one reason why H5N1 viruses did not spread efficiently in the human 
population. However, it might be that only few additional mutations enable an H5N1 
virus to efficiently spread in the human population. We therefore created a new 
strategy to attenuate influenza viruses by disruption of the polymerase formation. Due 
to its high conservation, the PB1-PA binding-domain could be a suitable target to 
improve live attenuated vaccines to be rapidly produced after emergence of a new 
dangerous influenza strain. 
Fig. 11: Polymerase assembly mutants can be used as life attenuated vaccines. 
(A,B) KAN-1 PA706E is attenuated in mice (C) Mice vaccinated with KAN-1 PA706E survive 
an otherwise lethal challenge with wildtype KAN-1. See also Manuscript 3.4 Fig. 4E 
A              B        C 
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We characterized a human H5N1 virus isolate (KAN-1) encoding a hemagglutinin (HA) with a K-to-E
substitution at amino acid position 222 that was previously described to be selected in the lung of the
infected patient. In mice, the growth of the HA222E-encoding virus was mainly confined to the lung, but
reversion to 222K allowed virus to spread to the brain. The HA222E variant showed an overall reduced
binding affinity compared to that of HA222K for synthetic Neu5Ac2-3Gal-terminated receptor analogues,
except for one analogue [Neu5Ac!2-3Gal"1–4(Fuc!1–3)(6-HSO3)GlcNAc", Su-SLe
x]. Our results sug-
gest that human-derived mutations in HA of H5N1 viruses can affect viral replication efficiency and organ
tropism.
The H5N1 avian influenza A virus is a highly contagious and
deadly pathogen in poultry (13). Although rare, infections of
humans occur and cause severe disease symptoms associated
with a high morbidity (13). Human and avian influenza A
viruses differ in the recognition of the host cell receptor (10).
Whereas human influenza A viruses preferentially bind to 2,6-
linked sialic acids, avian influenza A viruses preferentially bind
to 2,3-linked sialic acids. Although H5N1 viruses can infect
humans, they do not bind to 2,6-linked sialic acids, a property
believed to be one of the reasons for inefficient human-to-
human transmission (10). However, there is a recent report
indicating that adaptation involving changes in receptor spec-
ificity can occur in infected humans (9). In this study, the
authors analyzed viral quasispecies found in lung tissue, naso-
pharyngeal secretions, and intestinal tissue of three H5N1-
infected patients (9). Several variants with distinct mutations in
the receptor-binding site of hemagglutinin (HA) were ob-
served, including the variant with the mutation K222E (H3
numbering system), which is part of the 220 loop of the recep-
tor-binding site of HA. The aim of this study was to charac-
terize the replication efficiency and organ tropism in mice and
the receptor binding properties of the H5N1 virus with this
mutation.
The virus variant with K222E represented 45% and 6% of
the quasispecies present in the lung tissues of two out of three
patients (9). The virus A/Thailand/KAN-1/2004 (KAN-1), iso-
lated from the first patient in cell culture and passaged several
times in MDCK cells, was kindly provided to us by Pilaipan
Puthavathana (Mahidol University, Bangkok, Thailand). We
sequenced the HA gene of the virus stock and indeed revealed
the polymorphism at amino acid position 222 (Fig. 1A). Se-
quence analysis of all other open reading frames, including the
neuraminidase-encoding gene segment, did not reveal any het-
erogeneity (data not shown). Because H5N1 viruses are known
to be neurotropic (8, 18), we infected BALB/c mice with this
virus stock, collected lung and brain tissue 5 days postinfection
(p.i.), and determined the sequence of the viral HA. Whereas
both HA variants were present in the lung, we only identified
the HA222K variant in the brain (Fig. 1A), suggesting that the
polymorphism in HA affects organ tropism. To confirm these
findings, we used reverse genetics (7) to generate recombinant
KAN-1 virus encoding either HA222K (rKAN-1 HA222K) or
HA222E (rKAN-1 HA222E). For other gene segments, consen-
sus sequences were used that were determined from the virus
stock described above by sequencing overlapping reverse tran-
scription (RT)-PCR products. Comparisons of the growth char-
acteristics in various cell lines revealed that rKAN-1 HA222E
replicated slightly more efficiently in MDCK cells and A549
human lung carcinoma cells than rKAN-1 HA222K, whereas
both virus variants showed similar growth kinetics in avian
hepatoma cells (LMH) (Fig. 1B). In BALB/c mice, infection
with 100 PFU of either virus variant resulted in a pronounced
weight loss; however, in contrast to mice infected with rKAN-1
HA222K, 70% of all mice survived infection with rKAN-1
HA222E (Fig. 1C to F). The 50% lethal doses (LD50) from the
experiments whose results are shown in Fig. 1C to F were
determined as described previously (16) and revealed a 67-fold
difference between rKAN-1 HA222E (LD50 ! 200 PFU) and
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University of Freiburg, Hermann-Herder-Strasse 11, D-79104 Freiburg,
Germany. Phone: 49-761-203-6526. Fax: 49-761-203-6639. E-mail: martin
.schwemmle@uniklinik-freiburg.de.
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FIG. 1. Growth properties of KAN-1 variants with a polymorphism in HA. (A) Two 8-week-old female BALB/c mice (#1 and #2) were infected
intranasally with 103 PFU of the virus isolate A/Thailand/KAN-1/2004. Five days postinfection (p.i.), the sequences of the HA genes from lung and
brain tissue were determined and compared to the sequence obtained for the virus isolate used for infection. Sequences shown represent nucleotide
positions 725 to 733 (aa 221 to 223) of the HA gene. Arrows indicate the site of the nucleotide polymorphism. (B) Cells were infected with a
multiplicity of infection of 0.001 with rKAN-1 HA222K, rKAN-1 HA222E, or the virus isolate A/Thailand/KAN-1/2004 used in the experiment whose
results are shown in panel A. (C to F) Eight-week-old female BALB/c mice were infected intranasally with either rKAN-1 HA222K (C and D) or
rKAN-1 HA222E (E and F) using the indicated virus doses and were monitored for body weight loss and survival. Error bars show standard
deviations.
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rKAN-1 HA222K (LD50 ! 3 PFU), suggesting that rKAN-1
HA222K is more pathogenic for mice. Surprisingly, determina-
tion of the viral titers in the lung showed that rKAN-1 HA222E
replicated to higher titers than rKAN-1 HA222K at all time
points investigated (Fig. 2A). On the contrary, at 6 days postin-
fection, lower viral titers could be detected in the brain of
rKAN-1 HA222E-infected animals (Fig. 2B). Consistent with
earlier reports on H5N1-infected mice (15), only low viral
FIG. 2. Organ tropism of KAN-1 variants in mice. (A to D) Eight-week-old female BALB/c mice were infected intranasally with 1,000 PFU of either
rKAN-1 HA222K or rKAN-1 HA222E. At the indicated time points p.i., virus titers were determined in lung (A), brain (B), spleen (C), and liver (D).
Horizontal lines show the means of the results. (E) HA sequences obtained 6 days p.i. from lung and brain tissues of the BALB/c mice that were infected
with either rKAN-1 HA222E or rKAN-1 HA222K as described for panels A to D. (F) HA sequences obtained from lung and brain tissues of a BALB/c
mouse 10 days after infection with 10 PFU rKAN-1 HA222E as described for Fig. 1F. Arrows indicate the site of the nucleotide polymorphism.
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titers were observed for both virus variants in liver and spleen
of mice at 5 and 6 days postinfection (Fig. 2C and D). Inter-
estingly, sequencing analysis revealed that in all animals in-
fected with rKAN-1 HA222E, the virus isolated from the brain
was represented by a revertant with HA222K (Fig. 2E and data
not shown). However, no reversion was found in the lung of
rKAN-1 HA222E-infected animals. These results further high-
lighted the restriction of rKAN-1 HA222E to the lung. As ex-
pected, no changes in HA were observed in the lung and brain
of mice infected with rKAN-1 HA222K (Fig. 2E and data not
shown). In the lung of one mouse infected with 10 PFU, we
also observed the appearance of the mutation E222K in HA
and, as expected, only the HA222K variant in the brain (Fig.
2F). We therefore speculate that reversion to HA222K occurs in
the lung, thereby allowing virus to spread to the brain.
To verify these results with isolates of the original virus
stock, we plaque purified two viruses (ppKAN-1 HA222E and
ppKAN 1 HA222K). Both plaque-purified variants showed
characteristic differences in their plaque sizes, which resem-
bled those of the rescued viruses (Fig. 3A). With the exception
of the polymorphism in HA, both plaque-purified isolates re-
vealed complete sequence identity in all genes compared to the
rescued viruses (data not shown). Similar to the results ob-
served with the recombinant KAN-1 variants, the lung titers in
mice infected with ppKAN-1 HA222E were significantly higher
(P ! 0.05, Student’s t test) than the lung titers of ppKAN-1
HA222K at 4 days postinfection (Fig. 3B). At 6 days postinfec-
tion, high viral titers were observed in both ppKAN-1 HA222E-
and ppKAN-1 HA222K-infected animals. Consistent with the
results obtained with rKAN-1 HA222E, we only observed the
HA222K variant in the brain of all the ppKAN-1 HA222E-in-
fected animals (Fig. 3C and data not shown).
To assess the effect of K-to-E substitution in the viral HA on
the receptor-binding properties, we determined the affinity of
the viruses for synthetic sialylglycopolymers (SGPs) bearing
distinctive sialyloligosaccharide moieties as described previ-
ously (1, 5, 6, 12). The structures and designations of the
oligosaccharide parts of the SGPs are shown in Table 1.
rKAN-1 HA222K bound preferentially to Neu5Ac2-3Gal-ter-
minated receptors and displayed the highest binding affinity for
FIG. 3. Growth properties of plaque-purified KAN-1 variants. (A) Comparison of the plaque sizes of the virus isolate A/Thailand/KAN-1/2004
and its plaque-purified and recombinant variants. (B) Eight-week-old female BALB/c mice were infected as described in the Fig. 1 legend with
1,000 PFU of the indicated plaque-purified viruses. At 4 and 6 days p.i., virus titers were determined in lung and brain. Horizontal lines show the
means of the results. (C) HA sequences obtained from lung and brain tissues of two animals that were infected with either ppKAN-1 HA222E or
ppKAN-1 HA222K 6 days p.i. as described for panel B. Arrows indicate the site of the nucleotide polymorphism.
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the sulfated trisaccharide Su-3!SLN, which is a typical binding
pattern for Asian H5N1 viruses isolated from birds and hu-
mans in 1999 to 2004 (4, 17). The binding to other Neu5Ac2-
3Gal-containing receptors varied depending on the structure
of the oligosaccharide core. In particular, fucosylation of the
GlcNAc residue of Su-3!SLN decreased the binding affinity
(compare Su-3!SLN and Su-SLex), suggesting that the fucose
moiety does not fit into the receptor-binding site (4). There
was no binding to any of the Neu5Ac2-6Gal-terminated SGPs.
rKAN-1 HA222E bound more weakly than rKAN-1 HA222K
to most of the analogues tested. This result explains the reduced
hemagglutinin activity of H5N1 virus with the K222E mutation as
observed by others (2). We have looked into the prevalence of
222E in the HAs of H5 viruses in the influenza sequence
database (Influenza Virus Resource on http://www.ncbi.nlm
.nih.gov/genomes/FLU/FLU.html, accessed on 6 March 2010).
Among about 2,500 available nonredundant H5 HA1 se-
quences, only three sequences of avian viruses and one se-
quence of the human isolate studied here had E at position
222. Nineteen HAs of the H5N2 viruses from South America
and Japan contained 222Q. All other sequences contained
either K or (much less frequently) R. This analysis suggests
that a positively charged amino acid at position 222 is essential
for the survival of H5N1 virus in avian and occasional mam-
malian host species.
It is interesting that rKAN-1 HA222E is less pathogenic in
mice than the HA222K variant despite the higher lung titers of
the former virus. We speculate that the higher receptor-bind-
ing affinity of HA222K allows efficient infection of cells of the
central nervous system, resulting in enhanced pathogenicity.
This is consistent with the findings that only the HA222K vari-
ant is found in the brain of KAN-1 infected mice and that the
receptor distribution is different in brain and lung tissue (14).
We speculate that the increased LD50 of the HA222E variant
most likely reflects decreased probability of mutation to 222K
at lower infection doses.
The reasons for the apparent selection of HA222E in two
cases of human infection (9) are not clear. As noticed previ-
ously (11), a common feature of the human and swine viruses
as compared to their avian precursors is the substantially de-
creased affinity of mammalian viruses for Neu5Ac2-3Gal-con-
taining receptors. This feature may indicate that binding to
such receptors is disadvantageous for the virus’s replication in
humans, for example, owing to neutralization by decoy recep-
tors present on airway mucins (3). If this hypothesis is correct,
it could provide an explanation for the accumulation in hu-
mans of the variant with the mutation 222E and decreased
binding affinity to Neu5Ac2-3Gal-terminated oligosaccharides.
This could also explain the higher viral lung titers in mice
infected with rKAN-1 HA222E compared to the lung titers seen
with infections with the HA222K variant.
Interestingly, despite its overall reduced binding affinity,
rKAN-1 HA222E showed enhanced binding to one analogue
tested, Su-SLex, a receptor determinant commonly recognized
by poultry viruses with different HA subtypes (6, 10). It re-
mains to be determined whether enhanced binding of HA222E
to Su-SLex plays any specific role in H5N1 virus adaptation to
humans or if this effect is merely coincidental with the mu-
tation that serves to decrease viral binding to a majority of
Neu5Ac2-3Gal-containing receptors.
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Abstract 
Zoonotic transmission of avian influenza 
viruses into the human population 
requires adaptive mutations to achieve 
high-level replication in the new host. We 
provide evidence that this requirement for 
adaptation is caused by the inability of 
avian polymerases lacking the human 
signature lysine 627 in PB2 to generate 
bona fide cRNA templates in human cells. 
Characterization of the highly pathogenic 
human H5N1 isolate A/Thailand/1(KAN-
1)/2004, which contains E627, revealed 
that the RNA replication defect is only 
partially compensated by adaptive 
mutations in the KAN-1 polymerase, and 
that mutations in the nuclear export 
protein (NEP) were crucial for efficient 
polymerase activity. KAN-1 and other 
human isolates, acquired adaptive 
mutations in NEP which strongly 
enhanced the polymerase activity of avian 
polymerases in human cells, whereas 
NEP of avian isolates did not. Thus, when 
crossing the species barrier, avian 
influenza viruses acquire adaptive 
mutations in NEP to escape restricted 
viral genome replication in the 
mammalian host. 
 
Introduction 
Transmission of avian influenza viruses to 
mammals is dependent on the acquisition 
of adaptive mutations that allow efficient 
viral replication in the new host. Besides 
amino acid changes in the hemagglutinin 
and NS1 proteins1-3, mutations in the viral 
polymerase proteins have been shown to 
be major determinants of adaptation2,4,5. 
While avian influenza A virus isolates 
almost exclusively contain glutamic acid 
at position 627 in the polymerase PB2 
protein (PB2-E627), this position is 
frequently mutated to lysine in human-
derived isolates (PB2-E627K), including 
H5N1 isolates that cause a high morbidity 
in humans. Mutation to PB2-E627K was 
shown to increase viral polymerase 
activity in mammalian cells2,6, is 
accompanied by improved viral replication 
at low temperatures6,7 and enhanced 
binding of the viral polymerase to the 
nucleoprotein in human cells8. Intriguingly, 
fatal viral infections of humans with avian 
viruses of the H5N1 subtype that have 
retained the avian like PB2-E627 have 
been reported9. Moreover, the 2009 H1N1 
pandemic virus also harbors PB2-E627, 
but additionally possesses a lysine at 
position 591 (PB2-E591K), which is able 
to partially, but not completely, 
compensate for the lack of the PB2-
E627K mutation10,11, suggesting that other 
adaptive factors may account for the 
efficient replication of these viruses in 
humans. Other mutations in PB2 known 
to play a role in host adaptation are the 
exchange of aspartic acid with asparagine 
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at position 701 (PB2-D701N), which can 
confer high pathogenicity to avian H5N1 
and H7N7 viruses in mice4,12 and the 
substitution of threonine with alanine at 
position 271 (PB2-T271A) which has 
been suggested to enhance polymerase 
activity in mammalian cells13. 
Furthermore, adaptation to human 
importin α might play a crucial role in 
interspecies transmission and 
pathogenicity15,16. 
The human H5N1 isolate KAN-1 
(A/Thailand/1(KAN-1)/2004)17, originating 
from an avian influenza outbreak in 
Thailand in 2003, also encodes PB2-
E627, yet nonetheless is highly 
pathogenic in different animal models, 
including mice and ferrets14,15. To 
understand the molecular basis of this 
pathogenicity, we generated a probable 
avian precursor virus (AvianPr) of KAN-1, 
devoid of adaptive mutations. Using 
AvianPr, we could show that an avian 
influenza polymerase containing PB2-
E627 exhibits a distinct defect in vRNA 
replication in mammalian cells. This 
malfunction in vRNA replication is 
manifested by the generation of defective 
cRNPs, which cannot be utilized as 
templates for efficient vRNA synthesis. 
Furthermore, we provide evidence that 
this defect can be compensated by the 
PB2-E627K mutation or adaptive 
mutations in the nuclear export protein 
(NEP).  
 
Results 
Generation of an avian precursor virus 
of KAN-1 and identification of 
pathogenicity determinants of KAN-1 
The rapid evolution of H5N1 influenza in 
birds16 usually prevents isolation and 
assignment of a direct avian precursor to 
highly pathogenic human viruses. 
Discrimination between non-adaptive 
amino acid changes in avian isolates that 
have been acquired during circulation in 
the avian host and adaptive mutations 
that specifically facilitate infection in 
humans is a difficult task. To circumvent 
this problem, we used the influenza Virus 
Resource Database 
(http://www.ncbi.nlm.nih.gov/genomes/FL
U/FLU.html) and compared the amino 
acid sequences of various H5N1 viruses 
of avian or human origin (Supplementary 
Table 1). Reversion of non avian-like 
amino acids in the highly pathogenic 
human-derived H5N1 strain 
A/Thailand/1(KAN-1)/2004 (KAN-1) to 
avian-like residues allowed us to generate 
the sequence of a probable low 
pathogenic avian precursor virus 
(AvianPr) of KAN-1 that differs in 7 
positions in PB2, PB1, PA, NA, NS1 and 
NEP (Fig. 1a). To evaluate the 
pathogenicity of AvianPr in mammals, 
recombinant KAN-1 and AvianPr viruses 
were generated using reverse genetics17. 
Both viruses showed comparable growth 
kinetics in avian cells, whereas viral 
growth of AvianPr was strongly impaired 
in mammalian MDCK cells at 12 h p.i. by 
about three log10 compared to KAN-1 
(Supplementary Fig. S1). Similarly, 
infection of BALB/c mice revealed a 
strong attenuation of the AvianPr virus, 
demonstrated by an increase in the 50% 
lethal dose 50 (LD50) of approximately 
three log10 compared to the KAN-1 virus 
(Fig. 1b). These results suggest that the 
identified mutations in KAN-1 indeed 
contribute to the pathogenicity of this virus 
in mammalian hosts.  
To dissect the contribution of the 
individual mutations in more detail, 
reassortant viruses of the two strains 
were generated (Fig. 1b). Introduction of 
the KAN-1 polymerase into the low 
pathogenic avian precursor (AvianPr-3P-
KAN-1) resulted in reduction of the LD50 
from 103.2 to 101.3 (Fig. 1b), indicating that 
the mutations in the polymerase proteins 
are crucial for the high pathogenicity of 
the KAN-1 virus in mice. However, 
introduction of the KAN-1 NS (AvianPr-
NS-KAN-1) or NA segments (AvianPr-NA-
KAN-1) also enhanced the pathogenicity 
of AvianPr, leading to a decrease in the 
LD50 by 0.7 and 0.4 log10, respectively 
(Fig. 1b). Interestingly, AvianPr containing 
both the KAN-1 polymerase together with 
the KAN-1 NS segment (AvianPr-3P/NS-
KAN-1) was highly pathogenic with an 
LD50 of 100.8, suggesting that either NS1 
or NEP or both are important co-factors 
for KAN-1 pathogenicity. 
Although mice infected with 104 plaque 
forming units (pfu) of AvianPr succumbed 
to infection, there was a considerable 
delay in weight loss (Supplementary Fig. 
S2), suggesting the emergence of virus 
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mutants harboring disease-enhancing 
adaptive mutations. Interestingly, 
sequencing of the C-terminus of PB2 from 
infected lung tissue revealed that all 
viruses containing the avian polymerase 
acquired adaptive mutations in PB2 
during mouse infection, as well as 63 % of 
the AvianPr-3P-KAN-1 viruses containing 
the KAN-1 polymerase and 78 % of the 
AvianPr-NS-KAN-1 viruses containing the 
NS segment of KAN-1 combined with the 
AvianPr polymerase (Table 1). However, 
in mice infected with the reassortant virus 
AvianPr-3P/NS-KAN-1 harboring the 
KAN-1 polymerase and NS segment, no 
adaptive mutations in PB2 appeared, 
indicating that this virus might be 
sufficiently adapted to replicate in the 
mammalian host. 
 
Mutations in the KAN-1 polymerase 
only partially increase its activity in 
human cells 
Although introduction of the KAN-1 
polymerase increased the pathogenicity 
of AvianPr in mice, the appearance of 
compensatory mutations in PB2 during 
mouse infection suggests an incomplete 
adaptation of the KAN-1 polymerase to 
the mammalian host., We therefore 
compared the polymerase activity of KAN-
1 with the human H5N1 isolate A/Viet 
Nam/1203/2004 (Vn-1203), a highly 
active prototypical human H5N1 strain 
which encodes PB2-K627, using a 
polymerase reconstitution assay in human 
cells. For comparison we included both 
the AvianPr and an AvianPr polymerase 
containing PB2-E627K (AvianPr-PB2-
E627K). Measuring reporter gene activity 
at 3, 6, 9, 12 hours post transfection (p.t.), 
we found that the KAN-1 polymerase 
activity was approximately one log10 lower 
compared to the Vn-1203 and AvianPr-
PB2-E627K polymerases. However, after 
24 hours all three polymerases reached 
the same activity (Fig. 2a; Supplementary 
Fig. S3b), indicating that the KAN-1 
polymerase has a functional disadvantage 
in human cells, but is able to reach high 
productivity at later time points (Fig. 2a). 
As expected, the AvianPr polymerase 
lacking the adaptive mutations displayed 
the lowest polymerase activity, at least 2 
log10 less than the PB2-E627K containing 
polymerases at 9, 12 and 24 hours p.t. 
(Fig. 2a). In contrast, all polymerases 
exhibited comparable activity in avian 
LMH cells (Supplementary Fig. S4a), 
thereby confirming the functionality of the 
AvianPr polymerase, and indicating that 
the enhancing effect of the adaptive 
mutations is specific to mammalian cells. 
Detailed analysis of single amino acid 
substitutions highlighted the importance of 
the mutations PB2-D701N and PA-K142R 
for KAN-1 and PB2-E627K and PA-
K142E for Vn-1203 polymerase activity in 
mammalian but not avian cells 
(Supplementary Fig. S3a-e; 
Supplementary Fig. S4a-d). The increase 
in polymerase activity observed in human 
cells additionally correlated with 
enhanced formation of viral RNPs 
(Supplementary Fig. S5), as previously 
described8. 
Next, we performed a primer extension 
assay to analyze the accumulation of the 
three viral RNA species (mRNA, cRNA 
and vRNA) produced by the AvianPr, 
KAN-1 and AvianPr-PB2-E627K 
polymerases. In agreement with the 
results from the reporter assay (Fig. 2a), 
the AvianPr polymerase produced very 
low amounts of vRNA and mRNA and no 
detectable cRNA (Fig. 2b). Interestingly, 
the KAN-1 polymerase produced higher 
amounts of vRNA and mRNA than 
AvianPr, but,also only minor amounts of 
cRNA. In comparison, the highly active 
AvianPr-PB2-E627K polymerase 
produced high amounts of all three viral 
RNA species, correlating with the strong 
reporter gene activity in the reconstitution 
assay (Supplementary Fig. S3d). In 
summary, these results indicate that the 
adaptive mutations in the KAN-1 
polymerase are not able to fully 
compensate for the lack of PB2-E627K 
and are insufficient to reach the activity of 
the PB2-E627K containing polymerases.  
 
PB2-E627K compensates a defect in 
RNA replication of avian viruses in 
human cells 
According to the primer extension 
analysis, the AvianPr polymerase, which 
is identical to several avian isolates 
(Supplementary Table S1, data not 
shown) produces substantially lower 
amounts of viral cRNA, vRNA and mRNA 
compared to AvianPr-PB2-E627K 
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polymerase. However, it remains unclear 
if this impairment is a result of a 
deficiency in c/vRNA synthesis 
(replication), mRNA synthesis 
(transcription), or a combination thereof. 
In order to clarify which function of the 
polymerase is impaired in avian strains, 
we performed a PB2 complementation 
assay using the polymerase reconstitution 
system. In this assay, we co-expressed a 
modified AvianPr PB2 subunit (PB2-
E627K-Tdef) that harbors both the 
adaptive mutation E627K as well as 
mutations in the cap-binding region that 
diminish the cap-binding activity18 and 
therefore leads to inefficient transcription 
of mRNA from vRNA. If AvianPr is only 
defective for RNA replication in human 
cells, the avian precursor polymerase 
should be able to complement the 
transcription defect of PB2-E627K-Tdef, 
whereas no complementation should 
occur if the AvianPr polymerase also has 
a defect in transcription (Fig. 3a). As 
shown in Fig. 2b, polymerase containing 
AvianPr PB2 (PB2-AvianPr) produced 
only low levels of all three RNA species 
(Fig. 3b). In contrast, the transcription-
deficient polymerase (PB2-E627K-Tdef) 
produced high amounts of vRNA and 
cRNA, but no detectable amounts of 
mRNA. Co-expression of equal amounts 
of PB2-AvianPr and PB2-E627K-Tdef 
polymerases resulted in the restoration of 
full RNA synthesis and the production of 
all three RNA species to levels resembling 
the PB2-E627K phenotype. These results 
suggest that the AvianPr polymerase is 
not defective for mRNA synthesis and can 
synthesize mRNA when the vRNA 
template is provided in trans. Using the 
luciferase reporter construct, we could 
similarly observe strongly reduced 
reporter gene activity for PB2-AvianPr 
and PB2-E627K-Tdef, while the activity 
was restored by co-expression of both 
polymerases (Fig. 3c), confirming the 
results observed by primer extension 
analysis. We therefore conclude that the 
non-adapted AvianPr polymerase does 
not harbor a defect in viral mRNA 
synthesis. Supporting this hypothesis, 
AvianPr and AvianPr-E627K recombinant 
viruses exhibited equal primary mRNA 
synthesis after infection of 293T cells in 
the presence of cycloheximide 
(Supplementary Fig. S6), conditions 
which prevent viral RNA replication.  
We then investigated whether the 
replication defect of AvianPr is caused by 
impairment in cRNA synthesis, since no 
cRNA production by AvianPr was 
detectable in the primer extension assay 
(Fig.2b). Since this could be caused by 
impaired cRNA synthesis and/or rapid 
degradation of synthesized cRNA, we 
perfomed a cRNA stabilization assay19. As 
described by others, cRNA synthesis can 
be observed by pre-expression of NP and 
a catalytically inactive polymerase, 
containing an inactive PB1 subunit19 prior 
to viral infection in the presence of 
cycloheximide19. As shown in Fig. 3d 
(lane 1 and 2), in AvianPr and AvianPr-
E627K-infected cells polymerases 
produce substantial and equivalent 
amounts of cRNA. To further determine 
whether the cRNA transcripts can be 
utilized as templates for vRNA synthesis, 
we overexpressed functional AvianPr or 
AvianPr-PB2-E627K polymerase subunits 
and NP prior to infection and 
cycloheximide-treatment. Intriguingly, in 
cells infected with AvianPr, both 
polymerases failed to produce vRNA 
(Fig.3d, lanes 3 and 5) but synthesized 
substantial amounts of vRNA in AvianPr-
PB2-E627K infected cells (Fig.3, lanes 4 
and 6). Thus, avian polymerases lacking 
PB2-E627K appear incapable of providing 
bona fide cRNA templates in mammalian 
cells (see Discussion).  
These data suggest a general 
requirement of avian influenza 
polymerases to increase their RNA 
replication efficiency in mammals, which 
can be achieved by the adaptive mutation 
E627K in PB2. Based on the observation 
that the KAN-1 polymerase is not fully 
adapted to mammalian cells, we 
speculated that an additional co-factor is 
necessary for efficient RNA replication by 
KAN-1.  
 
The NEP protein of KAN-1 is involved 
in host adaptation.  
As we could show that the NS segment 
contributes to viral pathogenicity of KAN-
1, we speculated that either NS1 or NEP, 
both encoded by this segment, could 
have a stimulatory effect on viral 
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polymerase activity in human cells. Due to 
overlapping open reading frames of the 
two proteins, the single mutation in the 
NS segment of the KAN-1 virus results in 
an amino acid change at position 174 
(valine to isloleucine) in the NS1 protein 
and at position 16 (methionine to 
isoleucine) in NEP (Fig. 4a). To elucidate 
if these amino acid changes in NS1 or 
NEP stimulate the activity of a 
polymerase lacking adaptive mutations, 
we determined the polymerase activity of 
AvianPr in the presence of either protein 
in human cells. Co-transfection of either 
KAN-1 or AvianPr NS1 expression 
plasmids resulted in a reduction of 
AvianPr reporter activity (Fig. 4b), 
suggesting that the mutation in KAN-1 
NS1 is not important for viral polymerase 
function. In contrast, we could observe an 
enhancement of the AvianPr reporter 
activity by the NEP proteins of both the 
AvianPr and KAN-1 virus at low plasmid 
concentrations (Fig. 4c). However, 
reporter gene activity was up to 51-fold 
higher upon co-expression of the KAN-1 
NEP compared to NEP of AvianPr. This 
indicates that the mutation M16I in the 
KAN-1 NEP leads to an enhancement of 
the polymerase stimulating property of the 
avian NEP (Fig. 4c). On the other hand, 
we observed an inhibition of reporter gene 
activity at high plasmid concentrations for 
both NEP proteins. This inhibitory effect 
was much more pronounced for the 
AvianPr NEP upon co-transfection, 
leading to a reduction of reporter gene 
activity to background levels (Fig. 4c). 
Expression levels of the AvianPr and 
KAN-1 NEP in human HEK293T cells 
were comparable (Fig. 5c). At low levels 
of transfected NEP expression plasmids, 
primer extension analysis revealed that 
AvianPr NEP slightly increased the level 
of cRNA but not mRNA (Fig. 4d). In 
contrast, KAN-1 NEP greatly enhanced 
the synthesis of all viral RNA species, 
including cRNA. At 10-fold higher 
amounts of transfected NEP-expression 
plasmids viral polymerase was inhibited 
by NEP of both KAN-1 and AvianPr, 
however, the inhibitory effect of KAN-1 
NEP was less pronounced. Next, we 
tested whether the stimulatory effect of 
KAN-1 NEP is able to compensate the 
inefficient adaptation of the KAN-1 
polymerase in a polymerase 
reconstitution assay, as observed in Fig. 
2a. Co-expression of KAN-1 polymerase 
with KAN-1 NEP resulted in similar 
reporter activity as AvianPr-PB2-E627K 
co-expressed with AvianPr-NEP (Fig. 4e). 
As expected, the AvianPr NEP did not 
lead to a comparable increase of the 
AvianPr polymerase activity.  
We recently showed that NEP is 
associated with purified viral RNPs20. 
Since NEP appears to compensate for a 
defect in the viral polymerase, we tested 
whether these proteins physically 
associate using co-immunoprecipitation. 
KAN-1 NEP interacted with both PB1 and 
PB2, whereas no complex formation was 
detected with PA (Fig. 4f). Moreover, 
KAN-1 NEP associated with PB2 of KAN-
1, AvianPr as well as Avian-Pr-E627K 
(Fig. 4g), suggesting that the protein 
interaction domain on PB2 is conserved in 
all three PB2 subunits. Using PB2 
truncation mutants we could further map 
the interaction of NEP to the N-terminal 
part of PB2 comprising amino acids (aa) 
1-534, containing the Cap-binding 
domain, but not to a shorter fragment (aa 
1-299) or the C-terminal domain of PB2 
(aa 535-759)(Fig. 4h). 
Due to the overlapping open reading 
frames coding for NS1 and NEP, we 
cannot formally exclude a contribution of 
the NS1 protein of KAN-1 in the 
adaptation process to humans. However, 
we observed no difference in type I 
interferon induction between both strains 
after infection of a reporter cell line coding 
for firefly luciferase under the control of 
the interferon beta promoter with either 
AvianPr or AvianPr-NS-KAN-1 
(Supplementary Fig. S7).  
Together, these results indicate that the 
adaptive mutation M16I in the NEP 
protein of the KAN-1 virus enhances the 
capacity of NEP to stimulate viral 
polymerase activity, rendering NEP an 
essential co-factor in the adaptation 
process of the KAN-1 virus to a 
mammalian host.  
 
The KAN-1 NS segment enhances viral 
RNA synthesis of the AvianPr virus 
To investigate whether the RNA synthesis 
enhancing effect of the KAN-1 NEP is 
also relevant in the context of a viral 
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infection, HEK293T cells were infected 
with the recombinant viruses AvianPr, 
KAN-1, AvianPr containing the KAN-1 NS 
segment (AvianPr-NS-KAN-1) and 
AvianPr with the polymerase harboring 
the adaptive mutation E627K in the PB2 
protein (AvianPr-PB2-E627K), 
respectively. To monitor early phases of 
viral RNA synthesis, total RNA from cells 
harvested at 1, 2, 2.5 and 3 hours post 
infection (p.i.) were used for measuring 
the accumulation of vRNA, cRNA and 
viral mRNA by primer extension analysis. 
AvianPr failed to synthesize viral RNAs to 
levels comparable to KAN-1 and AvianPr-
PB2-E627K at any time point measured 
(Supplemental Fig. S8). However, 
introduction of the KAN-1 NS segment 
(AvianPr-NS-KAN-1) could rescue this 
defect and lead to enhanced synthesis of 
all three viral RNA species by the avian 
precursor polymerase (Supplemental Fig. 
S8). Together, these results indicate that 
the non-adapted avian polymerase has a 
disadvantage to replicate efficiently in 
mammalian cells and that an adaptive 
mutation in either PB2 (E627K) or in NEP 
(M16I) can compensate this defect.  
 
NEPs of different human influenza 
isolates containing PB2-E627 enhance 
viral polymerase activity in mammals 
We could show that the adaptive mutation 
in the KAN-1 NEP protein increases its 
capacity to enhance the avian viral 
polymerase activity. This polymerase 
enhancing activity is comparable to the 
effect mediated by the introduction of the 
PB2-E627K mutation into the AvianPr 
polymerase, suggesting that NEP may be 
an important pathogenicity factor for 
human influenza viruses that have 
retained the avian-like PB2-E627. We 
therefore investigated whether other 
H5N1 viruses encoding PB2-E627 
contained adaptive mutations in NEP.  
Through sequence alignment, we 
identified additional avian and human 
clade 1 and clade 2 H5N1 isolates that 
contain PB2-E627 and differ by only a few 
amino acids from the AvianPr NEP, which 
resembles the consensus sequence of 
H5N1 viruses (Fig. 5a). Whereas the 
mutations V14M, A115T, A48T and S7L 
are found in avian and human isolates, 
the mutations Y41C and E75G are 
restricted to human isolates. The mutation 
S7L is mainly restricted to H5N1 strains 
from Indonesia and, all 80 human isolates 
analyzed of this subtype contain this 
mutation. These mutations were 
introduced into the AvianPr NEP protein 
to investigate their polymerase enhancing 
capacity in the polymerase reconstitution 
assay. As the pandemic H1N1 virus also 
possesses PB2-E627 and is the dominant 
influenza A virus strain currently 
circulating in the human population, we 
also included the NEP of 
A/California/04/2009 (H1N1). In 
agreement with our assumption that only 
mutations in human-adapted strains lead 
to the enhanced NEP phenotype, the 
avian NEP variants harboring the 
mutations V14M and A115T retrieved 
from the avian isolates did not lead to an 
increase in reporter activity (Fig. 5b). The 
mutation A48T found in the human H5N1 
isolate A/Viet Nam/1203/2004 (Vn-1203), 
which harbors PB2-K627, only weakly 
enhanced the reporter activity. In contrast, 
the human-derived mutations Y41C and 
E75G in avian NEP and also the 
pandemic H1N1 NEP protein were able to 
increase reporter gene activity to a similar 
extent as KAN-1 NEP (Fig. 5b). Western 
blot analysis confirmed comparable 
expression of these proteins (Fig. 5c). 
The increased enhancing activity of the 
pandemic H1N1 NEP and the NEP 
variants containing the human-specific 
mutations Y41C and E75G was further 
supported by primer extension analysis, 
which showed a strong increase in all 
three viral RNA species (vRNA, cRNA 
and mRNA) upon co-expression 
(Supplemental Fig. S10). However, none 
of the NEP proteins encoding the avian-
derived mutations V14M, A115T or A48T 
was able to raise viral RNA levels to the 
same extent as KAN-1 NEP. Notably, the 
S7L mutation found in avian and human 
H5N1 isolates (Fig. 5a) also stimulated 
the AvianPr polymerase (Supplemental 
Fig. S9). Thus the increased polymerase-
enhancing phenotype of NEP can be 
achieved by many different amino acid 
changes. Therefore the utilization of NEP 
as a co-factor in the viral adaptation 
process to the human host is most likely 
not restricted to the KAN-1 virus, as it can 
also be observed for other highly 
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pathogenic human H5N1 isolates and the 
pandemic H1N1 strain containing the 
avian-like PB2-E627 signature. 
 
Discussion 
Zoonotic transmission of influenza A 
viruses is a constant threat to the human 
population. Although viral replication of 
avian viruses, including highly pathogenic 
avian H5N1 strains, is impaired in 
humans, incorporation of adaptive 
mutations enables the virus to overcome 
this defect. In this study, we characterized 
the supply of bona fide cRNA as the 
principle defect of avian polymerases in 
human cells. Furthermore, we provide 
evidence that the polymerase of the 
human H5N1 isolate KAN-1, which 
encodes PB2-E627, is only partially able 
to compensate for this defect, and that the 
NEP of KAN-1 acquired an adaptive 
mutation (M16I) to stimulate the inefficient 
polymerase activity of this virus in human 
cells. We further show that NEPs of 
circulating avian H5N1 viruses fail to 
compensate for the defect of avian 
viruses in human cells, while NEPs of 
human-derived H5N1 viruses encoding 
PB2-E627 contain adaptive mutations 
which enhance polymerase activity. Thus, 
we identified adaptive mutation of NEP as 
a strategy by which avian H5N1 viruses 
facilitate transmission from birds to 
humans. 
Our results suggest that the major defect 
of avian polymerases in human cells is an 
impairment in vRNA replication. We 
observed that an avian polymerase 
(AvianPr), which normally produces only 
very low levels of viral mRNA, 
synthesized much higher amounts of 
mRNA when cRNA and vRNA were 
provided by an alternative polymerase 
(Fig. 3b), suggesting that the avian 
polymerase is specifically impaired in 
either cRNA or vRNA synthesis. 
Interestingly, both avian and human-like 
(AvianPr-PB2-E627K) polymerases 
synthesized cRNA to an equivalent extent 
(Fig. 3d). However, cRNA produced by 
AvianPr was unable to support robust 
vRNA synthesis in the presence of an 
active polymerase (Fig. 3d lanes 5), while 
cRNA produced by AvianPr PB2-E627K 
supported robust vRNA synthesis (Fig. 
3d, lanes 4 and 6). Based on this finding, 
we speculate that avian polymerases do 
not have an impaired rate of RNA 
synthesis in human cells, but rather 
synthesize defective cRNPs which are not 
bona fide templates further RNA 
replication. This hypothesis is supported 
by our observation that AvianPr could 
efficiently synthesize vRNA when 
provided with competent cRNPs (Fig. 3d, 
lane 4), and by a previous report which 
showed that recombinant, purified 
polymerase is active in vitro regardless of 
the identity of PB2 residue 62721. 
Moreover, we observed reduced levels of 
cRNA after providing a competent 
polymerase compared to an incompetent 
polymerase (Fig. 3d, compare lane 3 and 
5 to lane 1). This suggests a decreased 
stability of cRNPs created by an avian 
influenza polymerase (Fig. 6, upper 
panel), as observed before for cRNPs at 
high temperature22. In summary, the well-
known adaptive mutation PB2 E627K 
appears to confer the ability to correctly 
synthesize cRNPs to avian polymerases 
in human cells.  
Intriguingly, 71% of the human H5N1 
virus isolates (127/179, Influenza virus 
research database) have not acquired the 
PB2-E627K mutation, likely reflecting an 
incomplete adaptation to human hosts. 
Nonetheless, many of these viruses are 
highly pathogenic, even fatal, in humans. 
Our results suggest that these viruses 
utilize NEP as a polymerase cofactor to 
elevate their low RNA replication capacity 
in humans (Fig. 6, lower panel). Adaptive 
mutations in NEP are required to 
efficiently stimulate avian and avian-like 
influenza polymerases. Interestingly, 
human H5N1 isolates that harbor the 
adaptive mutation E627K in PB2 do not 
contain adaptive mutations in NEP which 
enhance the polymerase activity to a 
similar degree as KAN-1 NEP (Fig. 5). We 
therefore speculate that viruses such as 
Vn-1203, which possess highly active 
polymerases due to the PB2-E627K 
mutation, are not dependent on the 
additional replication-enhancing property 
of NEP (Fig. 6, middle panel). 
Interestingly, our data also suggest that 
NEP directly interacts with the viral 
polymerase in human cells, as we could 
show an association with the PB1 and 
PB2 subunits. Since both subunits have 
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been implicated in promoter binding23, we 
speculate, that association with NEP 
might also lead to a stabilization of 
cRNPs, thereby increasing the synthesis 
of vRNA transcripts, as suggested by 
others24.  
Although the KAN-1-specific adaptive 
mutation M16I is located within the 
nuclear export signal (NES) of NEP (aa 
12-21)25, the replication enhancing 
property of NEP is most likely 
independent of its export function24. In 
addition, treatment of cells with 
leptomycin B, an inhibitor of nuclear 
export, had no effect on the reporter 
enhancing function of either KAN-1 NEP 
or AvianPr NEP (data not shown). 
Furthermore, other adaptive mutations 
found to enhance the polymerase activity 
(Y41C and E75G) are located outside the 
NES motif. The latter mutation (E75G) is 
known to be involved in M1 binding35, 
however since M1 is not included in the 
polymerase reconstitution assay, it is 
unlikely to be relevant.  
Interestingly, we observed that the 
mutation S7L promoted the polymerase 
enhancing activity of NEP. Sequence 
analysis revealed that this mutation is 
present in NEP of all avian and human 
H5N1 isolates from the Indonesian 
lineage. Correspondingly, 89% (80/90, 
Influenza virus research database) of the 
human isolates originating from this 
lineage have retained the avian like PB2-
E627. We hypothesize that the acquisition 
of the mutation S7L in NEP is responsible 
for the extraordinarily high frequency of 
PB2-E627 in this lineage. Through an 
increased stimulatory effect of NEP on 
polymerase activity, this mutation possibly 
lowered the selective pressure on these 
viruses to obtain the PB2-E627K mutation 
in humans.  
Our identification of NEP as a novel 
pathogenicity factor suggests that avian 
influenza viruses have developed multiple 
strategies to adapt to human hosts. The 
recognition of adaptive mutations in NEP 
might help to evaluate the potential risk of 
circulating avian viruses to the human 
population.  
 
Materials and Methods  
Plasmid constructions. The previously 
described pHW2000 vectors36,37 were 
used for influenza A virus rescue. To 
obtain rescue plasmids containing 
segments that encode mutant genes, site 
directed mutagenesis was performed. To 
create the pCAGGS expression plasmids 
encoding for mutant PB2, PB1 or PA, the 
required mutations were introduced by 
assembly PCR. The resulting PCR 
fragments were cloned into vectors 
expressing PB2 and PB1 with the 
restriction enzymes NotI and XhoI or PA 
using NotI and NheI. The NS1 and NEP 
coding plasmids were cloned using the 
gene-specific forward and reverse primers 
for NS1 and NEP and cloned into 
pCAGGS vectors using NotI and XhoI. 
The pCAGGS expression plasmids 
encoding the respective C-terminally HA-
tagged polymerase subunites (PA, PB1, 
PB2) or PB2 truncation mutants were 
generated by PCR and ligated into 
pCAGGS PASC35M-HA vector38 linearized 
with XmaI and NotI. The N-terminal Strep-
tag20 was cloned in pCAGGS-HA-NEPKAN-
1 expression plasmid linearized with 
EcoRI and NotI . 
 
Animal experiments. BALB/c mice were 
obtained from Janvier (Straßburg). Six to 
eight week-old mice were anesthetized 
with a mixture of ketamin (100 µg per 
gram body weight) and xylazine (5 µg per 
gram) administered intraperitoneally and 
inoculated intranasally with the indicated 
doses of viruses in 50 µl phosphate-
buffered saline (PBS) containing 0.2% 
bovine serum albumin (BSA). Animals 
were euthanized if severe symptoms 
developed or body weight loss 
approached 25% of the initial value. Lung 
homogenates were prepared using the 
FastPrep24 system (MP Biomedicals). 
Briefly, after addition of 800 µl of PBS 
containing 0.2% BSA, lungs were 
subjected to two rounds of mechanical 
treatment for 10 s each at 6.5 m/s. Tissue 
debris was removed by low-speed 
centrifugation. The LD50 values were 
calculated based on the infectious dose 
(PFU).  
 
Sequencing of viruses. RNA purification 
was carried out using 800 µl of TrizolTM 
reagent and 200 µl of virus stock or lung 
homogenate. Purified RNA was reversed 
transcribed using the one step RT-PCR 
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kit (Roche) and PCR was performed with 
KAN-1 specific primers. 
 
Cells. HEK293T, 3T3 and MDCK II cells 
were grown in Dulbecco’s modified 
Eagle’s medium supplemented with 10% 
fetal calf serum, 2 mM L-glutamine and 
1% Penicillin/Streptomycin. Chicken 
hepatocellular epithelial cell line (LMH) 
was grown in Dulbecco’s modified Eagle’s 
medium supplemented with 8% fetal calf 
serum 2% chicken serum, 2 mM L-
glutamine and 1% penicillin/streptomycin. 
All cells were maintained at 37°C and 5% 
CO2. Co-precipitation experiments were 
essentially carried out as described26 
using Strep-Tactin sepharose beads (IBA). 
 
Reconstitution of the influenza virus 
polymerase. As described27, HEK293T 
cells seeded into a 12-well plate were 
transiently transfected with a plasmid 
mixture containing either influenza A virus 
PB1-, PB2-, PA- (50 ng each), NP-
expression plasmids (200 ng), and a 
human polymerase I (Pol I) expression 
plasmid (25 ng) expressing an influenza 
virus-like RNA (vRNA-luciferase) coding 
for the reporter protein firefly luciferase to 
monitor viral polymerase activity. vRNA-
luciferase was flanked by non-coding 
sequences of segment 8 of FluA. The 
transfection mixture also contained a 
plasmid constitutively expressing renilla 
luciferase (25 ng), which served to 
normalize variation in transfection 
efficiency. Reconstitution of the viral 
polymerase complex in avian cells was 
performed as above with the exception 
that avian LMH cells were transfected and 
the minigenome RNA was expressed 
under the control of a chicken Pol I 
promoter (kindly provided by Daniel 
Mayer). 
 
cRNA stabilization assay. The experiment 
was essentially carried out as described 
in23. Briefly, human 293T cells were 
transiently transfected with the pCAGGS 
expression plasmids coding for various 
polymerase subunits (250 ng) and NP 
(1000 ng) for 16 to 18 hours and 
subsequently infected with the indicated 
virus strains at an MOI of 5 in the 
presence of 100µg of cycloheximide/ml. 
 
Primer extension analysis. For 
determination of viral transcript levels of 
reconstituted polymerases, 6-well plates 
with confluent HEK293T cells were 
transiently transfected with a plasmid 
mixture containing either FluA PB1-, PB2-
, PA- (125 ng each), NP-expression 
plasmid (500 ng), and a polymerase I (Pol 
I)-expression plasmid (25 ng) expressing 
an influenza virus RNA coding for the 
segment 6 of FluA. 25 ng of empty vector 
or NEP expression plasmid was 
contransfected for experiments involving 
NEP. For determination of viral transcript 
levels in virus-infected HEK293T cells, 
cells were seeded in 6-well plates. 
Infection was carried out with infection 
media (Dulbecco’s modified Eagle’s 
medium supplemented with 0.2% BSA, 2 
mM L-glutamine and 1% 
Penicillin/Streptomycin). For analyzing 
primary viral transcription, cycloheximide 
(100 µg/ml) was added to the infection 
media. After the indicated time point post 
transfection or infection, cells were 
harvested in TrizolTM and RNA was 
purified according to the manufacturer’s 
protocol (Invitrogen). Primer extension 
analysis was performed using specific 
primers for the NA and PB2 segment 
(mRNA, cRNA and vRNA) and cellular 
5sRNA as described41,42.  
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Figure legends 
 
Figure 1. Characterization of KAN-1 and AvianPr reassortant viruses in mice. (a) 
Amino acid differences between indicated viral proteins of KAN-1 and the avian 
precursor AvianPr. (b) Lethal dose 50 (LD50) of KAN-1, AvianPr, and the indicated 
AvianPr reassortant viruses after intranasal infection of BALB/c mice (n=5/group). 
Reassortant viruses include AvianPr harboring either all three polymerase segments 
(AvianPr-3P-KAN-1), NS (AvianPr-NS-KAN-1), NA (AvianPr-NA-KAN-1) or both the NS 
and polymerase segments (AvianPr-3P/NS-KAN-1) of KAN-1. Segments originating 
from KAN-1 virus are highlighted in grey. 
 
Figure 2. Activity of KAN-1 polymerase. (a) To determine the polymerase activity of 
the indicated viruses in a time-dependent manner, HEK293T cells were transiently 
transfected with expression plasmids coding for the corresponding PB2, PB1, PA and 
NP proteins, a human polymerase I-driven vRNA-luciferase reporter plasmid and a 
renilla-expressing plasmid. Omission of PB2 (-PB2) was used as a negative control. 
Renilla activity was used to normalize variation in transfection efficiency. Error bars 
indicate the standard error of the mean of three independent experiments. (b) 
Determination of the mRNA, cRNA and vRNA levels by primer extension analysis after 
reconstitution of the AvianPr, KAN-1 and AvianPr-PB2-E627K polymerases 24 hours 
post transfection using segment 6. Determination of the 5sRNA levels served as an 
internal loading control. 
 
Figure 3. Polymerase complementation assay. (a) Cartoon depicting the various 
PB2 mutants and the expected polymerase activity in the presence of these mutants. 
AvianPr-PB2-E627K-Tdef represents the AvianPr PB2 harboring the mutation E627K 
and two mutations (E361A, F404A) in the cap-binding domain. Black solid arrows refer 
to synthesis of high RNA levels by the indicated polymerase; arrows with dotted lines 
indicate synthesis of low viral RNA amounts. The question mark indicates unknown 
levels of RNA synthesis. (b) Determination of the mRNA, cRNA and vRNA levels by 
primer extension analysis after reconstitution of the AvianPr with the indicated PB2 
subunits using specific primers for segment 6. Determination of the 5sRNA levels 
served as an internal loading control. For reconstitution the total amount of 50 ng of 
PB2-expressing plasmids were transfected. The complementation assays included 25 
ng of AvianPr-PB2 and 25 ng AvianPr-PB2-E627K-Tdef. Omission of PB2 (-PB2) was 
used as a negative control. (c) Luciferase reporter activities of mutant polymerases 24h 
post transfection after reconstitution of the indicated polymerases as described in Fig. 
2. For each reconstitution a total amount of 50 ng of PB2-expressing plasmids were 
used. The complementation assays included 25 ng of AvianPr-PB2 and 25 ng AvianPr-
PB2-E627K-Tdef. Error bars indicate the standard error of the mean of three 
independent experiments. Student’s t-test was performed to determine the P value. 
*P<0.05; **P<0.01. (d) Rescue of cycloheximide-mediated inhibition of influenza virus 
replication. Human 293T cells were transiently transfected with the indicated 
polymerase subunits and viral nucleoprotein (NP) and subsequently infected with the 
indicated virus strain at an MOI of 5. Viral RNA species were analyzed 6 hours post 
infection by primer extension using specific primer for segment 1.  
 
Figure 4. Influence of NS segment encoded proteins on polymerase activity. 
(a) Cartoon depicting the amino acid mutations in NS1 and NEP of KAN-1 caused by a 
single nucleotide mutation in the KAN-1 NS segment. (b) Reporter activities after 
reconstitution of the AvianPr polymerase as described in Fig. 2 and co-transfection of 
the indicated amounts of NS1-AvianPr, or NS1-KAN-1 encoding plasmids. Vector, 
empty plasmid. (c) Reporter activities after reconstitution of the AvianPr polymerase as 
described in Fig. 2 and co-transfection of the indicated amounts of NEP-AvianPr, or 
NEP-KAN-1 encoding plasmids. Student’s t-test was performed to determine the P 
value. *P<0.05, **P<0.01. Vector, empty plasmid. (d) Determination of the mRNA, 
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cRNA and vRNA levels by primer extension analysis after reconstitution of the AvianPr 
polymerase in human cells and co-transfection of either empty plasmid (Vector), NEP-
AvianPr or NEP-KAN-1 using primers specific for segment 6. Determination of the 
5sRNA levels served as an internal loading control. (e) Time course of reporter 
activities of AvianPr, KAN-1 and Vn-1203 polymerases in human cells as described in 
Fig. 2a after co-transfection of 10 ng of the indicated NEP-expressing plasmids. (f) 
Complex formation of NEP with either PB1, PA or PB2. Human 293T cells were 
transiently transfected with Strep-tagged KAN-1 NEP and the indicated HA-tagged 
polymerase subunits and subjected to co-immunoprecipitations (IP). Precipitated 
polymerase subunits were identified by Western blot analysis using specific antibodies 
against the HA- and the Strep-tag. (g) Binding of Strep-tagged KAN-1 NEP to the 
indicated PB2 variants and (h) to PB2 truncation mutants. 
 
Figure 5. Identification of adaptive mutations in NEP of other human isolates. (a) 
Sequence alignment of NEPs of human and avian H5N1 viruses as well as the NEP of 
the 2009 pandemic H1N1 virus to the H5N1 consensus sequence. Bold letters indicate 
amino acids exclusively found in human H5N1 isolates. (b) Reporter activities after 
reconstitution of the AvianPr polymerase as described in Fig. 2 in human cells and co-
transfection of 10 ng of expression plasmids coding for AvianPr NEP harboring the 
indicated amino acid substitution. (c) Western blot analysis of the NEP expression 
levels after transient transfection of HEK 293T cells with equal amounts of expression 
plasmids (500 ng) encoding the indicated NEP variants.  
 
Fig. 6 Model of adaptive mutations contributing to the replication of avian H5N1 
isolates in human cells. See discussion for details. 
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Supplementary figure legends 
 
Supplementary Table 1: Alignment of human H5N1 isolates from Thailand used 
for the generation of the KAN-1 precursor virus AvianPr. NCBI influenza database 
was used to identify the amino acid sequence of the potential avian precursor virus of 
the human H5N1 isloate KAN-1. Amino acids of the clade 1 human H5N1 isolates from 
Thailand (KAN-1, Thai16, SP-33, KK-494 and SP83) that differ to the amino acids of 
the avian H5N1 consensus sequence (H5N1 consensus) were identified. Full-length 
sequence information (PB2: n=999, PB1: n=1059, PB1-F2: n=682, PA: n=1105, HA: 
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n=2638, NP: n=1081, NA: n=1668, M1: n=1584, M2: n=1229, NS1: n=1777, NEP: 
n=1220) was used to identify the avian H5N1 consensus. Amino acids shown in 
brackets represent common mutations found in avian isolates. Mutations that are 
exclusively found in human isolates and therefore most likely acquired after 
transmission to humans are highlighted in grey. * The mutation E627K in PB2 (PB2-
E627K) is also found in avian isolates, but not in isolates of the analyzed clade 1 
viruses. The amino acid sequence of the AvianPr virus was obtained by exchanging the 
exceptional mutations in the KAN-1 virus to common avian amino acids (H5N1 
consensus). Comparison of AvianPr to the closely related avian isolate VSMU-20 
(A/open-bill stork/Thailand/VSMU-20-AYA/2004 (H5N1)) revealed only 3 amino acid 
differences (HA-R341K, M1-T168I, M2-V86I). The virulence of the individual H5N1 
strains (HP, highly pathogenic; LP, low pathogenic) in mammals, as demonstrated by 
others is indicated1,2. KAN-1: A/Thailand/1(KAN-1)/2004 (H5N1); Thai16: 
A/Thailand/16/2004 (H5N1); SP-33: A/Thailand/2(SP-33)/2004 (H5N1); KK-494: 
A/Thailand/5(KK-494)/2004 (H5N1); SP83: A/Thailand/SP83/2004 (H5N1). 
 
Supplementary Fig. S1: Growth curves of infected cell culture. Confluent canine 
MDCKII (a) and avian LMH (b) cells were infected with an MOI of 0.001 and incubated 
at 37°C. At the indicated time points virus titer in the supernatant was analyzed by 
plaque assay. Error bars indicate the standard error of the mean of three independent 
experiments. Student’s t-test was performed to determine the P value. ***P<0.001.  
 
Supplementary Fig. S2: Weight curves of infected BALB/c mice. (a-d) 6-8 weeks 
old female BALB/c mice (n=5/group) were infected intranasally with indicated infectious 
doses of either AvianPr or KAN-1 virus. Weight loss was monitored for 14 days.  
 
Supplementary Fig. S3: Reporter activities of reconstituted polymerases in 
human 293T cells. (a) Amino acid differences between the polymerase subunits PB2, 
PB1 and PA of the avian precursor virus (AvianPr) and the H5N1 isolates KAN-1 and 
Vn-1203. Bold Amino acids represent mutations that differ from the AvianPr sequence. 
(b) Polymerase activity of the AvianPr, the AvianPr harboring a lysine at position 627 in 
PB2 (AvianPr-PB2-E627K) KAN-1 and Vn-1203 viruses in human cells. To determine 
the polymerase activities, HEK293T cells were transiently transfected with expression 
plasmids coding for PB2, PB1, PA and NP of the annotated viruses, a vRNA-luciferase 
reporter plasmid under the control of a human Pol I-promoter and for normalization, a 
renilla-expressing plasmid. Omission of PB2 (-PB2) was used as a negative control. 
Luciferase reporter activity was normalized to renilla activity and the levels obtained 
with the AvianPr polymerase was set to 100%. Error bars indicate the standard error of 
the mean of three independent experiments. (c) Relative polymerase activity as 
described in (b) after exchange of the indicated polymerase subunits. 
(d,e) Relative AvianPr polymerase activity as described in (b) after mutation of the 
indicated amino acid positions in PB2 (d) or PA (e). 
 
Supplementary Fig. S4: Reporter activities of reconstituted polymerases in avian 
LMH cells. (a) Polymerase activity of the AvianPr, the AvianPr harboring a lysine at 
position 627 in PB2 (AvianPr-PB2-E627K), KAN-1 and Vn-1203 viruses in avian cells. 
To determine the polymerase activity avian LMH cells were transiently transfected with 
expression plasmids coding for PB2, PB1, PA and NP of the annotated viruses, a 
vRNA-luciferase reporter plasmid under the control of the chicken Pol I promoter and 
for normalization, a renilla-expressing plasmid. Omission of PB2 (-PB2) was used as a 
negative control. Luciferase reporter activity was normalized to renilla activity and the 
levels obtained with the AvianPr polymerase was set to 100%. Error bars indicate the 
standard error of the mean of three independent experiments. (b) Relative polymerase 
activity as described in (a) after exchange of the indicated polymerase subunits. (c,d) 
Relative polymerase activity of the AvianPr as described in (a) after mutation of the 
indicated amino acid positions in PB2 (c) or PA (d). 
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Supplementary Fig. S5: RNP formation of reconstituted polymerases. HEK293T 
cells were transiently transfected with expression plasmids coding for PB2-HA with the 
annotated mutation, AvianPr-PB1, AvianPr-PA and AvianPr-NP, a vRNA-luciferase 
reporter plasmid under the control of a human Pol I-promoter and for normalization, a 
renilla-expressing plasmid. Luciferase reporter activity was normalized to renilla activity 
and the levels obtained with the AvianPr-PB2-HA was set to 100%. Error bars indicate 
the standard error of the mean of three independent experiments. Immunoprecipitation 
was carried out as described3. 
 
Supplementary Fig. S6: Analysis of primary viral transcription. HEK293T cells 
were treated with 100 µg/ml cycloheximide and infected with an MOI of 5 of either 
AvianPr or AvianPr-PB2-E627K. Cells were harvested 4 hours p. i. and mRNA, cRNA 
and vRNA levels were determined using primer extension analysis with primers specific 
for segment 6. Levels of cellular 5sRNA served as internal loading control. 
 
Supplementary Fig. S7: Interferon induction in infected cells. Mouse 3T3 cells 
stably transfected with a plasmid coding for firefly luciferase under the control of the 
interferon beta promoter were infected with AvianPr or AvianPr harboring the NS-
segment of KAN-1 (AvianPr-NS-KAN-1) at the indicated MOI. Mock infection or 
infection with either SC35M-WT or SC35M-delNS1 at a MOI of 0.5 known to induce β-
interferon served as internal controls. Luciferase activity was determined after 16 hours 
post infection. 
 
Supplementary Fig. S8: Accumulation of viral RNAs during infection with 
recombinant viruses. (a) Human HEK293T cells were infected with an MOI of 5 with 
AvianPr, KAN-1, AvianPr-NS-KAN-1 and AvianPr-PB2-E627K. After the indicated time 
points post infection (p.i.), cells were lysed and RNA levels were determined by primer 
extension analysis using primers specific for segment 6. Determination of the 5sRNA 
levels served as an internal loading control. -, primer extension analysis using 
uninfected cells. (b) Quantification of the radioactive signals shown in panel (a). 
Signals were normalized to 5sRNA level. Increase in mRNA and cRNA levels was 
normalized to the strain-specific vRNA levels at 1 hour p.i. 
 
Supplementary Fig. S9: Mutation S7L in NEP enhances reporter activity of the 
AvianPr polymerase. Reporter activities after reconstitution of the AvianPr polymerase 
as described in Fig. 2 in human cells and co-transfection of 25 ng of expression 
plasmids coding for an empty vector, AvianPr NEP, or the S7L mutant NEP. Error bars 
indicate the standard error of the mean of three independent experiments. Student’s t-
test was performed to determine the P value. *P<0.05. 
 
Supplementary Fig. S10: Influence of co-expressed mutant NEPs on the 
accumulation of viral RNAs. Determination of the mRNA, cRNA and vRNA levels by 
primer extension analysis after reconstitution of the AvianPr polymerase in human cells 
and co-transfection of either empty plasmid (Vector) or AvianPr NEP harboring the 
indicated amino acid substitution using primers specific for segment 6. Determination of 
the 5sRNA levels served as an internal loading control. 
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The Viral Nucleoprotein Determines Mx Sensitivity of
Influenza A Viruses!
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Host restriction factors play a crucial role in preventing trans-species transmission of viral pathogens. In
mammals, the interferon-induced Mx GTPases are powerful antiviral proteins restricting orthomyxoviruses.
Hence, the human MxA GTPase may function as an efficient barrier against zoonotic introduction of influenza
A viruses into the human population. Successful viruses are likely to acquire adaptive mutations allowing them
to evade MxA restriction. We compared the 2009 pandemic influenza A virus [strain A/Hamburg/4/09
(pH1N1)] with a highly pathogenic avian H5N1 isolate [strain A/Thailand/1(KAN-1)/04] for their relative
sensitivities to human MxA and murine Mx1. The H5N1 virus was highly sensitive to both Mx GTPases,
whereas the pandemic H1N1 virus was almost insensitive. Substitutions of the viral polymerase subunits or the
nucleoprotein (NP) in a polymerase reconstitution assay demonstrated that NP was the main determinant of
Mx sensitivity. The NP of H5N1 conferred Mx sensitivity to the pandemic H1N1 polymerase, whereas the NP
of pandemic H1N1 rendered the H5N1 polymerase insensitive. Reassortant viruses which expressed the NP of
H5N1 in a pH1N1 genetic background and vice versa were generated. Congenic Mx1-positive mice survived
intranasal infection with these reassortants if the challenge virus contained the avian NP. In contrast, they
succumbed to infection if the NP of pH1N1 origin was present. These findings clearly indicate that the origin
of NP determines Mx sensitivity and that human influenza viruses acquired adaptive mutations to evade MxA
restriction. This also explains our previous observations that human and avian influenza A viruses differ in
their sensitivities to Mx.
Zoonotic transmissions pose a constant risk for the intro-
duction of novel influenza A viruses into the human population
(25). At the beginning of a pandemic, humans are normally
immunologically naïve to the newly introduced viruses. There-
fore, innate host defenses play a major role in preventing virus
infection and spread (30). Influenza viruses trigger the synthe-
sis of type I and type III interferons (IFNs), which in turn
activate the expression of numerous IFN-inducible genes, in-
cluding the Mx genes (1, 29, 30). Mx proteins belong to the
family of dynamin-like large GTPases and are found in many
species (10). The human MxA protein and the murine Mx1
protein have antiviral properties and also protect cells from
infection with influenza A viruses (10, 11). The protective role
of Mx proteins is best illustrated in mice carrying the wild-type
Mx1 resistance gene (8, 9). Mx1-positive (Mx1!/!) mice are
highly resistant to influenza virus infection and survive large
challenge doses, whereas Mx1-negative (Mx1"/") mice with
defective Mx1 alleles are susceptible and die (24, 31).
Mx proteins are known to block an early step in the influenza
virus replication cycle. After entering a cell, the viral nucleo-
capsids (also called vRNPs) are imported into the cell nucleus,
where the associated viral RNA polymerase becomes active
and starts primary transcription. This process is inhibited by
the murine Mx1 protein, which is located in the nucleus (18).
Human MxA is predominantly cytoplasmic and interferes with
secondary transcription and viral replication (22). A variant of
MxA carrying a foreign nuclear localization signal moves into
the nucleus and blocks primary transcription, exactly as does
murine Mx1 (5, 35). This nuclear MxA variant was shown to
form a complex with the influenza virus nucleoprotein (NP),
and NP could also be coimmunoprecipitated with wild-type
MxA under cross-linking conditions (32). Influenza virus
strains were recently found to differ in their sensitivities to the
antiviral effect of Mx proteins. Avian influenza viruses proved
to be more sensitive than human strains, and this was influ-
enced by the viral NP in vRNP reconstitution assays (4).
Here we compared the Mx sensitivity of the 2009 pan-
demic influenza virus A/Hamburg/4/09 (pH1N1) strain with
that of the highly pathogenic avian influenza virus A/Thai-
land/1(KAN-1)/04 (H5N1) strain. Moreover, we determined
the role of the NP in Mx sensitivity, using reconstituted poly-
merase assays as well as reassortant viruses for infection of
Mx-positive cells and mice. Our results demonstrate that the
viral NP determines Mx sensitivity and that the NP of the
pandemic 2009 virus is relatively Mx insensitive. They also
suggest that human MxA may provide a natural barrier to
transmission of influenza A viruses from avian reservoirs and
that a degree of Mx resistance may develop due to natural
selection in the human population.
(This work was conducted by Petra Zimmermann in partial
fulfillment of the requirements for a Ph.D. degree from the
Faculty of Biology of the University of Freiburg, Freiburg,
Germany.)
* Corresponding author. Mailing address: Department of Virol-
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MATERIALS AND METHODS
Cells and viruses. Mouse 3T3 cell lines expressing murine Mx1 (3T3-Mx1),
human MxA (3T3-MxA), or Mx-negative control cells (3T3) have been described
previously (22). 3T3 cells, MDCK cells, and HEK 293T cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal
calf serum, 2 mM L-glutamine, and penicillin-streptomycin.
Generation of recombinant influenza A viruses. Recombinant viruses, includ-
ing pH1N1 (A/Hamburg/4/09), H5N1 [A/Thailand/1(KAN-1)/04], and the NP-
reassortant viruses H5N1-NP(pH1N1) and pH1N1-NP(H5N1), were generated
under biosafety level (BSL) 3 conditions by the eight-plasmid reverse-genetics
system as described previously (12, 20, 26). For generation of the pH1N1 viruses,
the HA rescue plasmid was mutated by quick-change site-directed mutagenesis
to encode the mouse-adapted mutations D131E and S186P (34). Successful
introduction of these mutations was confirmed by sequencing. All recombinant
viruses were plaque purified on MDCK cells in the presence of 1 !g/ml of
tosylsulfonyl-phenylalanyl-chloromethyl keton (TPCK)-treated trypsin. Virus
stocks were prepared on MDCK cells, and titers were determined by plaque
assay.
Mice. BALB/c mice with defective Mx1 alleles and congenic BALB.A2G-Mx1
mice (designated BALB-Mx1) carrying the functional Mx1 allele (28) were bred
locally. Six- to eight-week-old mice were anesthetized with a mixture of ketamine
(100 !g per gram body weight) and xylazine (5 !g per gram) administered
intraperitoneally (i.p.) and inoculated intranasally (i.n.) with the indicated doses
of viruses in 50 !l phosphate-buffered saline (PBS) containing 0.3% bovine
serum albumin (BSA). Mice were monitored daily for weight loss until 12 days
postinfection (p.i.). Animals with severe symptoms or more than 25% weight loss
were euthanized. For determination of lung titers and histopathological analysis,
mice were euthanized at the indicated time points. All animal work was con-
ducted under BSL 3 conditions in accordance with the guidelines of the local
animal care committee.
Titration of virus in lungs. Mice were infected i.n. with 1,000 PFU of the
indicated viruses. Lungs from infected mice were collected at 48 h p.i. and
homogenized using the FastPrep24 system (MP Biomedicals). Tissue debris was
removed by low-speed centrifugation, and virus titers in supernatants were de-
termined by performing 10-fold serial dilutions in PBS with 0.3% BSA followed
by plaque assay on MDCK cells.
Virus growth curves.MDCK cells seeded in 6-well plates were incubated with
virus at a multiplicity of infection (MOI) of 0.001 in PBS containing 0.3% BSA
for 1 h at 37°C. The inoculum was removed, and 2 ml infection medium (DMEM
supplemented with 0.3% BSA), additionally containing 1 !g/ml TPCK-treated
trypsin for pH1N1 viruses, was added. Virus titers in cell culture supernatants
were determined at the indicated time points by plaque assay and are expressed
as PFU per ml.
Tissue culture infection experiments.Mouse 3T3 cells were seeded at 106 cells
per well in 6-well plates and infected at an MOI of 5 for 1 h at 37°C. Subse-
quently, the inoculum was replaced by infection medium. Cells were lysed in
buffer containing 50 mM HEPES (pH 7.3), 125 mM NaCl, 1 mM EDTA, 1%
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM dithiothreitol (DTT), 25
U/ml of Benzonase, and protease inhibitors (Roche). Proteins were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and analyzed by
Western blotting. The blots were probed with the monoclonal antibody M143 to
detect Mx proteins (6), monoclonal mouse anti-PA antibody (G. Chase et al.,
unpublished data), and a rabbit antiactin antibody (Sigma). Horseradish perox-
idase-labeled secondary antibodies and a chemiluminescence detection system
(Pierce femto kit) were used to detect primary antibodies. Signal quantification
was performed using ChemiDoc XRS equipment (Bio-Rad).
Influenza A virus polymerase reconstitution assay (minireplicon assay). HEK
293T cells seeded in 12-well plates were transfected using the Nanofectin trans-
fection reagent (PAA Laboratories) according to the manufacturer’s protocol.
Ten nanograms of pCAGGs plasmids encoding PB2, PB1, and PA and 100 ng of
NP-encoding plasmid were cotransfected with 50 ng of the firefly luciferase-
encoding viral minigenome construct pPolI-FFLuc-RT, which is flanked by the
noncoding regions of segment 8 of influenza A virus (4). The transfection
mixture also contained 25 ng of pRL-SV40, a plasmid constitutively express-
ing Renilla luciferase under the control of the simian virus 40 promoter, used
to normalize variations in transfection efficiency. To evaluate the antiviral
potential of Mx1, we cotransfected increasing amounts of Mx1-encoding
plasmid. Cotransfection of the antivirally inactive mutant Mx1 (K49A) (23)
was used as a control. To achieve equal amounts of transfected DNA, an
empty vector plasmid was added. Twenty-four hours posttransfection, cells
were lysed and firefly and Renilla luciferase activities were determined using
the dual luciferase reporter assay (Promega) according to the manufacturer’s
protocol. Relative polymerase activity was calculated as the ratio of luciferase
to Renilla luminescence.
Histopathological analysis. Lungs were collected from BALB-Mx1 mice 3 and
4 days p.i. Lungs were inflated and fixed in 4% formaldehyde overnight at 4°C
and subsequently embedded in paraffin. Sections (4 !m) were stained with
hematoxylin and eosin (H&E) and examined under the light microscope for
histopathological changes. Representative images were obtained on a Nicon
Eclipse E400 microscope at magnification "10.
RESULTS
Mx sensitivity differs between human and avian influenza A
virus strains. Since Mx1 interferes with the transcriptional
activity of vRNPs (4), we determined the polymerase activities
of influenza virus strains A/Hamburg/4/09 (pH1N1) and A/Thai-
land/1(KAN-1)/04 (H5N1) in a minireplicon system in the
presence or absence of Mx1. The H5N1 polymerase activity
decreased to almost 10% at the largest amount (200 ng) of
cotransfected Mx1-expressing plasmid, whereas the pH1N1
polymerase activity was reduced to only 60% (Fig. 1A). The
dose of Mx1-expressing plasmid necessary to achieve 50%
inhibition of the H5N1 polymerase activity (ID50) was found
to be 25 ng (Fig. 1A). These results demonstrate that the
polymerase of the pandemic H1N1 isolate is less sensitive to
Mx1 inhibition than the polymerase of the avian H5N1
strain.
Mx sensitivity correlates with the nature of the NP. To
identify the viral factor determining Mx sensitivity, we ex-
changed each protein component of the resistant pH1N1
vRNP (i.e., the NP and the three polymerase subunits PA,
PB1, and PB2) with the corresponding components of the
sensitive H5N1 strain and determined the activity of the reas-
sorted vRNPs in the minireplicon assay. The NP of H5N1
origin increased the Mx1 sensitivity of the pH1N1 polymerase
(Fig. 1B and C), resulting in a drop in the ID50 from over 200
ng to 36 ng of transfected Mx1 expression plasmids. In con-
trast, substitutions with the polymerase subunit PA, PB1, or
PB2 of H5N1 did not result in enhanced Mx1 sensitivity (Fig.
1B). Conversely, the pH1N1 NP rendered the H5N1 polymer-
ase activity relatively resistant to Mx1 inhibition (Fig. 1B and
D), as demonstrated by an increase in the ID50 from 25 ng to
173 ng of transfected Mx1 expression plasmids. In the absence
of Mx1, the activities of both the pH1N1 and H5N1 poly-
merases were not affected by the source of the NP (data not
shown), excluding the possibility that subunit incompatibil-
ities were affecting Mx1 sensitivity. Together, these data
indicate that the nature of the NP is the main determinant
of Mx sensitivity.
The NP of avian H5N1 origin increases Mx sensitivity of the
reassortant pH1N1 virus. To verify the importance of NP as a
determinant of Mx1 sensitivity in vivo, we generated two re-
combinant strains, namely, wild-type strain A/Hamburg/4/09
(H1N1) (here designated pH1N1) and a reassortant A/Hamburg/
4/09 strain which carries the NP gene of A/Thailand/1(KAN-
1)/04 (H5N1) and is here designated pH1N1-NP(H5N1). Since
pandemic H1N1 viruses are almost avirulent in BALB/c mice
(14), we introduced two mutations (D131E and S186P) into
the hemagglutinin (HA) protein, which have been described as
increasing virulence (13, 34). Both pH1N1 and pH1N1-
NP(H5N1) grew to comparable titers in MDCK cells infected
with an MOI of 0.001. However, infection with the latter virus
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resulted in slightly higher titers 24 h p.i. (Fig. 2A). To test the
replication efficiency of both viruses in Mx-expressing cells, we
took advantage of stably transformed Swiss 3T3 cells that ex-
press high levels of murine Mx1 or human MxA under the
control of a constitutive promoter (22) (Fig. 2B). The cells
were infected with either pH1N1 or pH1N1-NP(H5N1) at an
MOI of 5, and viral replication was monitored 10 or 12 h later
by determining viral protein expression. The two viruses rep-
licated with comparable efficiencies in Swiss 3T3 cells that do
not express Mx proteins, as indicated by equal amounts of PA
protein levels (Fig. 2C, lanes 1 to 4). The two types of viruses
replicated less well in both Mx1- and MxA-expressing cells, as
expected (Fig. 2C and D). However, their replication efficien-
cies differed significantly in the presence of either Mx1 or
MxA. The PA antigen signals were much weaker following
infection with the reassortant pH1N1-NP(H5N1) virus than
with parental pH1N1 (Fig. 2C, lane 5 to 12). Quantification of
PA signal intensities from three independent experiments con-
firmed the differential reduction in antigen expression levels in
infected cells (Fig. 2D). These results indicate that the NP is
responsible for the relative resistance of pH1N1 viruses toward
the antiviral action of mouse and human Mx GTPases.
To evaluate the in vivo growth capacities of pH1N1 and
pH1N1-NP(H5N1), Mx1-negative BALB/c mice were infected
i.n. with 1,000 PFU. For both viruses, comparable lung titers
were obtained after 48 h which were in the range of 107
PFU/ml (Fig. 3A, left panel). These results indicated that the
NP of H5N1 is well tolerated and does not compromise fitness
FIG. 1. The origin of NP determines Mx1 sensitivity of influenza A virus polymerase activity. The viral polymerase of A/Hamburg/4/09,
designated pH1N1, and that of A/Thailand/1(KAN-1)/04, designated H5N1, were reconstituted in 293T cells by transfection with 50 ng of a firefly
luciferase (FF-luc)-encoding viral minigenome construct, 10 ng of expression constructs encoding the viral polymerase subunits PB2, PB1, and PA
of the respective strain, and 100 ng of the indicated NP-encoding plasmids. In addition, the indicated amounts of Mx1-encoding plasmids were
cotransfected. Twenty-four hours posttransfection, cells were lysed and luciferase activities were measured. Cotransfection of the inactive mutant
Mx1 (K49A) was used as a control, and polymerase activity in the presence of Mx1 (K49A) was set to 100%. Mean values of data from three
independent experiments are shown. Mx1 expression was monitored by Western blot analysis. Actin was used as a loading control (lower panels
in A, C, and D). Dotted lines indicate the amount of Mx1-encoding plasmid necessary for 50% inhibition of polymerase activity. (A) H5N1 and
pH1N1 polymerase activity in the presence of increasing concentrations of Mx1. (B) Polymerase activity after exchange of single vRNP components
in the presence of 100 ng of Mx1-encoding plasmid. (C) pH1N1 polymerase activity in the presence of increasing concentrations of Mx1 and either
NP of pH1N1 [NP (pH1N1)] or H5N1 [NP (H5N1)]. (D) H5N1 polymerase activity in the presence of increasing concentrations of Mx1 and NP
of either H5N1 [NP (H5N1)] or pH1N1 [NP (pH1N1)].
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of the reassortant pH1N1 virus. Next, Mx1-positive BALB-
Mx1 mice were challenged with a high dose of either parental
pH1N1 or reassortant pH1N1-NP(H5N1) virus. All animals
infected with the parental virus showed dramatic body weight
loss, and 70% of the animals succumbed within 4 days (Fig. 3B
and C). In contrast, infection with the reassortant pH1N1-
NP(H5N1) virus caused only moderate weight loss, and all
animals survived (Fig. 3B and C). To exclude the possibility
that the high virulence of pH1N1 resulted from a general
suppression of the interferon response, Mx1 expression in an-
imals was monitored 48 h after infection. Western blot analyses
of lung homogenates demonstrated that both viruses induced
the same amount of Mx1 protein (Fig. 3D). To determine
whether the clinical signs correlated with enhanced virus rep-
lication, BALB-Mx1 mice were infected with 1,000 PFU of
either pH1N1 or pH1N1-NP(H5N1), and lung titers were de-
termined 48 h after infection. Viral titers were 10-fold higher
in animals infected with pH1N1 than in animals infected
with pH1N1-NP(H5N1) (Fig. 3A, right panel). To deter-
mine whether the difference in lethality between pH1N1 and
pH1N1-NP(H5N1) correlated with altered lung pathology, his-
tological tissue sections of Mx-positive mice were examined 4
days after infection (Fig. 3E). Lungs of mice infected with
pH1N1 had a greater number of lesions and displayed more
massive infiltration of inflammatory cells than lungs of mice
infected with pH1N1-NP(H5N1). Together, these data indi-
cate that the nature of NP determines viral replication effi-
ciency and lung pathology in Mx1-positive mice.
The NP of the 2009 pandemic H1N1 virus confers increased
Mx resistance to an avian virus. The NP of the pandemic
H1N1 isolate A/Hamburg/4/09 negatively affected the Mx sen-
sitivity of the H5N1 polymerase of A/Thailand/1(KAN-1)/04,
as assessed in a minireplicon system (Fig. 1C). We therefore
anticipated that an A/Thailand/1(KAN-1)/04 reassortant virus
equipped with the pH1N1 NP gene should gain increased Mx
resistance. To prove this, we generated recombinant wild-type
A/Thailand/1(KAN-1)/04, designated H5N1, and a reassortant
of this parental virus, designated H5N1-NP(pH1N1), coding
for the NP protein of A/Hamburg/4/09. Growth of the reas-
sortant virus in MDCK cells infected at a lowMOI of 0.001 was
significantly impaired by up to 2 log10 compared to that of the
parental H5N1 strain (Fig. 4A). However, after infection at a
high MOI of 5, the two viruses replicated with comparable
efficiencies in Swiss 3T3 cells that do not express Mx proteins,
as demonstrated by the accumulation of equal amounts of PA
protein (Fig. 4B, lanes 1 to 4). Importantly, the replication
efficiency of H5N1 and H5N1-NP(pH1N1) clearly differed in
Mx-expressing cells. Compared to cells infected with H5N1-
NP(pH1N1), expression of the viral PA protein was strongly
reduced in H5N1-infected cells, irrespective of whether they
expressed murine Mx1 or human MxA (Fig. 4B, lanes 5 to 12).
Quantification of PA signal intensities from three independent
experiments confirmed that the observed differences between
H5N1-NP(pH1N1) and H5N1 were significant (Fig. 4C).
These findings indicated that the NP of the human pH1N1
strain is able to confer partial Mx resistance to the otherwise
sensitive avian H5N1 virus.
Next, we determined the growth capacity of H5N1 and
H5N1-NP(pH1N1) in lungs of Mx1-negative BALB/c mice.
Viral lung titers of animals infected with 1,000 PFU of reas-
FIG. 2. The NP of avian H5N1 origin increases Mx sensitivity of a reassortant pH1N1 virus. (A) Growth kinetics of pH1N1 and pH1N1-
NP(H5N1) in MDCK cells after infection at an MOI of 0.001. Culture supernatants were collected at the indicated time points, and virus titers
were determined by plaque assay. Error bars represent the standard errors of the means of data from three independent experiments. (B) Mx
expression in Swiss 3T3 cells expressing either recombinant murine Mx1 (3T3-Mx1), human MxA (3T3-MxA), or no Mx proteins (3T3) was
monitored by Western blot analysis. (C) The indicated Swiss 3T3 control and Mx-expressing cells were infected with 5 MOI of pH1N1 or
pH1N1-NP(H5N1). At the indicated time points p.i., cells were lysed and viral PA protein expression was monitored by Western blot analysis.
Cellular actin was detected as a loading control. (D) PA signals of the experiment shown in panel C and two additional independent experiments
were quantified and normalized to actin. The P values were calculated by Student’s t test comparing individual time points. ***, P ! 0.001; ns,
not significant.
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sortant H5N1-NP(pH1N1) were 100-fold lower than the titers
observed for mice infected with parental H5N1 virus, in full
agreement with the decreased viral replication found in cell
culture (Fig. 4D, left panel). Similar differences in viral lung
titers between the two virus strains were also observed in
BALB-Mx1 mice (Fig. 4D, right panel), indicating that the
reassortant H5N1-NP(pH1N1) virus is attenuated in both
Mx1-positive and Mx1-negative mice. However, despite these
differences in viral growth, the induction of Mx1 in the lungs at
48 h after infection with 106 PFU was comparable (Fig. 4E).
Notably, intranasal infection of BALB-Mx1 mice with 106 PFU
of H5N1-NP(pH1N1) virus caused rapid weight loss (Fig. 4F)
and almost 100% mortality (Fig. 4G). In contrast, all H5N1-
infected animals recovered rapidly (Fig. 4F) and survived (Fig.
4G). Consistent with the clinical outcome, multiple foci of
extended inflammatory cell infiltrates and thickening of bron-
FIG. 3. NP determines virulence of pH1N1 in Mx1-positive mice. (A) BALB/c (left columns) and BALB-Mx1 (right columns) mice were
inoculated i.n. with 1,000 PFU of the indicated viruses. Lungs from infected mice (n! 5) were collected 48 h p.i. and homogenized, and virus titers
were determined by plaque assay. (B and C) Changes in body weight (B) or survival (C) of BALB-Mx1 mice (n ! 10/group) intranasally infected
with 2" 106 PFU of pH1N1 and pH1N1-NP(H5N1). Survival and weight loss were monitored daily for 12 days. The P values for changes in weight
loss between the two groups were calculated by Student’s t test comparing individual time points. ** and ***, P # 0.01 and 0.001, respectively.
(D) Mx1 expression levels in lungs of mice infected with 2 " 106 PFU were determined 48 h p.i. by Western blot analysis of lung homogenates.
(E) Histopathological analysis of lungs from BALB-Mx1 mice intranasally infected with 2 " 106 PFU of the indicated viruses 4 days p.i. Serial
sections were examined for histopathological changes following hematoxylin-and-eosin (H&E) staining, and representative images were captured
at magnification "10. Sections are representative of three mice per group. uninf., uninfected.
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FIG. 4. The NP of the 2009 pandemic H1N1 virus confers increased Mx resistance to an avian virus. (A) MDCK cells were infected at an MOI
of 0.001 with the indicated viruses. Virus titers in the culture supernatants were determined by plaque assay at the indicated time points. Error
bars represent the standard errors of the means of data from three independent experiments. (B) Swiss 3T3 control and Mx1- or MxA-expressing
cells were infected with 5 MOI of the indicated viruses. At 5 and 6 h p.i., cells were lysed, and viral PA protein expression was monitored by Western
blot analysis. Actin was used as a loading control. (C) Signals of PA obtained for panel B and in two additional independent experiments were
quantified and normalized to actin expression. The P values were calculated by Student’s t test, comparing individual time points. *, **, and ***,
P ! 0.05, 0.01, and 0.001, respectively. ns, not significant. (D) Viral lung titers from BALB/c and BALB-Mx1 mice infected i.n. with 1,000 PFU
of the indicated viruses. Lungs from infected mice (n " 5) were collected 48 h p.i. and homogenized, and virus titers were determined by plaque
assay. (E) Mx1 expression levels in lungs of BALB-Mx1 mice (n " 2) infected with 106 PFU were determined 48 h p.i. by Western blot analysis
of lung homogenates. (F and G) BALB-Mx1 mice (n " 14/group) were infected i.n. with 106 PFU of the indicated viruses and monitored daily
for weight loss (F) and survival (G). (H) Histopathological analysis of lungs from BALB-Mx1 mice infected i.n. with 106 PFU of the indicated
viruses 3 days p.i. Serial sections were examined for histopathological changes following hematoxylin-and-eosin (H&E) staining. Images were
captured at magnification #10 and are representative of three mice per group.
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chiolar and alveolar walls were observed 3 days after infection
with H5N1-NP(pH1N1) virus (Fig. 4H). On the contrary, the
pulmonary pathology in mice infected with H5N1 was only
moderate (Fig. 4H). Thus, despite causing considerable atten-
uation in mice, NP of pH1N1 rendered the H5N1 virus less
sensitive to Mx1 restriction, thereby resulting in increased lung
pathology and death of infected animals.
DISCUSSION
Here we have shown that the pandemic H1N1 virus A/
Hamburg/4/09 is less sensitive to the inhibitory actions of the
human MxA and mouse Mx1 proteins than the highly patho-
genic avian H5N1 virus A/Thailand/01/04. Introduction of the
avian H5N1 NP into the pandemic H1N1 virus abrogated its
partial Mx resistance. We also show that the NP of pandemic
H1N1 virus was able to render the avian H5N1 virus less
sensitive to Mx restriction both in cell culture and in mice.
These results indicate that NP is a major viral determinant of
Mx sensitivity.
Infection of Mx1-positive mice with the pandemic H1N1
virus resulted in increased titers in lungs compared to in-
fection with the reassortant pH1N1-NP(H5N1) virus and
caused more-severe histopathological changes in the lung.
Similar severe lung pathology was observed after infection with
the reassortant H5N1-NP(pH1N1) virus. The lung viral titers,
however, were significantly lower than the lung viral titers of
mice infected with the parental H5N1 virus. Thus, increased
replication efficiencies in the lung do not necessarily correlate
with lung pathology and disease outcome. This discrepancy
between reduced replication efficiency and enhanced morbid-
ity and mortality in influenza A virus-infected mice has already
been noticed by others (2, 19). We can only speculate that
other factors, such as enhanced replication in specific cell
types, dysregulation of pulmonary cytokines, or other delete-
rious effects on tissue integrity might have contributed to the
severe pathogenicity of pH1N1 and H5N1-NP(pH1N1).
The present data with the reassortant viruses clearly suggest
that the viral NP is the target of Mx action. A direct physical
interaction between MxA and influenza A virus NP was pre-
viously demonstrated in immunoprecipitation assays under
cross-linking conditions (32). Furthermore, there is compelling
biochemical evidence for recognition and binding of the nu-
cleocapsids of Thogoto virus by human MxA (16, 17, 33).
Thogoto virus is an influenza virus-like virus transmitted by
ticks. It is highly sensitive to the antiviral action of MxA (17)
and may display high-affinity binding sites for the MxA
GTPase. We have previously shown that MxA has to form
highly ordered oligomers to exert its antiviral function (7). The
structural details of MxA oligomerization have recently been
elucidated (7). They suggest that oligomerization is a stepwise
process. The model predicts that MxA tetramers oligomerize
on the well-ordered surface of viral nucleocapsids into filamen-
tous or ring-like structures, thereby inhibiting the transcrip-
tional activity of the viral polymerase complex (10). Processiv-
ity may largely depend on appropriate binding sites on the viral
NP. Even small changes in the amino acid composition of NP
may greatly affect the strength of MxA binding, oligomeriza-
tion, and antiviral activity.
Introduction of the NP of pH1N1 origin into the H5N1 virus
caused considerable attenuation of the reassortant virus in cell
culture and in mice. This was interesting, because the polymer-
ase activity of the reassortant strain remained unchanged in a
minireplicon system. The present findings are in agreement
with those of a recent study for which a high degree of com-
patibility between components of the viral polymerase complex
of avian H5N1 and pandemic H1N1 strains, resulting in normal
polymerase activity but strong attenuation of viral growth, was
reported (21). Importantly, the reassortant H5N1-NP(pH1N1)
virus used in the present study showed increased Mx resistance
in tissue culture and in vivo, in addition to its partial attenua-
tion. It is conceivable that a gain of Mx resistance may reduce
virus fitness. If this were the case, successful adaptation of
avian viruses would require additional mutations to compen-
sate for the growth defects caused by Mx escape mutations in
the NP. Surprisingly, introduction of avian NP into the pan-
demic H1N1 strain was well tolerated and did not affect viral
fitness in the absence of Mx, indicating that the polymerase
complex of this pandemic H1N1 strain has gained a remark-
able flexibility in the cooperation with NPs of distantly related
strains. This capacity may have enabled the pandemic H1N1
progenitor virus to gain Mx resistance without obvious atten-
uation, facilitating its successful transmission and spread in
2009.
A picture is beginning to emerge which has implications for
influenza virus evolution and epidemiology. Virtually all NPs
of human influenza virus strains studied so far (including the
pandemic H1N1 isolate from 2009 described in this study or
the pandemic virus of 1918) show increased resistance to the
antiviral action of mammalian Mx proteins, whereas the NPs of
avian origin [including the H5N1 strain A/Thailand/(KAN-
1)/04 and others] are highly Mx sensitive (4; this study). Mx
genes are also present in avian species, and some antiviral
activity for chicken Mx linked to a serine-to-asparagine poly-
morphism at position 631 has been described (15). However,
recent studies could not detect any antiviral effect of chicken
Mx proteins against different strains of influenza A viruses (3,
27). In any case, it is conceivable that newly emerging influenza
A viruses acquire adaptive mutations in the mammalian host
which allow them to escape Mx restriction. As yet, the amino
acids that determine Mx resistance are not known. We are cur-
rently investigating the 32 amino acids of NP which differ between
the pandemic H1N1 and the avian H5N1 strain to identify the
crucial amino acid patch required for Mx sensitivity.
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To develop a novel attenuation strategy applicable to all in-
fluenza A viruses, we targeted the highly conserved protein-
protein interaction of the viral polymerase subunits PA and
PB1. We postulated that impaired binding between PA and
PB1 would negatively affect trimeric polymerase complex for-
mation, leading to reduced viral replication efficiency in vivo.
As proof of concept, we introduced single or multiple amino
acid substitutions into the protein-protein-binding domains of
either PB1 or PA, or both, to decrease binding affinity and po-
lymerase activity substantially. As expected, upon generation
of recombinant influenza A viruses (SC35M strain) containing
these mutations, many pseudo-revertants appeared that par-
tially restored PA-PB1 binding and polymerase activity. These
polymerase assembly mutants displayed drastic attenuation in
cell culture and mice. The attenuation of the polymerase as-
sembly mutants was maintained in IFN!/" receptor knock-out
mice. As exemplified using a H5N1 polymerase assembly mu-
tant, this attenuation strategy can be also applied to other
highly pathogenic influenza A virus strains. Thus, we provide
proof of principle that targeted mutation of the highly con-
served interaction domains of PA and PB1 represents a novel
strategy to attenuate influenza A viruses.
Infection with influenza viruses annually claims 250,000–
500,000 lives worldwide (1). As exemplified by the 1918 influ-
enza pandemic, which resulted in more than 50 million
deaths (2), global spread of a pandemic influenza virus strain
can lead to high morbidity and mortality. Besides inactivated
vaccines, a live attenuated influenza virus vaccine (FluMist)
(3, 4) is currently used for vaccination. Importantly, the de-
gree of attenuation is critical for the safety of the live vaccines,
but it also affects their efficacy. For safety reasons, children
below the age of two and immunocompromised persons are
excluded from vaccination with these live vaccines (3). Fur-
thermore, the live vaccine used in the 2007–2008 season was
50% less efficacious than the inactivated vaccine that was used
(5). In the currently used influenza A virus (FluA)3 live vac-
cine, the degree of attenuation is fixed because a specific mas-
ter strain is used (3). Thus, to vary the degree of attenuation
and to identify new sites that contribute to the safety of live
vaccines, new attenuation approaches applicable for all FluA
strains are desirable.
A promising target for attenuation of all known FluA
strains is the trimeric polymerase complex. Its assembly from
the subunits PA, PB1, and PB2 is crucial for polymerase activ-
ity and thus virus replication (6–8). PB1 represents the cen-
tral scaffold protein that binds to PA and PB2 (6, 9–11). Sev-
eral recently published crystal structures have defined the
highly conserved protein-protein-binding domains for PA-
PB1 and PB1-PB2 (11–13). Alteration of these conserved resi-
dues abrogates subunit interactions accompanied by re-
stricted assembly of polymerase heterotrimers, resulting in
decreased polymerase activities (6, 14).
We therefore hypothesized that inefficient polymerase as-
sembly would lead to impaired viral growth and thus attenua-
tion. We identified mutations in the PA-binding domain of
PB1 (PB1L8N), in the PB1-binding domain of PA (PAW706E),
or in both domains simultaneously (PB1L8IPAW706E), all of
which reduced PA-PB1 binding affinities, leading to impaired
polymerase assembly and activity. We observed a correlation
between reduction in polymerase activity and increased atten-
uation in cell culture and mice. Importantly, the attenuated
phenotype of the polymerase assembly mutants was main-
tained in the IFN!/" receptor knock-out mice. Thus, target-
ing of the highly conserved protein-protein interaction do-
mains of PA and PB1 represents a novel strategy to attenuate
influenza A viruses.
EXPERIMENTAL PROCEDURES
Generation of Recombinant Influenza A Viruses—Genera-
tion of the recombinant viruses A/SC35M (H7N7) (15) and
A/Thailand/KAN-1/2004 (H5N1) (16) was performed as de-
scribed (14, 16) in 6-well tissue plates with 106 293T cells per
well using the eight pHW2000 plasmids (300 ng of each) ex-
pressing the individual segments and the four pCAGGS plas-
mids (150 ng of each) coding for PA, PB1, PB2, and NP. After
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24 h, released virus was used to infect MDCK cells. Sequences
of viral genomes were determined from particles released in
the supernatant of the MDCK cells 48 h post infection. Res-
cued viruses were plaque-purified, and MDCK cells were in-
fected for propagation of virus stocks.
Virus Infections and Growth Assays—MDCK cells or hu-
man lung cells (A549) were infected at a multiplicity of infec-
tion of 0.001 at 37 °C. Virus titers in the cell supernatants
were determined at the indicated time points by plaque assay
and expressed as plaque-forming units (pfu)/ml. For passag-
ing the mutant viruses 10 times in cell culture, MDCK cells
were infected with!103 pfu corresponding to a multiplicity
of infection of 0.001 for 24–36 h.
Mouse Experiments—BALB/c mice were obtained from
JANVIER SAS (Strasbourg, France). IFN! receptor knock-out
(IFNAR0/0) mice (17) backcrossed 12 generations to C57BL/6
were generated by J. Sprent and M. Rubinstein (The Scripps
Research Institute, La Jolla, CA) and kindly provided by A.
Diefenbach (Institute of Medical Microbiology and Hygiene
(IMMH), Freiburg, Germany). 6–8-week-old animals were
used for all infection experiments, which were performed in
accordance with the guidelines of the local animal care com-
mittee. Animals were euthanized if severe symptoms devel-
oped or body weight loss approached 25% of the initial value.
Lung homogenates were prepared using the FastPrep24 sys-
tem (MP Biomedicals). For passaging the mutant viruses in
vivo, 6–8-week-old BALB/c mice were infected with 103 pfu
intranasally. 48 h post infection, total lung was homogenized,
and an infectious dose of 103 pfu was used for another round
of infection of BALB/c mice. In total, three passages were
performed.
Molecular Modeling—Based on the structural model of PB1
(aa 1–15) bound to PA (Protein Data Bank (PDB) 2znl), a
homology model was derived for SC35M using Prime
(Schroedinger Suite 9.1.107) on an Intel 6600 Core2Duo pro-
cessor machine (3 GB of RAM) running openSUSE 11.2. To
accurately reflect conformational shifts in PA and PB1 in-
duced by the V12I exchange, the side chains of amino acids
forming the proximate shell around this residue were refined
using Prime Refinement with default settings. Thereby,
mainly a shift of the side chain of Met-595 is observed, which
is displaced by the bulkier substituent of V12I.
Plasmid Constructions—The pHW2000 plasmid system
(18) was used for influenza A virus rescue. To obtain rescue
plasmids containing the mutant PB1 or PA genes, site-di-
rected mutagenesis was performed. To generate the pCAGGS
expression plasmids encoding PA or PB1 mutants, parts of
the corresponding open reading frames were PCR-amplified,
digested with AgeI and NotI (PB1) or CFR9I and Bsp119I
(PA), and subsequently cloned into pCAGGS-SC35M-
PB1-HA and pCAGGS-SC35M-PA-HA.
Co-immunoprecipitation and Immunoblot Analysis—293T
cells were transfected with the indicated plasmids in 6-well
plates using METAFECTENE (Biontex, Martinsried, Ger-
many). Cells were incubated 24 h post transfection with lysis
buffer (20 mM Tris, pH 7.5, 100 mM NaCl, 0.5 mM EDTA,
0.5% Nonidet P-40, 1% protease inhibitor mix G, (Serva,
Heidelberg, Germany), 1 mM DTT) for 15 min on ice. After
centrifugation by 13,000 rpm at 4 °C, supernatant was incu-
bated with HA- or FLAGM2-specific antibodies (Sigma) cou-
pled to agarose beads, respectively, for 1 h at 4 °C. After three
washes with 1 ml of washing buffer (lysis buffer without pro-
tease inhibitor mix), bound material was eluted under dena-
turing conditions, separated on SDS-PAGE gels, and trans-
ferred to PVDF membranes. Viral polymerase subunits were
detected with antibodies directed against the HA (Covance,
Berkeley, CA) or His (Qiagen) or FLAG tag (Sigma).
Enzyme-linked Immunosorbent Assay (ELISA)—ELISA was
essentially performed as described previously (19) using bio-
tinylated PB11–15 peptides bound to streptavidin-coated mi-
crowell plates and cell extract containing HA-tagged PAWT
or mutant proteins.
Cells—293T, A549, and MDCK cells were grown in
Dulbecco’s modified Eagle’s medium supplemented with
10% fetal calf serum, 2 mM L-glutamine, and 1% penicillin/
streptomycin. All cells were maintained at 37 °C and 5%
CO2.
Peptides—Peptides were synthesized as described in Ref. 19
using a Pioneer automatic peptide synthesizer (Applied Bio-
systems, Foster City, CA).
Reconstitution of the Influenza Virus Polymerase Activity—
293T cells were transiently transfected with a plasmid mix-
ture containing the influenza A virus-derived PB1, PB2, PA,
and NP expression plasmids and a polymerase I-driven plas-
mid transcribing an influenza A virus-like RNA coding for the
reporter protein firefly luciferase to monitor viral polymerase
activity (14). The transfection mixture also contained a plas-
mid constitutively expressing Renilla luciferase, which served
to normalize variation in transfection efficiency. The reporter
activity was determined 24 h post transfection and normal-
ized using the Dual-Glu! luciferase assay system (Promega).
Statistical Analysis—With the exception of the mouse ex-
periments, error bars represent S.E. from at least three inde-
pendent experiments. For the animal experiments, the indi-
cated number of mice was used for calculating S.E.
Ethics Statement—All animal experiments were performed
in compliance with the German animal protection law
(Tierschutzgesetz). Themice were housed and handled in ac-
cordance with good animal practice as defined by the Federa-
tion of Laboratory Animal Science Associations (FELASA)
and the national animal welfare body GV-SOLAS. The animal
welfare committees of the University of Freiburg (Regier-
ungspra¨sidium Freiburg) approved all animal experiments.
RESULTS
Mutation at the PA-PB1-binding Interface Leads to Escape
Mutants with Impaired Viral Replication—To identify muta-
tions in PA or PB1 that attenuate FluA to a desirable level, we
devised an experimental procedure to force spontaneous es-
cape mutants (Fig. 1A). The first step is the generation of PA
or PB1 mutant proteins with substantially impaired polymer-
ase activity and subunit interaction. In a second step, viruses
expressing these mutant proteins are created by reverse ge-
netics techniques. Taking into account the rapid mutability of
FluA, we expected, dependent on the severity of the intro-
duced mutations, the following possible outcomes: (i) mainte-
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nance of the inserted mutations, resulting in attenuated vi-
ruses; (ii) maintenance of the inserted mutations, leading to
non-viable viruses; or (iii) introduction of compensatory mu-
tations. These mutations could restore wild-type (WT) viabil-
ity or display an attenuated phenotype (Fig. 1A).
To efficiently disrupt the highly hydrophobic binding inter-
face between PA and PB1 (12, 13), we replaced either single or
multiple aa in the PA-binding domain of PB1 by the charged
aa aspartic acid (Fig. 1B) and determined viral polymerase
activity in human 293T cells (Fig. 1C). Single substitutions by
Asp outside (P13D) or at the border (K11D) of the PA-bind-
ing core region (12, 13, 19) resulted in a moderately decreased
or unchanged polymerase activity (Fig. 1C). In contrast, re-
placement of the leucine at position 8 (L8D), which lies within
the core-binding 310 helix and is known to be essential for
binding to PA (9, 19), abrogated polymerase activity to a level
below 1% of WT activity (Fig. 1C). Double substitutions at
other positions in the N terminus of PB1 (PB11–15) reduced
the polymerase activity below 3% of WT activity (Fig. 1C).
Next, rescue experiments were performed to generate recom-
binant SC35M viruses encoding for the above mentioned PB1
mutants. To prevent simple reversion to the WT sequence,
2–3 nucleotide exchanges were performed to mutate the indi-
vidual aa positions in PB1 (supplemental Fig. S2). As
expected, we could generate the mutant virus coding for
PB1K11D without compensatory mutations (Table 1) and im-
paired growth (supplemental Fig. S1A). However, besides the
PB1K11D mutant, we were also able to generate recombinant
SC35Mmutated to PB1T6D,L7D, PB1L8D, PB1L8D,F9D, and
PB1L10D,K11D, respectively (Table 1, Fig. 1D). However, the
majority of these viruses represented pseudo-revertants,
which we defined as viruses containing a non-introduced,
non-WT mutation at the site of the mutated residue, which
partially or fully restores the WT phenotype. Specifically, dur-
ing the rescue of SC35M coding for PB1T6D,L7D, the pseudo-
revertant PB1T6D,D7Y emerged frequently (Fig. 1D), whereas
rescue of the PB1L10D,K11D mutant virus produced two viruses
coding for PB1L10D,K11D and PB1L10D,D11V (Fig. 1D, Table 1).
Importantly, several independent attempts to rescue mutant
viruses coding for PB1L8D resulted exclusively in virus mu-
tants harboring changes to PB1D8A, PB1D8V, or PB1D8N (Fig.
1D, Table 1). PB1D8V or PB1D8A mutant viruses showed only
slightly reduced viral growth (Fig. 1E, data not shown),
whereas the mutant virus coding for PB1D8N displayed a pro-
nounced attenuation at 12 h p.i. (Fig. 1E). No additional mu-
tations were found in the polymerase genes of this virus (Ta-
ble 1, supplemental Fig. S2A). Independent attempts to
generate SC35M coding for PB1L8D,F9D yielded three virus
mutants: PB1D8N,D9F, PB1D8V,D9F, and PB1L8D,F9D* (Fig. 1D).
Because PB1D9F represents the wild-type aa at this position,
the PB1D8N,D9F and PB1D8V,D9F mutants were phenotypically
indistinguishable from the PB1D8V or PB1D8N mutants, re-
spectively. However, the PB1L8D,F9D* mutant represents a re-
combination event that resulted in restoration of the PB1
open reading frame downstream of the mutated PB1 site
(supplemental Fig. S3). As shown in Fig. 1E, the PB1L8D,F9D*
mutant showed no attenuation in cell culture (Fig. 1E).
Pseudo-reversions in PB1 Partially Restore Polymerase Ac-
tivity and Trimeric Polymerase Complex Assembly—We rea-
soned that the pseudo-reversions PB1D8N and PB1D8V would
FIGURE 1. Characterization of influenza A viruses with mutations in the PA-binding domain of PB1. A, flowchart of the experimental procedure used
to identify attenuated influenza A virus mutants. B, graphic depicting the PB1 mutants used in panel Cwith single or multiple Asp substitutions within or
near the core PA-binding domain (gray box). 8D, L8D; 11D, K11D; 13D, P13D; 4D,5D, N4D,P5D; 6D,7D, T6D,L7D; 8D,9D, L8D,F9D; 10D,11D, L10D,K11D;
4D,8D,11D, N4D,L8D,K11D 4D,5D,10D,11D, N4D,P5D,L10D,K11D; 6D,7D,8D,9D, T6D,L7D,L8D,F9D. C, determination of FluA polymerase activity in the presence
of the indicated PB1 mutants. The activity observed with PB1 WT was set to 100%. The omission of PB1 (!PB1) in the transfection mixture served as a nega-
tive control. D, emergence of revertants after rescue of PB1 mutants with impaired polymerase activity. PB1 sequences were determined from individual
rescue attempts, indicated by #. Virus mixtures with polymorphisms in PB1 were further subjected to plaque purification (indicated by pp and the number
of the picked plaque). The arrows indicate the site of polymorphism in the PB1 sequence. PB16D7D, PB1T6D,L7D; PB18D, PB1L8D; PB18D9D, PB1L8D,F9D; PB110D11D,
PB1L10D,K11D. E, viral growth of PB1 mutant viruses. MDCK cells were infected with the indicated SC35Mmutants at a multiplicity of infection of 0.001, and
virus titers in the cell supernatant were determined by plaque assay. PB18N, PB1D8N; PB18V, PB1D8V.
TABLE 1
Characteristics of SC35 Mmutant viruses
ND, not determined;!. no mutations.
Mutation
Minireplicon
activity
Successful rescue
attempts/attempts Compensatory mutations
%
PB1
L8D 0.5 4/6 D8N (1"); D8V (2"); D8A (1")
L8Na 67 2/2 No
K11D 113 2/2 No
L4D,L5D 0.2 0/4 !
T6D,L7D 0.4 3/4 D7Y(3")
L8D,F9D 0.6 2/5 L8N,D9F (1"); L8D,F9D (1")
L10D,K11D 1.6 6/8 D10V (2")
L4D,L8D,K11D 0.2 0/3 !
L4D,L5D,L10D, 11D 1.0 0/4 !
L6D,L7D,L8D,F9D 0.2 0/3 !
PA
W706E 10 2/2 No
W706R 2 1/2 W706G (1")
PB1# PA
L8N#W706E 12 2/2 PB1 N8I (1"); PB1 N8L (1")
L8I#W706Ea ND 2/2 No
a Direct rescue.
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rescue polymerase activity through restoration of PA-PB1
binding and thus polymerase complex assembly. Indeed, 60%
of WT polymerase activity was achieved with PB1D8N,
whereas PB1D8V even exceeded WT activity (Fig. 2A). Using
an ELISA-based binding assay (19) and peptides correspond-
ing to the 15 N-terminal aa of PB1 (pPB1x), we determined
FIGURE 2. Effect of PB1mutations on polymerase activity and formation of the trimeric polymerase complex. A, determination of FluA polymerase
activity in the presence of the indicated PB1 mutants. The activity observed with PB1 WT was set to 100%. The omission of PB1 (PB1!) in the transfection
mixture served as a negative control. 8D, L8D; 8N, D8N; 8V, D8V. B, determination of the PA binding affinities of the PB1 mutants. An ELISA-based binding
assay was carried out with biotinylated peptides corresponding to the N-terminal 15 aa of the indicated PB1 mutants and a cell extract containing HA-
tagged PA. * and ** indicate p values (Student’s t test) of"0.05 and"0.01, respectively. OD, optical density. C and D, dimer (C) and trimer (D) formation in
the presence of the indicated PB1 mutants was assayed by immunoprecipitation (IP). CE, cell extract. The PB1 mutant 6789D, T6D,L7D,L8D,F9D served as a
negative control. E–H, four helices of PA (gray/brown drawings) are involved in the formation of the binding interface for PB1; nitrogen atoms are in blue,
and oxygen atoms are in red. E, crystal structure of the WT PB18L. F–H, model of the interface containing the mutations PB1L8D (F), PB1D8N (G), and PB1D8V
(H). In H, the surface complementarity between the binding partners is illustrated by visualization of the surface of PA in opaque style and of the surface of
PB18L inmesh style.
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that PA did not bind to pPB1L8D, whereas binding was ob-
served to both pPB1D8N and pPB1D8V, although with signifi-
cantly lower affinity than pPB1WT (Fig. 2B). To test whether
the pseudo-reversions affect the formation of PA-PB1 dimers,
we performed co-immunoprecipitation studies. Although
PB1D8N weakly interacted with PA, no interaction was de-
tected between PB1L8D and PA (Fig. 2C). In contrast, complex
formation between PA and PB1D8V was comparable with that
of PA and WT PB1 (Fig. 2C). When co-immunoprecipitation
was performed with all three polymerase subunits, both
PB1D8N and PB1D8V supported trimeric polymerase complex
assembly, whereas PB1L8D did not (Fig. 2D). Consistent with
earlier observations (14), lack of trimeric polymerase assembly
was accompanied by reduced levels of PB2 (Fig. 2D, cell ex-
tract). We speculate that the reduced levels of PB2 are the
result of an enhanced degradation of the unbound PB2. To
better understand the reason for the diminished binding, we
modeled the PA-binding domain of PB1L8D, PB1D8V, and
PB1D8N into the PA-PB1 crystal structure. Within the hydro-
phobic groove of PA (12, 20), Leu-8 plays a key role in protein
binding affinity by mediating contacts to Ile-621, Val-636, and
Leu-640 (Fig. 2E). Most strikingly, mutation to L8D causes
total affinity loss by repulsion of the charged amino acid from
this non-polar region (Fig. 2F). L8N still places hydrophilic
chemical functionalities unfavorably in this binding groove
but may establish a hydrogen-bond interaction with Pro-620
that likely increases the binding affinity (Fig. 2G). In contrast,
the D8V mutation apparently causes a reduction of the hydro-
phobic interaction area due to its smaller dimensions when
compared with 8L (Fig. 2H), resulting in weaker binding but
not in a complete loss of binding affinity.
Molecular Modeling Reveals Attenuating Mutations in the
PB1-binding Site of PA—To test whether mutations in the
PB1-binding domain of PA have the potential to cause attenu-
ation of FluA, we mutated the highly conserved tryptophan at
aa position 706 (Fig. 3A) to either glutamine (PAW706E) or
arginine (PAW706R). Molecular modeling suggests that the
negatively charged carboxylate moiety of W706E will attract
Lys-643 of PA to form a salt bridge (Fig. 3B). This mutation
abrogated binding of PA to PB1 in a biochemical pulldown
assay (12). We also expected that the mutation W706R would
abrogate the interaction with PB1 because W706R positions a
positively charged group in the close vicinity of Lys-643 of PA,
resulting in the destabilization of the PA protein conforma-
tion (Fig. 3C). Both mutants, PAW706E and PAW706R, failed to
bind to peptides comprising the N-terminal 15 aa of WT PB1
(Fig. 3D). When compared with WT PA, the polymerase ac-
tivity was reduced by!90% for PAW706E and 98% for
PAW706R (Fig. 3E). SC35M coding for PAW706E could be gen-
erated by reverse genetics without further compensatory mu-
tations in PA (Fig. 3F) or both PB1 and PB2 (Table 1). As ex-
pected, this mutant virus was significantly attenuated by 2.5
log10 24 h p.i. in MDCK (Fig. 3G) and A549 cells (supplemen-
tal Fig. S1B). Attempts to rescue SC35M-PAW706R revealed a
pseudo-reversion (PAW706G) (Fig. 3F), which was barely im-
paired in viral growth in MDCK cells (Fig. 3G) and attenuated
by 2 log10 24 h p.i. in A549 cells (supplemental Fig. S1B).
To test the feasibility of generating viruses harboring muta-
tions in both PB1 and PA, we tried to rescue a virus coding for
both PAW706E and PB1D8N. In one rescue attempt, we ob-
tained a virus mutant harboring a reversion to WT PB1 and
no changes in PA (Table 1). In a second independent rescue
attempt, we obtained a virus mutant (SC35M-PAW706EPB1L8I)
harboring amutation in PB1 to N8I without changes in PA (Fig.
3H), which displayed considerably impaired growth inMDCK
(Fig. 3I) and A549 cells (supplemental Fig. S1C) with 3–4 log10
titer reduction 24 h p.i., corresponding to a small plaque pheno-
type of SC35M-PAW706EPB1L8I when compared withWT virus
(supplemental Fig. S4). Thus, virus mutants with aa changes in
both PB1 and PA can be generated and show impaired growth
properties.
Polymerase Assembly Mutants Are Attenuated in Mice—To
evaluate the degree of attenuation of our mutant viruses in
vivo, we infected BALB/c mice with SC35Mmutants. Follow-
ing intranasal infection, we monitored for weight loss and
survival and determined viral lung titers. Although WT-in-
fected mice succumbed to death following infection with 103
pfu, all mice infected with 104 pfu of SC35M-PB1D8N survived
despite an initial weight loss (Fig. 4A). Consistent with the
lack of attenuation in cell culture, infection with SC35M-
PB1D8V was as pathogenic as WT SC35M (supplemental Fig.
5). Mice infected with 103 or 104 pfu of SC35M-PAW706E (Fig.
4B) or SC35M-PAW706EPB1L8I (Fig. 4C) survived with only
marginal reduction of body weight, whereas at 105 pfu, 25 and
37.5% of the animals survived infection with SC35M-PAW706E
and SC35M-PAW706EPB1L8I, respectively. The degree of at-
tenuation observed with the polymerase assembly mutant
viruses correlates with decreased viral lung titers (Fig. 4D).
To demonstrate that our findings apply to other influenza
A viruses, we introduced the W706E mutation in PA of the
highly pathogenic H5N1 virus A/Thailand/(KAN-1)/2004
(clade 1) (21). When compared with infection with WT
KAN-1, this mutant virus (KAN-1-PAW706E) was attenuated
by 4 log10 24 h p.i. in MDCK cells (supplemental Fig. 1D) and
showed an increase in LD50 of!10,000-fold (Fig. 4E, data not
shown) as well as significantly lower lung titers ("5 log10) in
BALB/c mice (Fig. 4F).
To determine the safety of our mutant viruses, we infected
IFNAR0/0 mice, which are highly susceptible to virus
infection (17, 22, 23), with up to 103 pfu of the attenuated
strain SC35M-PAW706E or 10 pfu of WT virus. All SC35M-
PAW706E-infected mice survived, whereas all animals infected
with WT virus succumbed to infection (Fig. 4G). At an infec-
tion dose of 104 pfu, 66% of the SC35M-PAW706E-infected
mice survived. As expected, the viral lung titer of mice in-
fected with 103 pfu SC35M-PAW706E for 48 h was at least
1000-fold reduced when compared with WT-infected mice
(Fig. 4H).
Polymerase Assembly Mutants Remain Attenuated after
Passaging in Cell Culture and Mice—To determine whether
the polymerase assembly mutants can easily revert to WT, we
performed three serial lung passages of SC35M-PB1D8N,
SC35M-PAW706E, and SC35M-PAW706EPB1L8I in BALB/c
mice. No changes were observed in PA, whereas mutations to
either V92M or V92L outside the PA-binding domain (12, 13,
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FIGURE 3.Mutations in the PB1-binding site of PA affect viral growthproperties.A–C, Trp-706 contributes to PA-PB1 binding by formation of surface contacts
with PB1 Asn-4 and PB1 Pro-5 to PA. A, amodel of these contacts as in Fig. 2H. The surface of PA around Trp-706 is shown inmesh style, and the surface of PB1 is
shown in opaque style, respectively. B, the negatively charged carboxylatemoiety introduced by the PAW706Emutationmay attract PA Lys-643 to form a salt
bridge (wild-typemodel in gray; conformation predicted for themutant in green). C, the positive charge introduced by theW706Rmutation is likely to have a repul-
sive effect due to the positive charge of Lys-643.D, determination of the PB1 binding affinities of the PAmutants by ELISA using cell extracts containingmutant
PA-HA.OD, optical density; 706E, W706E; 706R, W706R. E, determination of the FluA polymerase activity in the presence of the indicated PAmutants. PA!, omission
of PA. F, rescue of SC35Mmutants coding for PAmutants. The arrow indicates the site of polymorphism. 706G, W706G.G, viral growth of PAmutant viruses in
MDCK cells.H, rescue of a SC35Mmutantwithmutations in PA and PB1. 8N, D8N; 8I, L8I. I, viral growth curve of SC35M-PAW706EPB1L8I inMDCK cells.
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19) appeared in PB1 of SC35M-PAW706E and SC35M-
PAW706EPB1L8I, respectively (Fig. 5, A and B). Infection of
IFNAR0/0 mice with 100 pfu of SC35M-PAW706E passaged
three times in mice resulted only in a transient weight loss
(Fig. 5C), demonstrating that this virus was still strongly at-
tenuated. Furthermore, serially passaging SC35M-PAW706E
and SC35M-PAW706EPB1L8I 10 times in MDCK cells also led
to a mutation to PB1V92M (Fig. 6, A and B), as well as PAT639A.
Importantly, growth of both passaged viruses remained im-
paired in MDCK cells (Fig. 6C). Together, these results indi-
cate that the polymerase assembly mutants can acquire muta-
tions in the viral genome during the passages in mice or cell
culture but that these mutations do not reverse their attenu-
ated phenotype. Therefore, the polymerase assembly mutants
are phenotypically stable.
DISCUSSION
The objective of this study was to generate attenuated influ-
enza A viruses based on defects in the assembly of the polymer-
ase complex. Accordingly, we reasoned that alteration of key
amino acids involved in the subunit interactions would force the
virus to escape by acquisition of newmutations, some of which
would fail to restore efficient polymerase complex assembly and
activity. Indeed, the majority of the rescuedmutant viruses rep-
resent pseudo-revertants with various degrees of attenuation.
Only a few intentionally introducedmutations (e.g. PB1L10D,K11D
and PAW706E) were tolerated and, as predicted, recombinant
viruses expressing these proteins were attenuated. However, the
occurrence of compensatory mutations at other aa positions in
FIGURE 4. Polymerase assembly mutants are attenuated in mice. A–C, survival (right) and weight loss (left) of 6–8-week-old female BALB/c mice (n!
6/group) after intranasal infection with the indicated doses of SC35Mmutant viruses encoding PB1D8N (PB18N) (A), PAW706E (PA706E) (B), or both PAW706E and
PB1L8I (PB18I) (C).WT, wild-type virus SC35M. D, BALB/c mice (n! 5) were infected with 10
3 pfu of the indicated virus mutants. 48 h p.i., lung titers were de-
termined by plaque assay. E, weight loss and survival of 6–8-week-old female BALB/c mice (n! 10/group) after intranasal infection with the indicated
doses of KAN-1 or KAN-1-PAW706E. F, lung titers in mice (n! 5) infected with 10
3 pfu of either KAN-1 or KAN-1-PAW706E at 48 h p.i. G, weight loss and survival
of 8–10-week-old IFNAR0/0 mice (n! 7/group) infected with the indicated doses of WT virus or SC35M-PAW706E. H, lung titer in IFNAR
0/0 mice (n! 3) in-
fected with 10 pfu of either WT or SC35M-PAW706E at 48 h p.i.
FIGURE 5. Characterization of polymerase assembly mutants after serial
passages in mice. A, mutations in PB1 and PA observed after serial pas-
sages of the indicated virus mutants in BALB/c mice.mP1–3, mouse passage
1–3.", no mutations found. B, electropherogram of PB1 and PA sequences
after serial passages of the indicated viruses in BALB/c. The arrows indicate
the site of mutation or polymorphism. SC35M-PB18N, SC35M-PB1D8N;
SC35M-PA706E, SC35M-PAW706E. C, survival and weight loss of 8–10-week-old
IFNAR0/0 mice (n! 6) infected with the SC35M-PAW706E passaged three
times in mice (PA706E (mP3)).
FIGURE 6. Characterization of polymerase assembly mutants after
serial passages in cell culture. A, mutations in PB1 and PA observed
after serial passages of the indicated virus mutants in MDCK cells. cP5
and cP10, cell passage 5 and 10. ", no mutations found. B, electrophero-
gram of PB1 and PA sequences after serial passages of the indicated
viruses in MDCK cells. The arrows indicate the sites of mutation or poly-
morphism. SC35M-PA706E, SC35M-PAW706E; SC35M-PA706EPB181, SC35M-
PAW706EOPB1L8I; C, viral growth of the indicated mutant viruses in MDCK
cells.
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PA or PB1 was not observed. This strongly suggests that only few
aa exchanges are tolerated within these binding domains without
loss of affinity. The lack of compensatory mutations especially in
the relatively small core PA-binding domainmight be caused by
the involvement of several aa of the 310 helix in mediating con-
tact to PA (12, 13, 19).
The amino acids within the PA-binding domain of PB1 (e.g.
Leu-8) and the PB1-binding domain of PA (e.g. Trp-706),
which are essential for polymerase subunit interaction, are
highly conserved and identical among all known influenza A
virus strains (12–14, 24). We therefore infer that targeting
these key residues results in attenuation of virtually all influ-
enza A virus strains. As exemplified by two unrelated viruses,
the highly pathogenic H5N1 strain KAN-1 and the mouse-
adapted strain SC35M (H7N7) mutation in PA (W706E) re-
sulted in severe attenuation of both viruses in mice. However,
the degree of attenuation is higher for the H5N1 mutant virus.
This might reflect differences in intrinsic PA/PB1 binding
affinities between these virus strains, as described recently for
FluA and influenza B viruses (14).
We also observed that targeting different key residues
within the PA- or PB1-binding domains could vary the degree
of attenuation because the mutation L8N in PB1 resulted in a
less attenuated phenotype of SC35M in cell culture and
mouse models when compared with the W706E mutation in
PA or a combination of both mutations. The possibility to
fine-tune the individual degree of attenuation by defined sub-
stitutions in PA or PB1 represents a unique tool to avoid over-
attenuation. The repertoire of suitable mutations could possi-
bly be extended to the similarly conserved PB2-PB1-binding
site (11).
The polymerase assembly mutant viruses are also drasti-
cally attenuated in mice with immune system defects, as dem-
onstrated in IFNAR0/0 mice, which are highly susceptible to
virus infection (17, 22, 23). We attribute this observation to
the host-independent polymerase assembly defect of these
viruses, which forces attenuation under all conditions. Our
findings suggest that live vaccines harboring these mutations
should possess a good safety profile in patients with impaired
antiviral defense mechanisms.
Several reasons might account for the genetic stability of
the polymerase assembly mutants in mice and cell culture.
The observed reduction in growth kinetics of these mutants
further decreases the population size and thus the likelihood
that viable escape mutants will emerge. Furthermore, the
PB1/PA-binding interface is highly conserved and cannot tol-
erate many aa changes without reducing the binding affinity
(12–14, 24). Thus, we speculate that point mutations, which
cause reversions to wild-type polymerase activity, are unlikely.
Live attenuated viruses confer several advantages as vac-
cines over traditionally used inactivated viruses, including
induction of cellular as well as humoral immunity, broader
protection among influenza virus subtypes, and better protec-
tion in children (3). However, the currently used cold-adapted
influenza vaccine (FluMist) is not approved for children under
the age of two or immunocompromised patients (3). Our at-
tenuation strategy might contribute to a better safety profile for
these viruses, as demonstrated by infection of IFNAR0/0 mice.
Furthermore, the cold-adaptedmaster strain A/AnnArbor/
6/60 H2N2 contains a fixed degree of attenuation (3), whereas
we have developed a strategy to easily identify new mutations,
which allow attenuation to be fine-tuned.
Overall, generation of polymerase assembly mutants can be
applied to all influenza A viruses, resulting in adjusted degrees
of attenuation. Thus, this novel approach may also contribute
to the development of phenotypically stable live vaccines
against seasonal and pandemic influenza. Furthermore, this
attenuation strategy could also be used to make successful
reassortment between attenuated live vaccines and circulating
influenza A viruses less probable. Such reassortment events
are of great concern because the resulting viruses might have
an increased pathogenicity. By targeting a protein-protein
interaction domain encoded on two segments, exchange of
only one segment should maintain attenuation. However, our
mutations could be combined with several other attenuation
strategies, which have been described (3, 25–28).
We provide proof of principle that disruption of a protein-
protein interaction site essential for polymerase complex for-
mation results in an attenuation of influenza viruses. Thus,
targeting the interaction domains of viral proteins that are
essential for productive infection may represent a universal
approach that could be applied to many other viruses.
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Supplementary figure legends: 
 
Fig. S1 Growth properties of polymerase assembly mutants in MDCK and A549 cells 
(A to C) MDCK or A549 cells were infected with the indicated SC35M virus mutants at a MOI of 
0.001 and virus titers in the cell supernatant were determined by plaque assay.  
(D) MDCK cells infected with either KAN-1 or KAN-1-PA706E at a MOI of 0.001 and virus titers in 
the cell supernatant were determined by plaque assay.  
 
 
Fig. S2 Sequence changes obtained in the escape mutants 
(A) Nucleotide changes in PB1. Nucleotides highlighted in blue represent the changes introduced into 
the rescue plasmid coding for PB16D7D, PB18D, PB18D9D and PB110D11D. Nucleotides marked in red are 
the nucleotide changes observed in the escape mutant viruses coding for the indicated PB1 mutants. *, 
sequence changes observed after the rescue attempt of SC35M-PB18NPA706E.  
(B) Nucleotide changes in PA. Nucleotides highlighted in blue represent the changes introduced into 
the rescue plasmids coding for PA706E and PA706R. Nucleotide marked in red represent the changes 
observed in the escape mutant viruses coding for PA706G.  
 
 
Fig. S3 Rescue of SC35M-PB18D9D* is a result of a recombination event 
During rescue of SC35M-PB18D9D a virus mutant emerged that maintained both D substitutions (Fig. 
2A, 8D9D*). Sequencing of the complete PB1 segment revealed a recombination event, which 
inserted a complete wt PB1 open reading frame. 
(A) RT-PCR amplification products corresponding to a fragment of the PB1 open reading frame (nt 1 
- 863) from SC35M viruses generated by transfection with the rescue plasmids coding for either wt 
PB1 or PB18D9D*. Note the difference in length of the amplification products.  
(B) Cartoon depicting the sequences involved in the recombination event. Red highlights the region of 
the helper plasmid (pCA-PB1 (wt)) found in the viral PB1 genome of SC35M-PB18D9D*. The 
recombination site shortly after a residual PB18D9D open reading frame could be identified by a partial 
NotI restriction site. The complete Not1 restriction site is only present in the helper plasmid but not in 
the rescue plasmid pHW2000-PB18D9D. The site of the downstream recombination event, indicated by 
a dashed arrow cannot be identified due to the identical sequence of helper and rescue plasmid.  
 
Fig. S4 The plaque size of the polymerase assembly mutants differ from wt SC35M. 
Plaque assay of SC35M coding for PA706E (PA706E) or PA706E and PB18I (PA706EPB18I) and wt SC35M 
48h p.i.    
 
Fig. S5 Pathogenicity of SC35M-PB18V in mice 
Survival and weight loss of 6-8 week old female BALB/c mice (n=5/group) after intranasal infection 
with SC35M mutant viruses encoding PB18V.  
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